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SUMMARY 
 
Endometriosis is one of the major threats to women’s health that leads toward 
infertility. The inheritable predisposition to endometriosis develops a growing interest 
in identifying the genes and genomic variants involved in the pathogenesis of 
endometriosis. Polycystic ovary syndrome (PCOS) is the major cause of anovulatory 
infertility. The genetic basis of PCOS is not well understood, it is a common 
metabolic and endocrine disorder.  The current study aimed to investigate for the first 
time, the possible genomic variants and single nucleotide polymorphism (SNP) in 
selective genes associated with endometriosis and PCOS in Pakistani women from the 
Punjab region. DNA samples from fifty-two genetically unrelated endometriosis 
patients and fifty-two controls were analyzed by direct sequencing to determine the 
polymorphisms of estrogen receptor alpha ESR1 (rs2234693, rs9340799), estrogen 
receptor beta ESR2 (rs4986938), progesterone receptor PGR (rs1042838, 
rs10895068), interleukin 10 IL10 (rs1800871, rs1800872 and rs1800896) and follicle 
stimulating hormone receptor FSHR (rs6166, rs6165) genes. Genetically unrelated 
PCOS patients and controls, 96 each, were selected on the basis of their Body Mass 
Index (BMI) and degree of obesity. The polymorphisms of different loci on 
adiponectin ADIPOQ (rs2241766, rs1501299 and rs2241767), insulin receptor INSR 
(rs1799817, rs1799815 of rs2059806 and rs2229429), FSHR (rs6164, rs6165), 
Follicle stimulating hormone beta FSHB (rs6169), Luteinizing hormone 
choriogonadotropin receptor LHCGR (rs61996318 and rs111834744), Luteinizing 
hormone beta LHB (rs1800447 and rs4002462), ESR1 (rs2234693, rs9340799) and 
ESR2 (rs4986938) genes were analyzed by direct sequencing. The rs4986938 of ESR2 
and rs1042838 of PGR gene show strong association (p = 0.006, OR: 1.360; CI: 0.16-
0.80; p < 0.003, OR = 1.935, 95% CI = 0.10-0.62) with endometriosis. The genotype 
and allele frequency of ESR1 gene polymorphisms were distributed similarly among 
patients and control groups (p > 0.050). The allele A of rs1800872 (p < 0.006, OR = 
2.379, 95% CI = 0.23-0.75), T of rs1800871 (p = 0.010, OR = 0.443, 95% CI = 0.19-
0.92) and G of rs1800896 ((p = 0.007, OR = 1.435, 95% CI = 0.24-0.77) at IL10 gene 
were strongly associated with the predisposition of endometriosis in Pakistani women. 
Significant (p < 0.001) associations were observed within the genotype frequencies, 
allele frequencies and multi-SNP haplotype analysis of the genetic polymorphisms of 
FSHR gene with endometriosis. This study identified new single nucleotide 
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polymorphisms (SNPs) at positions +349 A/G in ADIPOQ, +1638 T/C in INSR and 
+657 del/T in LHCGR genes associated with PCOS (p < 0.005) in Pakistani women. 
The polymorphisms in the ADIPOQ (r
2
= 0.78), ESR1 (r
2
= 0.48) and FSHR (r
2
= 0.76) 
genes were in strong (p < 0.001) linkage disequilibrium. The highly significant (p = 
0.030, OR = 0.436, 95% CI = 0.21-0.89) SNP of ADIOPQ gene associated with 
PCOS was rs2241766 when compared with their controls. In INSR gene the most 
common haplotypes CGT, CAC and CAT were found to be more prevalent in the 
PCOS than controls (p < 0.001). The FSHR and LHB gene polymorphism seems to be 
stable loci in Pakistani PCOS women (p > 0.050). Whereas, the rs6169 of FSHB gene 
was strongly (p= 0.020, OR= 0.606, 95% CI= 0.40-0.91) associated with PCOS in this 
subpopulation. The rs111834744 of LHCGR (p < 0.001, OR = 1.270, 95% CI = 0.18-
0.42), rs2232693 of ESR1 and rs4986938 of ESR2 genes were significantly (p < 
0.005) associated with the onset of PCOS in Pakistani women. Significant (p < 0.005) 
associations were observed within the genotype frequencies, allele frequencies and 
multi-SNP haplotype analysis of most polymorphisms studied. Serum progesterone 
level was lower in endometriosis patients while the serum testosterone and FSH titres 
were higher in PCOS women when compared with their controls (p < 0.001). The 
current findings suggest that the functional promoter polymorphism of IL10 gene 
ATG genotype may contribute in the risk of endometriosis. Current study provides the 
novel and new to science associations of ADIPOQ, INSR, FSHB, LHCGR, ESR1 and 
ESR2 genes with PCOS in Pakistani women. The genetic variants of above mentioned 
gene loci might influence the fertility status of endometriosis and PCOS patients. This 
suggests that the susceptible loci for endometriosis and PCOS lie within or very close 
to the chromosomal regions spanning these genes. 
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CHAPTER 1 
INTRODUCTION 
The need for research related to female reproduction is one of the most 
significant issues presently faced by the health sector in Pakistan today. 
 
1.1 Infertility 
Infertility is the most prevalent health disorders in young adults worldwide; 
approximately 8-10% of couples are unable to conceive during their reproductive age 
(Inhorn, 2003). This refers to the biological inability to conceive after regular 
unprotected intercourse (Makar and Toth, 2002). Infertility can be immunological, 
psychological, resulting from certain surgery or blockage, or be associated with 
defined abnormalities in the gametes. In 20% of couples the cause of infertility is 
unexplained (Uehara et al., 2001). According to a study carried out in a Gynaecology 
and Obstetrics Department at the Federal Government Services Hospital, Islamabad, 
Pakistan, the estimated infertility rate in the observed population from the last three 
years was 7 % (Shaheen et al., 2010). 
A complete physical examination of both partners is required for infertility 
evaluation. Six factors have been reported to be responsible for the cause of infertility. 
These include male factor, cervical factor, endometrial-uterine factor, tubal factor, 
peritoneal factor and ovulatory factor (Clark and Keefe, 1989). 
 
1.1.1 Causes of infertility in women 
The major causes of infertility comprise ovulatory dysfunction (OD), tubal 
damage and endometriosis in women. According to World Health Organization 
(WHO) criteria, OD is classified in to various categories including low gonadotropins, 
hyperprolactinaemia, and primary ovarian failure (Lunenfeld and Insler, 1974). The 
function of female reproductive organs is remarkably influenced by many genetic 
factors. Different studies on various populations investigated the susceptible genes for 
female reproductive disorders such as endometriosis, polycystic ovary syndrome 
(PCOS), ovulation disorder, pelvic inflammatory disease (PID), premature ovarian 
failure, pelvic adhesions and benign uterine fibroids (Escobar-Morreale et al., 2005). 
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1.2 Endometriosis 
Endometriosis is a common cause of infertility and pelvic pain. This disease 
affects approximately 7-10% of all women worldwide during their reproductive age 
(Baldi et al., 2008) with substantial annual health costs (Simoens et al., 2007) and 
health burdens for individuals (Jones et al., 2002). Endometriosis accounts for $22 
billion annually in US healthcare costs (Simoens et al., 2007). Clinically the major 
concern of endometriosis is its predisposition of infertility. It was expected that 25-
50% of endometriosis women are infertile (Gao et al., 2006). Whereas 25-30% of 
women have developed endometriotic lesions and identified for infertility (Missmer 
and Cramer, 2003; Giudice and Kao, 2004). Many genetic factors strongly influence 
the reproductive functions of female and different studies investigated the susceptible 
and candidate genes involved in the female reproduction and fertility (Missmer and 
Cramer, 2003; Giudice and Kao, 2004; Montgomery et al., 2008). 
Recently, the genetic polymorphisms have been suggested as genetic 
biomarkers of disease (Falconer et al., 2007; Vietri et al., 2007). The human genome 
project discovered the single nucleotide polymorphism (SNP) as new markers and this 
opened new novel ways to establish the genetic association of complex disorders with 
candidate and susceptible genes. A mutation that results in base substitution is called 
single nucleotide polymorphism. SNPs in protein coding region could be classified as 
non-synonymous and synonymous; the former results in missense mutation that 
causes change in amino acid or may be nonsense mutation resulting in codon 
termination. While the synonymous mutations are silent and do not change the amino 
acid. SNPs in promoter region can cause increased or reduced expression of gene. In 
addition SNPs in intron region alter the transcription rate due to mutation of 
regulatory elements. The average occurrence of SNPs in genome is every 1.9 kb 
whereas 1.42 million SNPs had been mapped. More than 60,000 SNPs were 
represented in untranslated and exon regions (Marth et al., 2001). 
The pathogenesis of endometriosis remains enigmatic (Figure 1.1). It is a 
condition in which endometrial tissue implants and grows outside the uterus and 
subsequently affects the function of ovaries, uterus and fallopian tubes resulting in 
reduced fertility (Sasson and Taylor, 2008). The primary symptoms of endometriosis 
include infertility, abdominal and pelvic pain, back pain, dysmenorrhea, dysuria, 
dyschezia and dyspareunia (Giudice and Kao, 2004). Among several hypotheses  
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Figure 1.1: Pathogenesis of endometriosis; hormone and endometrial 
inflammatory related manifestation. 
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proposed to explain the endometriosis pathogenesis the retrograde mensuration is 
widely accepted (Sasson and Taylor, 2008). Endometriosis exists in at least three 
distinct forms: peritoneal endometriosis, rectovaginal endometriotic nodules and 
endometriomas. These three types might be variants of the similar pathological 
process; however it is likely that they are caused by distinct mechanisms (Brosens, 
2004). Endometriosis is a complex disease that is not likely due to a single heritable 
genetic defect. Endometriosis was indicated as risk factor for multiple malignancies 
especially ovarian cancer in numerous epidemiological studies (Borgfeldt and Ellika, 
2004; Kobayashi et al., 2007). 
The development of endometriotic lesions includes genetic predisposition and 
environmental factors (Sasson and Taylor, 2008). Endometriosis is recognized as 
polygenic multifactorial disease with heritable tendencies (Simpson and Bischoff, 
2002; Simpson et al., 2003). The candidate and susceptible genes responsible for 
pathogenesis of endometriosis have been investigated in various genetic association 
studies (Hadfield et al., 2001; Vigano et al., 2003). 
In recent years various lines of genetic association studies have explore the 
association between genetic polymorphisms with the development of endometriosis 
(Luisi et al., 2006; Chun et al., 2012; Gallegos-Arreola et al., 2012), although the 
exact genes involved in the pathogenesis and susceptibility of endometriosis 
development are unknown.  
Endometriosis is clearly a hormone dependent disease that is characterized by 
responsiveness to estrogens, prostaglandins, metalloproteinases, cytokines, 
chemokines and resistance to progesterone (Giudice and Kao, 2004; Borghese et al., 
2010). Estrogen is responsible for persistent growth of endometriotic tissue; however 
the cytokines and prostaglandins are significant in the pathogenesis and development 
of endometriosis (Jabbour et al., 2006). The large quantities of prostaglandin E2 
produced by stromal cells induce local estrogen production and biosynthesis in 
women with endometriosis and impair pelvic pain (Soysal et al., 2004). The 
aromatase converted cholesterol into estradiol locally in endometriosis (Bulun et al., 
2005). Due to the multiple contributors and pathways leading to disease, genes 
encoding inflammatory mediators, sex hormones and enzymes involved in 
metabolism and biosynthesis have been investigated for their putative role in 
endometriosis. For example, the inflammatory mediator interleukin-10 (1q31-q32, 
IL10); sex hormone receptors, estrogen receptor alpha (6q25.1, ESR1), estrogen 
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receptor beta (14q23.2, ESR2), and progesterone receptor (11q22-q23, PGR) 
(Arvanitis et al., 2003; Hsieh et al., 2005; Kim et al., 2005; De Carvalho et al., 2007; 
Lee et al., 2007) have been studied by different laboratories on various populations. 
Recently, the interest has focused on identifying genetic polymorphisms in various 
genes underlying susceptibility to endometriosis (Falconer et al., 2007).  
Estrogen and progesterone receptors mediated the pathological and 
physiological activities of the sex steroid hormons. SNPs in ESR1 (rs2234693 and 
rs9340799), ESR2 (rs4989638) and PGR (rs10895068) genes were associated with 
expression and alteration of these sex steroid receptors (Gomes et al., 2006). 
Endometriosis seems to be inhibited by progesterone (Young and Lessey, 2010) and 
progression of disease is stimulated by estrogen (Bulun et al., 2000; Ness, 2003). 
Gurates and Bulun, (2003) emphasized the potential involvement of PGR in the 
molecular mechanism underlying the development of endometriosis. Indeed the 
particular genes regulated by progesterone showed abnormal expression and defect in 
function of endometrium in women with endometriosis. Moreover, alternation of PGR 
gene expression was demonstrated in endometrium tissue (Gurates and Bulun, 2003; 
Kao et al., 2003). Estrogen and progesterone are gonadotrophic hormones and are 
essential for human reproduction. Alteration in any of these genes causes infertility 
including endometriosis (Gurates and Bulun, 2003). 
Similarly, many immunological factors are reported to be associated with the 
pathogenesis of endometriosis (Wu and Ho, 2003). An important immune-modulatory 
cytokine is IL10 was recognized for its function to inhibit activation and function of 
T-cells, macrophages and monocytes. IL10 acts as to limit and terminate the 
inflammatory response (Moore et al., 2001). The polymorphisms, rs1800872, 
rs1800871 and rs180089 of interleukin 10 gene in the promoter region and their 
relationship with endometriosis have been analyzed in recent years (Xie et al., 2009; 
Riiskjaer et al., 2011), although the role of these polymorphisms in disease 
development is not recognized. A study on Taiwanese patients with endometriosis 
reported the association of IL10 gene polymorphism with this disease (Juo et al., 
2009). 
The polymorphism in follicle stimulating hormone receptor (FSHR) gene in 
relation with endometriosis is least studied. The polymorphism rs6166 is most studied 
as compared to polymorphism rs6165 (Mohiyiddeen and Nardo, 2010). The amino 
acid coded by this region is present in extracellular domain of follicle stimulating 
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hormone (FSH) protein binding region (Simoni et al., 2002). This is the fundamental 
region for FSH mediated events of signal transduction therefore affects the hormone 
binding ability of the receptor (Kene et al., 2005). The homozygous polymorphism 
GG at 680 of FSHR enhanced aromatase activity which induce more production of 
estrogens and stimulate the proliferation of endometriotic tissues (Wang et al., 2011). 
In addition, the lower risk of endometriosis was investigated with non-synonymous 
SNPs of FSHR gene including homozygous GG (Ser/Ser) and GA (Ser/Asn) at 680 in 
Taiwan population (Wang et al., 2011). 
A study on Taiwanese Chinese females suggests that the non-synonymous 
SNP rs6165 of FSHR gene mediated the extracellular recognition events which 
modulate the risk and development of endometriosis. Moreover, the conversion of 
680Ser from 680Asn as a result of A to G of rs6166 showed significant association with 
endometriosis suggests that phosphorylation of the cytoplasmic residue may be 
important for normal signaling pathways against the development of endometriosis 
(Wang et al., 2012).  
 
1.3 Polycystic ovary syndrome (PCOS) 
PCOS is a heterogeneous ovarian disorder associated with obesity, 
anovulation, hyperandrogenism, hirsutism, and infertility that affect 6-10 % of women 
at reproductive age worldwide (Goodarzi et al., 2011) and accounts for 70% cases of 
anovulatory infertility (Brassard et al., 2008). Stein and Leventhal first described the 
PCOS in 1935 (Stein and Leventhal, 1935). The etiology of PCOS is still not clear. 
Some genetic and hormonal factors have been implicated for the pathogenesis of 
PCOS including altered ovarian synthesis of steroids, hyperinsulinemia, aberrant 
folliculogenesis, abnormal secretion of gonadotropin and neuroendocrine 
abnormalities (Goodarzi et al., 2011). Among different criteria for the diagnosis of 
PCOS the most widely used was proposed by Rotterdam (2004). This includes any 
form of hyperandrogenemia either clinical (hirsutism and acne) or endocrine (high 
level of androgens), oligomenorrhea and the ultrasound examination of polycystic 
ovary. These three major criteria make PCOS a heterogeneous disease. The diagnosis 
can be made if 2 out of 3 criteria are met (Rotterdam, 2004).  
Both environmental and genetic factors make PCOS a heterogeneous disorder 
(Figure 1.2). The multifactorial etiology of PCOS is underpinned by multiple genetic 
architecture that initiated to elucidate in recent years (Fauser et al., 2011). An 
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interaction between environmental factors and polymorphisms of various genes 
makes PCOS a complex polygenic disorder (Luque-Ramírez et al., 2006; Vink et al., 
2006). However the molecular genetic mechanisms and inheritance pattern of PCOS 
is not fully known (Valdés et al., 2008). PCOS is an endocrinological disorder 
therefore the genes involved in the sex hormones or their regulators have been studied 
for polymorphisms (Simoni et al., 2008). Different studies provide evidences that 
PCOS is a familial disorder (Legro et al., 1998; Ehrmann, 2005). This indicates the 
significance of genetic component and involvement of multiple gene variants 
contributing the metabolic and endocrine effects in PCOS (Diao et al., 2004; Roldan 
et al., 2004; Ehrmann, 2005). 
A number of studies investigated the association of various candidate genes 
with PCOS while the pathogenesis of diseases is not accepted with any of the gene 
universally (Nam and Straus, 2007; Unluturk et al., 2007; Urbanek, 2007). The 
heritable basis and genetic etiology of PCOS has also been indicated by clinical 
evidences (Legro et al., 1998; Vink et al., 2006). 
The candidate and susceptible genes for PCOS includes: polymorphisms of 
genes encoding regulatory proteins and sex hormones like follicle stimulating 
hormone beta (FSHB), follicle stimulating hormone receptor (FSHR), estrogen 
receptor alpha (ESR1) and estrogen receptor beta (ESR2) (Tong et al., 2000; de Castro 
et al., 2004; Jun et al., 2006; Yang et al., 2006;)  and variants of genes encoding 
protein expressions involved in insulin resistance like adiponectin (ADIPOQ), insulin 
receptor gene (INSR), (Xita et al., 2005; Jin et al., 2006). A number of genetic 
variants were implicated in the susceptibility of PCOS, whereas no single marker was 
associated repeatedly and conclusively with the disorder (Urbanek, 2007). 
PCOS is a metabolic syndrome, therefore adiponectin was considered as 
potential candidate gene for PCOS. Adiponectin possesses insulin sensitizing, anti-
atherosclerotic and anti-inflammatory properties, accumulating evidence suggest that 
adiponectin has key roles in regulating female reproductive functions (Brochu-
Gaudreau et al., 2010). The ADIPOQ gene consists of 17 kb, consisting of two introns 
and three exons located on chromosome 3q27 (Hu et al., 1996). Adiponectin is a 
protein produced by an active endocrine organ the adipose tissue (Magkos and 
Sidossis, 2007). The region 3q27 of ADIPOQ gene has been revealed as susceptibility 
locus for metabolic syndromes including obesity (Kissebah et al., 2000) and insulin 
resistance (Francke et al., 2001).  
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Figure 1.2: Pathogenesis of PCOS; hormone and metabolic syndrome 
related manifestation. 
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Among adipose protein the adiponectin modulate insulin activity and 
represents a connection between adipocity and insulin resistance (Stefan et al., 2002). 
The PCOS women showed abdominal adiposity and obesity due to occurrence of 
hyperinsulinemia and insulin resistance (Dunaif, 2006). The women with PCOS 
showed reduced fertility linked with metabolic syndrome including hyperinsulinemia 
and insulin resistance (Tosca et al., 2008). PCOS women exhibit more susceptibility 
for metabolic syndrome when compared with general population (Cussons et al., 
2008). 
To date, the identified SNPs in adiponectin gene is 13 however among the 
multiple polymorphisms of ADIPOQ, the two polymorphisms rs2241766 in exon 2 
and rs1501299 in intron 2 attracted the most consideration. These two SNPs were 
involved in alteration of serum level of adiponectin (Xita et al., 2004; Pollin et al., 
2005). To some extent these polymorphisms of adiponectin may determine the 
phenotypic expression of certain metabolic syndrome. A study reported the 
interaction between steroid hormone synthesis and adiponectin polymorphisms 
(Meigs et al., 2005). However the gene expression or function of adiponectin under 
the influence of these polymorphisms is not completely known, as rs1501299 is 
intronic polymorphism while rs2241766 is synonymous polymorphism (Xita et al., 
2004). 
Insulin resistance is defined as decrease in insulin mediated glucose 
consumption. It is found in 50-90% PCOS women while its prevalence is 10-25% in 
general population (Goodarzi et al., 2005). The beta (β) cells of pancreas produce 
insulin which affects the various organs in the body. In female reproductive system 
insulin enhances the growth of ovaries and stimulates the production and secretion of 
androgens from ovaries; this inhibits ovarian follicle apoptosis and results in cyst 
formation (Baillargeon and Nestler, 2006). 
Insulin stimulates ovarian androgen production that affects ovarian 
steroidogenic responses to luteinizing hormone and follicle-stimulating hormone. 
Women develop PCOS because of hypersensitivity of the intra-ovarian insulin 
androgen signaling pathway (Baillargeon and Nestler, 2006). In PCOS women the 
major cause of insulin resistance is defect in post-binding region of INSR signiling 
transduction pathway that reduced the autophosphorylation of tyrosine kinase domain 
(Azziz, 2002). The insulin receptor gene located on chromosome 19p13.2 (Urbanek et 
al., 2005) and the exon 17-21of INSR gene codes for tyrosine kinase residue of the 
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receptor required for insulin signal transduction. To date, among the different SNPs 
detected in the region of exon 17 of INSR gene, the significant association was shown 
by the rs1799817 with PCOS (Panz et al., 1996; Siegel et al., 2002). The substitution 
from C to T allele at exon 17 was associated with the defect of tyrosine kinase domain 
of INSR in PCOS women possibly due to its effects on the auto phosphorylation of the 
INSR function (Lee et al., 2008). This also showed that polymorphism in INSR gene 
may be associated with the patients of PCOS who are obese. 
Follicle-stimulating hormone (FSH) is a pituitary glycoprotein that plays an 
important role during folliculogenesis by promoting the proliferation and 
differentiation of granulosa cells and maturation and development of follicles. The 
effect of FSH is mediated by binding to a specific follicle stimulating hormone 
receptor (FSHR) that is situated on the granulosa cells of the ovary (Moyle and 
Campbell, 1996). Because of this important role of FSHR in the signaling 
transmission of FSH, the FSHR gene may be an important candidate gene for PCOS. 
A previous genome-wide association study in Chinese women with PCOS identified a 
region on chromosome 2p16.3 that encodes the FSH receptor (FSHR) gene as a 
reproducible PCOS susceptibility locus (Shi et al., 2012). The FSHR gene contains 
two polymorphisms in exon 10 and change in amino acids at position N680S and 
A370T. The rs6165 (A370T) is in the extracellular domain of FSHR gene which is the 
high affinity binding site of FSH hormone (Du et al., 2010; Dolfin et al., 2011). The 
polymorphisms of FSHR gene are in linkage disequilibrium therefore the haplotype of 
these polymorphisms affected the FSH level (Orio et al., 2006). A number of genetic 
studies showed the association between polymorphisms of FSHR gene and PCOS 
(Orio et al., 2006; Bon-Hee et al., 2010). 
FSHR is crucial for reproduction and mutations in this gene greatly affect the 
fertility. It has been previously reviewed that mutations in FSHR cause loss of 
function or gain of function in various cases (Lussiana et al., 2008; Thompson et al., 
2008; Salvi and Pralong, 2010). The mutations of FSHR gene inhibit the proper 
ovarian function and causes infertility (Meduri et al., 2003; Kuechler et al., 2010). In 
human the infertility including hypergonadotrophic, hypogonadism, amenorrhea and 
ovarian failure is caused by inactivating mutations in the FSHR gene (Doherty et al., 
2002; Allen et al., 2003; Meduri et al., 2003; Kuechler et al., 2010). The mutations 
found in any region of FSHR gene cause suppression in hormone binding capacity 
and abnormality in signal transduction (Rannikko et al., 2002; Tranchant et al., 2011). 
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Estrogens play an important role in the function and development of the 
reproduction system. The estrogen action was mediated by two specific high affinity 
receptors, the ESR1 and ESR2, both of which belong to superfamily of nuclear 
receptor and act as ligand activated transcription factor. Both receptors are necessary 
for the proper functioning of the hypothalamic-pituitary-ovarian axis. Both ESR1 and 
ESR2 are expressed in the human ovary, ESR2 is the main type of receptor and its 
activation enhances folliculogenesis and ovulation (Hegele-Hartung et al., 2004). 
Furthermore, the expression of ESR2 is lower in follicle derived from women with 
PCOS compared with healthy women, while the ESR1 expression is markedly 
increased in theca cells of polycystic ovaries, causing alteration in the ESR1/ESR2 
ratio in PCOS and possibly abnormal follicular development (Jakimiuk et al., 2002). 
Based on these observations, variants of ESR1 and ESR2 may be implicated in the 
pathogenesis of PCOS. A number of polymorphic sites in ESR1 and ESR2 have been 
identified with the most widely studied being rs2234693, rs9340799 polymorphism in 
ESR1 and rs4986938 in ESR2.  
The LHCGR gene encodes a receptor for luteinizing hormone (LHR) and 
human chorionic gonadotropin (hCG) and mutations in LHCGR was associated with 
infertility (Yariz et al., 2011). In PCOS women the polymorphisms of LHR gene 
effect the ovarian androgen production  and concentration of luteinizing hormone 
(LH) which is expressed in the theca and granulose cells that leads toward anovulation 
(Norman et al., 2007). Different studies investigated that mutations in LHR gene and 
luteinizing hormone beta (LHβ) gene altered their structure and function by activating 
and inactivating the bioactivity, moreover this cause amenorrhea, anovulation and 
PCOS in women (Huhtaniemi and Themmen 2005; Huhtaniemi and Alevizaki 2006). 
There were strong evidences that polymorphisms of LHβ and LHR genes involved in 
the development of PCOS, however the inconsistent results were observed in different 
populations and loci. LHβ gene polymorphism in exon 3 was examined to be mutant 
in Singapore Chinese women with menstrual disorders (Ramanujam et al., 1999). A 
Korean study found no associtaion between LHβ gene polymorphisms with PCOS 
(Kim et al., 2001). However the women with LHR mutations often show infertility 
and amenorrhea (Themmen, 2005). A genome wide association study (GWAS) in 
Han Chinese women observed strong association between LHR gene polymorphism 
and PCOS (Chen et al., 2011). 
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In most of the anovulated PCOS women the level of gonadotropic and 
estrogen remains normal (Broekmans et al., 2006). The women with PCOS showed 
frequent elevation in serum LH concentration and the LH to FSH ratio (Rebar et al., 
1976). The most common biochemical feature of PCOS is hyperandrogenemia 
(Goodarzi et al., 2005). The high level of circulating androgen was observed in 80-
90% of PCOS women with oligomenorrhea (Hull, 1987; Goodarzi et al., 2005). 
About 60% of PCOS women are hirsute due to hyperandrogenemia. This is the most 
common clinical sign for PCOS phenotype (Azziz et al., 2009). Snehalatha reported 
that Asian Indians have higher insulin resistance both with lean Body Mass Index 
(BMI) and central obesity (Snehalatha et al., 2003). 
The reproductive function is regulated by FSH, luteinizing hormone (LH) and 
chorionic gonadotropin hormones; these are functionally and evolutionary related 
hormones (Pierce and Parson, 1981). The elevated level of insulin stimulates the 
granulosa cells to secrete FSH that results in ovarian steroidogenesis regulation and 
growth of follicular cyst. As FSH plays important role in oogenesis and follicular 
development, the increased FSH level leads to maturation of follicles (Simoni et al., 
1997; Sudo et al., 2002). Biochemical measurements of testosterone showed elevated 
level of hormone in PCOS toward the upper limit than normal and cause 
hyperandrogenism (Cho et al., 2008). The LH and FSH receptors mediate the function 
in gonads, as these hormones are produced in a pulsatile manner by the anterior lobe 
of pituitary gland (Dalkin et al., 2001; Ascoli et al., 2002; Dias et al., 2002). In 
women the FSH stimulate estrogen production in ovaries and required for follicle 
maturation (Mcgee and Hsueh, 2000). In females the LH stimulate the synthesis of 
progesterone, ovulation and androgen in the theca cells (Moyle and Campbell, 1996). 
Some studied have reported significant association of genetic variants with 
infertility while others have not found any relationship. So far the evidence of an 
association between PCOS and endometriosis with specific genetic polymorphism 
giving consistent results in different populations is missing or very weak. Therefore, 
large scale, well defined case control studies are required to validate these 
associations in poly cystic ovary syndrome and endometriosis employing the 
improved methodology for SNP detection.   
In view of the important roles already identified for ESR1, ESR2, IL10, PGR, 
and FSHR in endometriosis, we studied polymorphisms previously associated with 
endometriosis at these loci to determine whether there is evidence for similar 
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associations in women from a previously unstudied distinct population. We are not 
aware of any previous endometriosis association studies reported in Pakistani women; 
here we identify conservation of these associations in this population. PCOS is one of 
the major threats to women’s health that leads to anovulatory infertility, amenorrhoea, 
hirsutism and oligomenorrhoea. No research evidence examining the role of genetic 
polymorphisms in PCOS has been reported previously for Pakistani women. We 
elucidate, for the first time in Pakistani women of the Punjab the putative functional 
significance of different polymorphisms on the ADIPOQ, INSR, FSHR, FSHB, 
LHCGR, LHB, ESR1 and ESR2 genes in the development of PCOS. 
With this comprehensive database of information provided by the present 
study about the reproductive endocrinology and genetics the possible association 
between single nucleotide polymorphisms (SNPs) of genes related with PCOS and 
endometriosis are likely to be identified. This will provide a starting point for 
functional and biological studies to develop better diagnosis and treatment for these 
debilitating diseases. There is no therapeutic treatment for the control of the 
endometriosis and PCOS. The identification of genetic risk factors for female 
reproductive disorders will be beneficial for the early prediction of the disease that 
will potentially lead to the better diagnosis and treatment. The present project is 
designed to evaluate the indigenous SNP database of genes and role of sex steroids 
involved in reproductive disorders. 
 
Aims and Objectives 
The major aims and objectives of this research Project are: 
1. To determine the genetic and endocrinological causes of female reproductive 
disorders like endometriosis and PCOS. 
2. To find the reasons of genetic disorder linked with gene SNPs for inflammation, sex 
hormone regulation and steroid biosynthesis associated with endometriosis and 
PCOS. 
3. To compare the serum level of sex steroids and gonadotropins in diagnosed women 
patients of the above mentioned syndromes with their controls. 
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CHAPTER 2 
REVIEW OF LITERATURE 
 
Infertility is a common public health problem in developing countries.  The 
pathogenesis of diseases is better understood due to genetic studies, this help to 
improve our ability to treatment for patients (Simoni et al., 2008). 
 
2.1 Endometriosis 
Endometriosis is strongly linked with infertility, ovarian maturation, implantation and 
fertilization affected by growth factors and alteration in the production of different 
cytokines (Vassiliadis et al., 2005).The symptoms of endometriosis depends on the 
localization of the implants, this includes dyspareunia, dysmenorrhea, dysuria, 
dyschezia, chronic pelvic pain and infertility (Bulun et al., 2000; Missmer and 
Cramer, 2003; Marques et al., 2004). Moreover, many inflammatory mediator 
response factors and immunologic factors were investigated for their significant role 
in the development and pathogenesis of endometriosis (Wu and Ho, 2003). 
 
2.1.1 Estrogen receptor alpha (ESR1) 
Endometriosis is a multifactorial and polygenic disease and associated with genetic 
factors and complex interaction of cytokine activation, hormones and immuno-
inflammatory process (Vigano et al., 1998). A study on Japanese population observed 
the association of ESR2 gene polymorphism with endometriosis while no association 
with ESR1 SNPs (Wang et al., 2004).  
Hsieh et al., (2007) elucidated the association of ESR1 -351 A/G and -397 T/C 
polymorphisms of 112 women with endometriosis and 110 controls in Taiwan 
population. ESR1 mutant related genotype revealed higher percentage in affected 
women when compared with control. The genotype proportion AA/AG/GG of ESR1 -
351 was 26.8/57.1/16.1 in endometriosis women while 33.6/64.6/1.8 in control group. 
The genotype proportion TT/TC/CC of ESR1 -397 was 24.1/60.7/15.2 in 
endometriosis group and 54.5/40/5.5 in control group. They conclude that both 
polymorphisms were correlated with the pathogenesis and susceptibility of 
endometriosis. 
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A study on 214 Chinese women with endometriosis and 160 controls investigated no 
significant association with the genotype frequency of PvuII, although the XbaI of 
ESR1 showed distinct variations in allele and genotype frequency suggesting that this 
SNP was associated significantly with endometriosis in studied Chinese population 
(Xie et al., 2009). The data of association studies of ESR1 gene with endometriosis in 
various populations is presented in Table 2.1. 
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Table 2.1: Summary of association studies between ESR1 gene polymorphisms (rs9340799 and rs2234693) and endometriosis. 
a. rs9340799 
Sr. 
 No 
Population Endometriosis Control Endometriosis 
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
A Allele 
n (%)  
 G Allele 
n (%)  
A Allele 
n (%)  
G Allele 
n (%)  
1 Japan 194 (79.5)  50 (20.5) 262 (76.6)  80 (23.4) 122 171 0.402 Negative Wang et al., 2004 
2 Taiwan 124 (55.4) 100 (44.6) 145 (65.9) 75 (34.1) 112 110 0.005 Positive Hsieh et al., 2007 
3 China 316 (73.83)  112 (26.17) 260 (81.25)  60 (18.75) 214 160 0.017 Positive Xie et al., 2009 
 
b. rs2234693 
Sr. 
 
No 
Population Endometriosis Control Endometriosis 
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
A Allele 
n (%)  
 G Allele 
n (%)  
A Allele 
n (%)  
G Allele 
n (%)  
1 Japan 145 (59.9)  97 (40.1) 182 (52.9)  162 (47.1) 121 172 0.09 Negative Wang et al., 2004 
2 Taiwan 122 (54.5) 102 (45.5) 164 (74.5) 56 (25.5) 112 110 0.005 Positive Hsieh et al., 2007 
3 China 246 (57.48) 182 (42.52)  204 (63.75)  116 (36.25) 214 160 0.083 Negative Xie et al., 2009 
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2.1.2 Estrogen receptor beta (ESR2) 
The rs1042838 (G/A) polymorphism of ESR2 gene and its association with the risk of 
endometriosis were investigated in Korean women. In this study 239 cases of 
endometriosis and 287 controls were assessed by restriction fragment length 
polymorphism analysis. The allele G and A frequency were not different in cases and 
control group 87.4%, 12.6% vs. 85.5%, 14.5% respectively. This suggests that the 
polymorphism was not associated with the pathogenesis of endometriosis in Korean 
population (Lee et al., 2007). 
In Brazilian women the genotype and allele frequencies showed significant difference 
for rs1042838 at +1730 position, G/A polymorphism of ESR2 gene between 
endometriosis and controls. The frequencies of genotypes AA, GA and GG of ESR2 
gene was 1.9%, 47.2% and 50.9% in women with endometriosis while 1.4%, 24.3% 
and 74.3% in controls respectively (Bianco et al., 2009). The inconsistency in results 
may be due to different ethnic origin and genetic background. Genetic factors 
involved in pathogenesis of disease varied in different populations. 
The ESR2 +1730 G/A polymorphism were also investigated in a case control study on 
another group of infertile Brazilian women. This study includes 201 women with 
endometriosis and control group of 206 healthy women. A statistically significant (p = 
0.003) difference was observed in endometriosis infertile women and control 
regarding to the isolated frequencies of polymorphism (Christofolini et al., 2011). The 
allele frequencies of ESR2 gene associated with endometriosis in different population 
is given in Table 2.2.  
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Table 2.2: Summary of association studies between ESR2 (rs4986938) gene polymorphisms and endometriosis. 
Sr. 
No 
Population Endometriosis Control Endometriosis 
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
G allele 
n (%)  
 A allele 
n (%)  
G allele 
n (%)  
A allele 
n (%)  
1 Japan 230 (90.5)  24 (9.5) 309 (85.8)  51 (14.2) 127 180 0.08 Negative Wang et al., 2004 
2 Brazil 161 (74.5)  55 (25.5) 363 (86.4)  57 (13.6) 108 210 0.003 Positive Bianco et al., 2009 
3 Brazil 216 (79.4)  56 (20.6) 368 (88.0)  50 (12.0) 136 209 0.003 Positive Zulli et al., 2010 
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2.1.3 Interleukin 10 (IL10) 
The promoter region of IL10 gene spans 5 kb upstream from transcription start site, 
both the promoter and coding region contain several polymorphisms (Lazarus et al., 
2002). The IL10 gene was recognized on chromosome 1q31-32 (Kim et al., 1992; 
Opdal, 2004).  
The associations of IL10 promoter polymorphisms with endometriosis have been 
investigated in various populations. In Japanese population no significant difference 
was examined in genotype and allele frequencies at position -592 (rs1800872) and -
1082 (rs1800896) in endometriosis and controls (Kitawaki et al., 2002). In addition 
the frequency of haplotype GCC at rs1800872, rs1800871 and rs1800896 (-592 A>C, 
-819 T>C and -1082 A>G) is about 50% in European females, 20% in African 
females while lowest below 5% in Asian female (Meenagh et al., 2002). In contrast, a 
significant association of endometriosis with A allele at -592 position of rs1800872 in 
the promoter region of IL10 was investigated in Taiwanese population (Hsieh et al., 
2003).  
A study on Chinese patients with endometriosis revealed the higher frequency of C 
allele of rs1800872 and rs1800871 as compared to controls. No difference was 
observed in allele frequency at position -1082 (rs1800896) (Zhang et al., 2007).  
The genomic variants of IL10 gene in promoter region was studied in 214 women 
with endometriosis and 160 controls in China. The variations in allele frequency was 
observed at -592 and -819 regions of IL10 and seems associated with endometriosis 
while the polymorphism at -1082 region was conserved with no difference in allele 
frequency (Xie et al., 2009). The allele frequencies of various polymorphisms of IL10 
gene associated women with endometriosis in various populations are shown in Table 
2.3. 
 
2.1.4 Progesterone receptor (PGR) 
The progesterone receptor mediates the action of progesterone, encoded by 
progesterone receptor gene (PGR) on chromosome 11q22-q23 consisting of seven 
introns and eight exons (Gurates and Bulun, 2003). 
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Table 2.3: Summary of association studies between IL10 (rs1800896, rs1800871 and rs1800872) gene polymorphisms and endometriosis. 
a. rs1800896 
Sr. 
No 
Population Endometriosis Control Endometriosis 
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
A allele 
n (%)  
 G allele 
n (%)  
A allele 
n (%)  
G allele 
n (%)  
1 Japan 310 (96.9)  10 (3.1)  379 (96.7) 13 (3.3) 160 196 0.885 Negative Kitawaki et al., 2002b 
2 China 402 (93.2) 26 (6.0) 300 (93.7)  20 (6.2) 214 160 0.921 Negative Xie et al., 2009 
3 Denmark 92 (46.0) 108 (54.0)  326 (45.5) 390 (54.5) 100 358 >0.050 Negative Riiskjaer et al., 2011 
 
b. rs1800871 
Sr. 
No 
Population Endometriosis Control Endometriosis 
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
T allele 
n (%)  
 C allele 
n (%)  
T allele 
n (%)  
C allele 
n (%)  
1 China 278 (64.95)  150 (35.0) 232 (72.5) 88 (27.5) 214 160 0.028 Positive Xie et al., 2009 
2 Denmark 40 (20.0)  160 (80.0)  552 (22.9) 164 (77.1) 100 358 >0.050 Negative Riiskjaer et al., 2011 
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Table Continued…… 
c. rs1800872 
Sr. 
No 
Population Endometriosis  Control Endometriosis 
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
A allele 
n (%)  
 C allele 
n (%)  
A allele 
n (%)  
C allele 
n (%)  
1 Japan 214 (66.9) 106 (33.1)  233 (59.4) 159 (40.6) 160 196 0.041 Positive Kitawaki et al., 2002b 
2 China 278 (64.9) 150 (35.0) 232 (72.5) 88 (27.5) 214 160 0.028 Positive Xie et al., 2009 
3 Denmark 40 (20.0) 160 (80.0)  164 (22.9) 552 (77.1) 100 358 >0.050 Negative Riiskjaer et al., 2011 
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2.2 PCOS 
The association of various genetic variants with PCOS was studied in different 
ethnicities. 
 
2.2.1 Adiponectin (ADIPOQ) 
The association of PCOS and polymorphism in adiponectin gene was investigated in 
several studies. In 2001, 2 independent groups identified that adiponectin effects the 
insulin sensitivity (Berg et al., 2001; Yamauchi et al., 2001). 
The Japanese population was examined for the association of rs2241766 (T45G) 
polymorphism with increased risk of type 2 diabetes mellitus (Hara et al., 2002). A 
significant association was investigated between T45G polymorphism with insulin 
resistance and obesity in an Italian population (Menzaghi et al., 2002). PCOS being 
metabolic syndrome show insulin resistance and type 2 diabetes mellitus (T2 DM); it 
is suggested that the polymorphism of adiponectin gene was related with the 
development of T2 DM (Filippi et al., 2004). 
Conversely an association was observed between PCOS and adiponectin 
polymorphism in various studies. Panidis et al., (2004) observed low frequency of T 
allele and high frequency of G allele at T45G position of rs2241766 adiponectin gene 
in Greek population of obese PCOS women; however this difference was not 
statistically significant (p > 0.050). 
Haap et al. (2005) investigated the adiponectin gene polymorphism with higher 
frequency of T to G substitution at +45 position of rs2241766 in PCOS women as 
compared to control. Studies provide the evidences that the polymorphism in 
adiponectin gene in women with PCOS showed abnormalities in reproductive system 
as well as high risk of T2 DM, obesity and cardio vascular disease (CVD) when 
compared with normal control (Kadowaki and Yamauchi, 2005). The association of 
ADIPOQ gene with PCOS in various populations is given in Table 2.4.
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Table 2.4 (a): Summary of association studies between ADIPOQ (rs2241766) gene polymorphisms and PCOS. 
Sr. 
No 
Population PCOS Control PCOS 
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
T allele 
n (%) 
G allele 
n (%) 
T allele 
n (%) 
G allele 
n (%) 
1 Spain 54(37.5) 90(62.5) 28 (19.4) 56 (66.6) 72 42 0.004 
 
Positive San Millan et al., 2004 
2 Spain 53 (34.9) 99 (65.1) 29 (36.3) 51 (63.7) 
76 40 0.201 Negative Escobar-Morreale et al., 2005 
3 Finland 74(25.9) 212(74.1) 160 (32.9) 330 (67.3) 143 245 0.005 
 
Positive Heinonen et al., 2005 
4 Greece 73(36.5) 127(63.5) 103 (32.5) 177 (63.2) 100 140 0.061 
 
Negative Xita et al., 2005 
5 Spain 53(34.9 99(65.1) 29 (19.08) 51 (63.7) 76 40 0.050 
 
Positive Escobar-Morreale et al., 2006 
6 China 82(34.2) 158(65.8) 108 (45.0) 132 (55.0) 120 120 0.050 
 
Positive Zhang et al.,2008 
7 Korea 93 (32.3) 195 (67.7) 135 (42.5) 183 (57.5) 144 159 0.010 
 
Positive Li et al., 2011 
8 Iran 101(27.9) 261(72.1) 101(27.9) 261(72.1) 181 181 0.52 
 
Negative Ranjzad et al., 2012 
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Table 2.4 (b): Summary of association studies between ADIPOQ (rs1501299) gene polymorphisms and PCOS. 
Sr. 
No 
Population PCOS Control PCOS  
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
T allele 
n (%) 
G allele 
n (%) 
T allele 
n (%) 
G allele 
n (%) 
1 Greece 217 (82.2) 47 (17.8) 179 (89.5) 21 (10.5) 132 100 0.050 Positive Panidis et al., 2004 
2 Spain 118 (81.9) 26 (18.0) 70 (83.3) 14 (16.6) 72 42 0.005 Positive San Millan et al., 2004 
3 Germany 84 (79.2) 22 (20.7) 940 (86.7) 144 (13.2) 53 542 0.005 Positive Haap et al., 2005 
4 Finland 267 (93.3) 19 (6.6) 466 (95.1) 24 (4.9) 143 245 0.402 Negative Heinonen et al., 2005 
5 Greece 177 (88.5) 23 (11.5) 242 (86.4) 38 (13.5) 100 140 0.004 Positive Xita et al., 2005 
6 Spain 130 (85.5) 22 (14.5) 65 (81.3) 15 (18.8) 76 40 0.201 Negative Escobar-Morreale et al., 2005 
7 Finnish 267(93.4) 19(6.6) 466(95.1) 24(4.8) 143 245 0.601 Negative Heinonen et al., 2005 
8 Spain 130 (85.5) 22 (14.4) 65 (81.2) 15 (18.7) 76 40 0.004 Positive Escobar-Morreale et al., 2006 
9 China 168 (70.0) 72 (30.0) 190 (79.1) 50 (20.8) 120 120 0.020 Positive Zhang et al.,  2008 
10 Turkey 160 (83.3) 32 (16.6) 164 (88.1) 22 (11.8) 96 93 0.004 Positive Demirci et al., 2010 
11 Korea 217 (75.3)  71 (24.7) 228 (71.7) 90 (28.3) 144 159 0.350 Negative Li et al., 2011 
12 Iran 296(81.8) 66(18.2) 322(88.9) 40(11.1) 181 181 0.005 Positive Ranjzad et al., 2012 
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In Finnish population no difference was reported in genotype and allele frequencies of 
rs2241766 ADIPOQ gene variants between PCOS and control group (Heinonen et al., 
2005). A study conducted on Greek population had detected no difference in genotype 
frequencies and association with the development of PCOS (Xita et al., 2005). A 
study on women of Spain confirmed the same findings with no association of PCOS 
and rs2241766 polymorphism when compared with their control (San Millian et al., 
2004; Escobar-Morreale et al., 2006). An association was observed between SNPs of 
adiponectin gene rs2241766 and rs1501299 in Han Chinese PCOS women than 
controls (Zhang et al., 2008). 
 
2.2.2 Insulin receptor (INSR) 
Insulin receptor gene consists of 22 exons (Seino et al., 1990). Insulin resistance and 
hyperinsulinemia was observed in PCOS women with polymorphisms in the region of 
exon 17-21 of INSR gene. This region codes for tyrosine kinase residue of the 
receptor necessary for insulin transduction pathway (Krook et al., 1994). The patients 
with PCOS were examined with several polymorphisms in exons and introns of INSR 
gene (Siegel et al., 2002). 
The evidences showed that the susceptible loci for PCOS are present in the INSR gene 
at chromosome 19 suggested that it might be the susceptible region for disease (Tucci 
et al., 2001). According to Azziz, insulin receptor has post binding defect in 
signalling pathway that considered as one of the major contributor in pathogenesis of 
PCOS (Azziz, 2002). The polymorphisms in INSR gene bring mild change in function 
of the gene which may contribute in the development of PCOS (Siegel et al., 2002). 
Insulin resistance has metabolic consequences and play important role in development 
and pathogenesis of PCOS (Azziz, 2002; Ehrmann, 2005).  
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Table 2.5: Summary of association studies between INSR (rs1799817 and rs2059806) gene polymorphisms and PCOS. 
(a) rs1799817 
Sr. 
No 
Population PCOS Control PCOS 
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
T allele 
n (%) 
C allele 
n (%) 
T allele 
n (%) 
C allele 
n (%) 
1 Korea 130(37.4) 218(62.6) 75(40.3) 111(59.6) 174 93 >0.050 Negative Lee et al., 2007 
2 Korea 79(29.9) 185(70.0) 68(34) 132(66.0) 132 100 >0.050 Negative Lee et al., 2008 
3 India 125(34.7) 235(65.2) 80(27.7) 208(72.2) 144 180 >0.050 Negative Mukherjee et al., 2009 
4 Turkey 66 (75.0)  22 (25.0)  71 (71.0) 29 (29.0) 44 50 0.538 Negative Unsal et al., 2009 
5 Iran 88 (24.3) 274 (75.7) 79 (21.8) 283 (78.2) 181 181 0.427 Negative Ranjzad et al., 2012 
(b) rs2059806 
        
1 
 
Iran 265 (73.2) 97 (26.8) 256 (70.7)   106 (29.3) 181 181 0.456 Negative Ranjzad et al., 2012 
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PCOS being metabolic syndrome is also called as insulin resistant disease (Rotterdam, 
2004; Legro et al., 2004).  
Insulin resistance has an important role in the pathogenesis and metabolic 
consequences of PCOS (Azziz, 2002; Legro et al., 2004; Ehrmann, 2005). Legro et al,  
(2004) described that 50-70% of PCOS women exhibits insulin resistance and insulin 
insensitivity that leads toward the hyperandrogenism; a major contributor of PCOS 
symptoms and sign. 
 
2.2.3 Follicle stimulating hormone receptor (FSHR) 
FSH is a pituitary glycoprotein responsible for folliculogenesis by activating the 
maturation of follicles; this cause granulosa cells to proliferate and trigger the 
synthesis of aromatase which is an androgen converting enzyme (Gharib et al., 1990; 
Moyle and Campbell, 1996). The FSH receptor (FSHR) which belongs to G-protein 
coupled receptor mediates the action of FSH signal transduction (Segaloff and Ascoli, 
1993). The first inactivated mutation in FSHR gene with ovarian failure was observed 
in some Finnish women (Aittomaki et al., 1995). The substitution of A to G of rs6165 
polymorphism causes change of threonine (ACT) codon to alanine (GCT) at 307 
coding position of protein. The replacement of G with A of rs6166 SNP at coding 
position 680 leads to change of amino acid serine (AGT) codon to asparagine (AAT) 
(Aittomaki et al., 1995). 
The worldwide screening of patients and control in different ethnicities for FSHR 
gene explore two non-synonymous SNPs in exon 10. These SNPs in the coding region 
had been identified for frequency of >30% in the normal population. The rs6165 at 
position 919 showed substitution of A to G changing the amino acid threonine to 
alanine. Whereas the rs6166 at position 2039 replaced G with A, this change the 
amino acid sequence from serine to asparagine (Aittomaki et al., 1995). 
The two polymorphisms N680S and A307T of FSHR gene in exon 10 were in linkage 
disequilibrium. The polymorphism A307T of FSHR gene is located in the high 
affinity binding site of FSH hormone in extracellular domain of (Davis et al., 1995). 
This site affects the signal transduction and hormone trafficking (Hipkin et al., 1995). 
The FSHR gene consist of 10 exons in which the largest one encodes for intracellular 
domain while the remaining nine smaller encodes for extracellular domain (Simoni et 
al., 1997).  
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In a study of Japanese PCOS women a significant increase was observed in the 
Ala307Thr frequency with 66.7% compared with 43.5% in normal ovulating women 
(Sudo et al., 2002). 
The alteration in the amino acid affects the function of receptors of FSHR protein at 
post-translational modifications (de Castro et al., 2004). The genetic association 
between women with PCOS and FSHR gene polymorphisms has been studied 
previously (Tong et al., 2001; Orio et al., 2006) 
The candidate genes involved in insulin metabolism, gonadotropin secretions, 
steroidogenesis and inflammation were studied in the previous years. The 
susceptibility genes for PCOS have been explored and identified in women of Spain 
(Escobar-Morreale et al., 2005). However the results of various studies were so far 
inadequate (Diamanti- Kandarakis et al., 2006). 
The existence of association of Ala307Thr polymorphism with PCOS was not 
confirmed in Turkish women (Unsal et al., 2009) and in women with Caucasian 
origin (Valkenburg et al., 2009). However a study on Chinese women reported 
significant association of Ala307Thr polymorphism of FSHR gene with PCOS (du et 
al., 2010). The associations of PCOS and polymorphisms of FSHR gene have been 
studied extensively in various ethnicities (de Koning et al., 2006; Jun et al., 2006; 
Simoni et al., 2008; Achrekar et al., 2009; Livshyts et al., 2009; Overbeek et al., 
2009; Valkenburg et al., 2009; Du et al., 2010; Gu et al., 2010; Kuijper et al., 2010; 
Rendina et al., 2010), however the consistency of these findings are not without 
contradictions. 
Previous genetic studies revealed that the genes involved in the hormone metabolism 
and energy regulation, such as INSR, LH and CYP19 play important role in 
pathogenesis of PCOS (Rajkhowa et al., 1995; Kahsar-Miller et al., 2004; Witchel et 
al., 2005; Unsal et al., 2009). 
Mohiyiddeen and Nardo (2010) reviewed 15 studies and examine the polymorphism 
of FSHR gene; this review suggest that the homozygous serine variant was associated 
with higher FSH level in all ovulatory patients but three studies did not showed 
consistent results with these findings (Falconer et al., 2005; Klinkert et al., 2006; 
Loutradis et al., 2006). More recent studies could not confirm the association of 
homozygous serine variant with the FSH concentration at follicular phase as was  
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Table 2.6: Summary of association studies between FSHR (rs6165) gene polymorphisms and PCOS. 
 
 
 
Sr. 
No 
Population PCOS Control PCOS 
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
A allele 
n (%)  
G allele 
n (%) 
A allele 
n (%)  
G allele 
n (%) 
1 UK 92 (49.5) 94 (50.5) 41 (40.2) 61 (59.8) 93 51 >0.050 Negative Conway et al., 1999 
2  Singapore 162 (65.3) 86 (34.7) 314 (66.5) 158 (33.5) 124 236 >0.050 Negative Tong et al.., 2001 
3 Japan 18 (50.0) 18 (50.0) 219 (65.2) 117 (34.8) 18 168 >0.050 Negative Sudo et al., 2002 
4 Italian 43 (43.0) 57 (57.0) 43 (43.0) 57 (57.0) 50 50 >0.050 Negative Orio et al., 2006 
5 Caucasian 496 (50.1) 494 (49.9) 3064 (50.0) 3060 (50.0) 495 3062 >0.050 Negative Valkenburg et al., 2009 
6 Turkey 51 (58.0) 37 (42.0) 57 (57.0) 43 (43.0) 44 50 >0.050 Negative Unsal et al., 2009 
7 China 72 (65.5) 38 (34.5) 117 (63.6) 67 (36.4) 55 92 0.007 Positive Du et al., 2010 
8 China 228(29.7) 540(70.3) 483(31.4) 1053(68.8) 384 768 0.390 Negative Fu et al., 2013 
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Table 2.7: Summary of association studies between FSHR (rs6166) gene polymorphisms and PCOS. 
 
Sr. 
No 
Population PCOS Control PCOS 
(n) 
Control 
(n) 
p Association Reference 
Allele frequency 
A allele 
n (%)  
G allele 
n (%) 
A allele 
n (%)  
G allele 
n (%) 
1 UK 92 (49.5) 94 (50.5) 41 (40.2) 61 (59.8) 93 51 >0.050 Negative Conway et al., 1999 
2  Singapore 162 (65.3) 86 (34.7) 314 (66.5) 158 (33.5) 124 236 >0.050 Negative Tong et al.., 2001 
3 Japan 18 (50.0) 18 (50.0) 219 (65.2) 117 (34.8) 18 168 >0.050 Negative Sudo et al., 2002 
4 Italian 43 (43.0) 57 (57.0) 43 (43.0) 57 (57.0) 50 50 >0.050 Negative Orio et al., 2006 
5 Caucasian 496 (50.1) 494 (49.9) 3064 (50.0) 3060 (50.0) 495 3062 >0.050 Negative Valkenburg et al., 2009 
6 Turkey 51 (58.0) 37 (42.0) 57 (57.0) 43 (43.0) 44 50 >0.050 Negative Unsal et al., 2009 
7 China 72 (65.5) 38 (34.5) 117 (63.6) 67 (36.4) 55 92 0.007 Positive Du et al., 2010 
8 China 228(29.7) 540(70.3) 483(31.4) 1053(68.8) 384 768 0.390 Negative Fu et al., 2013 
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observed previously (Kuijper et al., 2010; Genro et al., 2012; Mohiyiddeen et al., 
2012). 
 
2.2.4 Follicle stimulating hormone beta (FSHB) 
The non-coding region of FSHB gene comprises less number of polymorphism but 
consider as highly frequent alleles in human. However the variants of this gene are in 
strong linkage disequilibrium (Simoni et al., 2008). 
 
2.2.5 Estrogen receptor alpha (ESR1) 
Both ESR1 and ESR2 genes were involved in the physiological action on estrogen 
production in the ovary (Byers et al., 1997; Drummond et al., 1999). The alternation 
in the expression of ESR1 and ESR2 genes may cause anomalous development of 
follicles (Jakimiuk et al., 2002). 
Estrogen play substantial role in the function and development of reproductive 
system. The estrogen action is mediated by two specific receptors, the ESR1 and 
ESR2 which belongs to nuclear receptor family. Both ESR1 and ESR2 are required for 
the proper function of hypothalamus pituitary ovarian axis.  Estrogen acts on the 
ESR1 to regulate the cyclic process of gonadotropin release in the hypothalamic 
pituitary axis (Hillisch et al., 2004), and enhance the process of folliculogenesis and 
ovulation by its action on ESR2 in the ovary (Hegele-Hartung et al., 2004). The ESR1 
gene found on chromosome 6q25.1and consists of 1 intron and 8 exons spanning 140 
Kb, contains two SNPs r2234693 and rs9340799 (Ale´ssio et al., 2007). 
Kim et al, (2010) in Korean population observed significant difference in allele and 
genotype frequencies between women with PCOS and controls. The “A” allele was 
significantly different with 11.7% in PCOS and 19.1% in control. The study 
concludes that the ESR2 polymorphism was significantly associated with the 
pathogenesis of PCOS (Kim et al., 2010). 
A study conducted on Greece population showed the association of rs9340799 
polymorphism of ESR1 gene with FSH level in PCOS women. The association of 
allele A was observed with low serum FSH level indicates the contribution of this 
genomic variant with reduced development of follicles (Nectaria et al., 2012). 
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2.2.6 Estrogen receptor beta (ESR2) 
ESR2 gene spans approximately 62 Kb, consists of 9 exons and resides on 
chromosome 14q23.1 (Pettersson and Gustafsson, 2001). 
 
2.2.7 Luteinizing hormone choriogonadotropin receptor (LHCGR) 
LHR mediate the effect of LH and this is expressed in granulosa and theca cells 
(Balen, 1993). LHCGR belongs to G-protein receptor located on 2p16.3 chromosome 
(Atger et al., 1995). A single non synonymous mutation at G1052A of LHβ replaces 
amino acid glycine with serine in exon 3 (Tapanainen et al., 1999). The LHR gene 
comprises of 10 introns and 11 exons (Ascoli et al., 2002). The anomalous signalling 
of LH is believed to enhance the production of ovarian androgen in women with 
PCOS and leads toward anovulation (Norman et al., 2007). 
The LHCGR is expressed in various tissues including testis, ovaries and some non-
gonadal tissues (Rahman and Rao, 2009). In Han Chinese PCOS women the two 
susceptible loci were identified at 9q33.3 and 2p21 encoding for LHCGR and FSHR 
gene respectively in a genome wide association study (Chen et al., 2011). The 
LHCGR gene comprises a receptor for chorionic gonadotropin (HCG) and luteinizing 
hormone (LH) and mutations in these receptors were related with infertility (Yariz et 
al., 2011). 
Studies have investigated that the mutations in LHR and LHβ gene may alter the 
function or structure of LHR and LH, either inactivating or activating their bioactivity. 
The mutations in LHR cause amenorrhea, anovulation, infertility and PCOS in women 
(Themmen and Huhtaniemi, 2000; Themmen, 2005; Huhtaniemi and Themmen, 
2005; Huhtaniemi and Alevizaki, 2006). 
 
2.2.8 Luteinizing hormone beta (LHβ) 
The convincing evidences suggest the LHR and LHB gene as the genetic determinant 
of PCOS. Whereas, the studies on different populations showed inconsistent results 
with polymorphisms of this gene.  The mutations in LHβ gene Trp8Arg and Ile15Thr 
polymorphisms were associated with the PCOS women of Japan and UK whereas the 
low frequency of mutations was observed in North European obese PCOS women 
(Rajkhowa et al., 1995; Suganuma et al., 1995; Tapanainen et al., 1999). A study on 
Singapore Chinese women speculated that G1052A mutation of LHβ gene affect the 
function of gonads and this polymorphism was related with menstrual disorder. The A 
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allele (4%) was present only in women with menstrual irregularities and absent in 
controls (Ramanujam et al., 1999). Kim et al. (2001) found no homozygous 
polymorphic variant at G1052A of LHβ in 108 Korean women with PCOS. The 
secretion of androgens was mediated by LH in theca cells of ovaries and help in 
follicles maturation (Laven et al., 2002). The LHR was over-expressed in theca and 
granulosa cells of women with PCOS (Jakimiuk et al., 2001). 
These findings suggest that different regional and ethnical groups may express 
different genotypes of G1052A polymorphism of LHβ. A genome-wide association 
study on Han Chinese women with PCOS investigated significant association with 
LHR gene polymorphisms (Chen et al., 2011). 
A study conducted on Chinese women showed that the frequency of heterozygous and 
homozygous variants were 3.2% (10/315) and 1.0% (3/315) respectively at G1052A 
polymorphism of LHβ in PCOS. In contrast no polymorphism (0/212) was observed 
at G1052A of LHβ gene in control. The mutant allele A of LHβ gene was significantly 
associated (p = 0.001) with PCOS (Liu et al., 2012). 
In PCOS women the LHR is expressed in theca cells, the LHR function is altered by 
multiple polymorphisms in the LH receptor (Jakimiuk et al., 2001). LHR stimulates 
the ovarian theca cells to secrete androgens which consequently arrest follicular 
maturation (Laven et al., 2002). The PCOS women have normal limits of FSH level 
(Laven et al., 2002). 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Sampling size and study design 
This research has been approved by the research ethics Committee Board of Advance 
Studies and Research (BASR) of Government College University Lahore as well as 
from infertility clinics of obstetrics/gynecology teaching hospitals. This was a Case 
control analytical study and the sample size was calculated by the following formula 
(Lwanga and Lemeshow, 1991).  
n = z
2
α/2 π (1- π)/e
2
 
 
3.2 Subjects 
The diagnosed female subjects with known infertility (endometriosis and PCOS) were 
recruited from the outpatient’s infertility clinics of Gynecology /Obstetrics wards of 
tertiary hospitals (Sir Ganga Ram hospital Lahore and Lady Willington hospital 
Lahore). The women were referred from clinics, hospitals and physicians from all 
over the Punjab province. The written informed consent on a prescribed performa was 
obtained from all subjects (Annexure I). The anthropometric data of all the subjects 
were collected and every individual was assessed after registering their medical 
history on specially designed subject data sheets (Annexure II) (Sue et al., 2007). The 
healthy Pakistani women from the Punjab with regular menses and history of 
spontaneous conception volunteered as controls.  
 
 3.3 Sample selection 
There were separate cases for endometriosis and PCOS. 
 Ninety-six (96) Pakistani women with PCOS. 
  Fifty-two (52) Pakistani women with endometriosis. 
 One hundred forty eight (148) healthy Pakistani women as control. 
 
3.3.1 Inclusion criteria: 
 Age 20 to 40 years. 
 Females married for at least 1 year. 
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 The diagnosed cases of PCOS according to Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group, 2004 (Rotterdam, 2004). 
Therefore, diagnostic criteria included women who displayed two of the 
following three criteria: clinical and/or biochemical signs of 
hyperandrogenism, oligo- or anovulation and polycystic ovary morphology. 
 The patients of endometriosis were diagnosed clinically (e.g. pelvic pain, 
dysmenorrhea and infertility).  
 The reproductively active age group was taken.  
 
3.3.2 Exclusion criteria: 
 Known causes of congenital adrenal hyperplasia, hyperandrogenism, Cushing 
syndrome, hyperprolactinemias, adrenal tumor and virilizing ovarian tumor 
were excluded. 
 Hyperthyroidism, Pregnancy, Smoking, Hypertension. 
 Intake of any medications including hormonal treatment in last 1 year. 
 Use of anti-obesity drugs, anti-diabetic, glucocorticoids. 
 Any neoplastic, metabolic, Cardiovascular, or other relevant medical illness.  
 Inflammatory conditions of pelvis and abdomen. 
 On treatment of infertility i.e. IVF. 
 Laparotomy/laparoscopy. 
 
3.3.3 Selection of controls 
 Females of age 20 to 40 year married for more than 1 year. 
 BMI matched healthy controls with regular menstruation. 
 No symptoms of hyperandrogenism, e.g. hirsutism, Virilism.  
 History of spontaneous conception. 
 Had not taken any hormonal contraception. 
 Agreeable to participate in the study. 
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Figure 3.1 Diagrammatic and schematic presentation of research layout. 
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3.4 Physical examination 
 
3.4.1 Determination of weight, height and Body Mass Index 
The standing height of each subject was measured using a portable Standiometer, 
whereas weight was determined with a digital weight scale nearest to 0.1 cm. The 
Body Mass Index (BMI) of every subject was calculated by using the equation 
demonstrated by Cole et al. (1997): 
BMI = Weight in kilogram / (Height in meter)
 2
 
 
3.4.2 Physical examinations and interviews 
All participants completed a structured questionnaire covering family history, 
education level, weight and height, waist and hip ratio (WHR), patient’s medical, 
gynecological and surgical history. Complete physical examination and pelvic 
ultrasonography was conducted. All the eligible controls were matched on the bases 
of age, residential area and were genetically unrelated to minimize possible selection 
bias. Hence all subjects had the same similar socioeconomic status and ethnicity. All 
subjects were recruited by gynecologists after reviewing patient’s medical records to 
meet with eligibility criteria.  
 
3.5 Blood sampling and Storage 
The blood samples (5-10ml) were drawn from each patient and were stored at 4 
o
C 
after dividing into sub-samples until further process for genetic and hormonal 
analysis. The sub-samples of blood for molecular genetic studies were collected in 
tubes containing ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. 
Whereas the blood samples for serum separation were collected in gel coated tubes. 
The serum was stored at -80 
o
C for further analysis. All the collected blood samples 
were transported to laboratory on ice. 
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3.6 Genotyping and DNA sequencing 
 
3.6.1 Genomic DNA extraction  
Genomic DNA of all subjects including endometriosis, PCOS and healthy controls 
were extracted from the blood using a modified standard extraction method 
(Sambrook et al., 1989). (The recipe of solutions prepared for DNA extraction was 
presented in Annexure III). 
The protocol followed for genomic DNA isolation consists of following steps.  
 1) In 500 µl of blood 500-700 µl of  Tris-EDTA (TE) buffer was added, mixed the 
buffer by inverting tubes ups and down several times. The tubes were left at room 
temperature for 10-15 min. 
 2) Centrifugation was performed at 25 
o
C with 13500 rpm for 5-10 min. 
 3) Supernatant was discarded leaving the white blood cells (WBCs) pellet at the 
bottom of 1.5 ml eppendorf. The pellet was broken by gentle tapping and vortexing. 
After adding 1 ml of TE buffer the step 2 was repeated until the WBCs pellet became 
clear or light pink. 
 4) The broken clear pellet was dissolved into 375 µl of 3M sodium acetate, 25 µl of 
10% sodium dodecyl sulphate (SDS)  and 10 µl of proteinase K (10 µg/µl) and 
incubated at 37 
o
C overnight in a shaking water bath. 
 5) One volume of chilled chloroform: isoamyl alcohol (24:1) was added into three 
volumes of digested pellet, mixed by gently inverting eppendorfs ups and down until 
a milky emulsion was formed and centrifuged at 25 
o
C with 13500 rpm for 5-10 min. 
 6) Three layers can be visualized after centrifugation. The upper layer contains DNA, 
the lower layer chloroform: isoamyl alcohol and the middle whitish layer proteins. 
The DNA layer was carefully transferred into a new labeled eppendorf avoiding 
contamination from other layers, mixed with equal volume of chilled absolute ethanol 
by gently inverting eppendorfs ups and down until DNA threads became visible, left 
at room temperature for 10 min and centrifuged at 25 
o
C with 13500 rpm for 5-10 
min. 
 7) Supernatant was discarded and the DNA pellet was washed with 500-1000 µl 
chilled 70% ethanol by centrifuging at 25
o 
C with 13500 rpm for 5-10 min. 
 8) Ethanol was discarded and the DNA pellet was dried by air keeping eppendorfs 
open inside the laminar air flow at room temperature for 15-30 min. 
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 9) The dried DNA pellet was dissolved into 30-50 µl low TE buffer, incubated in a 
shaking water bath at 70 
o
C for 30 min, cooled at room temperature and spinned by 
brief centrifugation. 
 10) DNA was stored in duplicate at -20
o
C and -80
o
C after assessing its quality and 
quantity by nanodrop (Thremoscientific, Nanodrop 2000) and gel electrophoresis. 
11) All the DNA samples (endometriosis, PCOS and control) were extracted in 
duplicate to avoid the mishandling waste and troubleshooting with optimization. 
 
3.6.2 Candidate Genes 
Various candidate genes were selected from three metabolic pathways that have been 
implicated in the etiology of endometriosis and PCOS (Table 3.1, 3.2). These genes 
map to distinct chromosomal locations. The common variants in these regions, 
1q32.1, 6q25.1, 11q22.1, 2p21, 3q27.3, 6q25.1, 11p14.1, 15q21.2, 19q13.2, and 
19p13.33 were analyzed. The single nucleotide polymorphisms (SNPs) of ESR1, 
ESR2, PGR, IL10, FSHR, FSHB, LHCGR, LHB, ADIPOQ and INSR genes were 
selected (Table 3.1, 3.2). The NCBI reference sequence assembly was used for 
chromosome position, gene ID and gene symbol GRCh37.p5 along with build 37.3. 
Nomenclature guidelines suggested by the Human Genome Variation Society 
(HGVS) was followed, the coding reference position of the relevant DNA used along 
with the Ensemble accession file is shown in Table 3.1 and 3.2. 
 
3.6.3 Single nucleotide polymorphism (SNPs) selection 
All SNPs were selected for their functional relevance to PCOS and endometriosis 
after searching databases of “University of California, Santa Cruz” (UCSC) 
(https://genome.ucsc.edu/), “National center for biotechnology information” (NCBI) 
(http://www.ncbi.nlm.nih.gov) and prior publications. The SNPs were searched using 
the NCBI website (http://www.ncbi.nlm.nih.gov/snp/). The search for endometriosis 
susceptible SNPs has been focused on genes encoding inflammatory mediators, sex 
hormones, enzymes involved in metabolism and steroid biosynthesis. The susceptible 
and candidate genes for PCOS involved in insulin sensitivity, steroid biosynthesis, 
detoxification and sex hormone regulation were selected.   
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Table 3.1: Genotyping panel for endometriosis candidate genes. 
 
Marker locus Candidate 
 genes 
Gene 
symbol 
Gene 
ID 
Ensemble accession  *SNP ID *Chr Genomic 
position  
Coding DNA 
reference 
position 
Gene 
mode 
Protein 
position 
Residue 
change 
Sex Steroid 
hormone 
Estrogen receptor α ESR1 2099 ENST00000440973 rs2234693 6q25.1 g.152163335 c.453-397T>C Intron     
rs8179176 g.152163334 c.453-398C>T Intron     
rs9340799 g.1521633381 c.453-351A>G Intron     
Estrogen receptor β ESR2 2100 ENST00000557772 rs4986938 14q23.2 g.64699816 c.1859G>A UTR-3     
Progesterone 
receptor 
PGR 5241 ENST00000325455 rs10895068 11q22.1 g.101000214 c.-413G>A UTR-5     
rs1042838 g.100933412 c.1978G>T missense 660 Val-Leu 
Inflammatory 
mediators 
Interleukin 10 IL10 3586 ENSG00000136634 rs1800872 1q32.1 g.206946407 c. -592 A>C UTR-5     
rs1800871 g.206946634 c.-819C>T UTR-5     
rs1800894 g.206946666 c.886G>A UTR-5     
rs1800896 g.206946897 c.-1082A>G UTR-5     
Gonadotropin 
action 
Follicle-stimulating 
hormone receptor 
FSHR 2492 ENST00000406846 rs6166 2p16.3 g.49189921 c.2039G>A missense 680 Ser-Asn 
rs6165 g.49191041 c.919G>A missense 307 Ala-Thr 
 
Assembly used for chromosome position, gene ID and gene symbol is GRCh37.p5 along build 37.3  
 SNP: Single nucleotide polymorphism; * Chr: Chromosome 
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Table 3.2: Genotyping panel for PCOS candidate genes. 
 
Assembly used for chromosome position, gene ID and gene symbol is GRCh37.p5 along build 37.3; * Chr: Chromosome; SNP: Single nucleotide polymorphism 
Marker locus Candidate gene Gene 
symbol 
Gene 
ID 
Ensemble accession SNP ID *Chr Genomic 
position  
Coding DNA 
reference 
position 
Gene  
mode 
Protein 
position 
Residue 
change 
Steroid 
hormone 
Estrogen receptor α ESR1 2099 ENST00000440973 rs2234693 6q25.1 g.152163335 c.453-397T>C Intron     
rs8179176 g.152163334 c.453-398C>T Intron     
rs9340799 g.1521633381 c.453-351A>G Intron     
Estrogen receptor β ESR2 2100 ENST00000557772 rs4986938 14q23.2 g.64699816 c.1859G>A UTR-3     
Gonadotropin 
action 
Follicle-stimulating 
hormone beta 
FSHB 2488 ENST00000417547 rs6169 11p14.1 g.30255185 c.228C>T cds-Synon 76 Tyr-Tyr 
Follicle-stimulating 
hormone receptor 
FSHR 2492 ENST00000406846 rs6166 2p16.3 g.49189921 c.2039G>A missense 680 Ser-Asn 
rs6165 g.49191041 c.919G>A missense 307 Ala-Thr 
Luteinizing 
hormone 
LHCGR 3973 ENST00000294954 rs61996318 2p21 g.48941162 c.568C>A missense 190 Gln-Lys 
choriogonadotropin 
receptor 
rs111834744 g.48941073 c.605+52delT intron     
Luteinizing 
hormone beta 
LHB 3972 ENST00000221421 rs1800447 19q13.33 g.49519905 c.82T>C missense 28 Trp-Arg 
  rs4002462 g.49519997 c.16-26T>C intron     
Insulin action Adiponectin ADIPOQ 9370 ENST00000412955 rs2241766 3q27.3 g.186570892 c.45T>G intron     
rs1501299 g.186571123 c.214+62G>T missense 190 Gln-Lys 
rs2241767 g.186571196 c.214+135A>G intron     
Insulin receptor INSR 3643 ENST00000341500 rs1799817 19p13.2 g.7125297 c.3219C>T cds-Synon 1085 HiS-His 
rs1799815 g.7125519 c.2997C>T cds-Synon 1011 Tyr-Tyr 
rs2059806 g.7166376 c.1650G>A cds-Synon 550 Ala-Ala 
rs2229429 g.7166388 c.1638C>T missense 546 Asp-Glu 
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Table 3.3: Primers, PCR program, annealing temperatures and PCR nucleotide product size of endometriosis polymorphisms. 
 
Gene 
ID 
*SNPs ID Primer sequence Annealing 
temperature 
(◦C) 
PCR Program 
(35 cycles) 
Product size 
(*bp) 
ESR1 
(2099) 
rs2234693 F: CTGCCACCCTATCTGTATC 
R: ACCCTGGCGTCGATTATCT 
53 ⁰C 95⁰C 15min, 95⁰C 45 Sec 
53⁰C 45 Sec, 72⁰C 1 min 
1366 
rs9340799 F: CTGCCACCCTATCTGTATC 
R: ACCCTGGCGTCGATTATCT 
53 ⁰C 95⁰C 15min, 95⁰C 45 Sec 
53⁰C 45 Sec, 72⁰C 1 min 
1366 
ESR2 
(2100) 
rs4986938 F: CGGCAGAGGACAGTAAAAGC 
R: TGAGAGTTGGGAAGGTGGAG 
58 ⁰C 95⁰C 15min, 94⁰C 45 Sec 
58⁰C 45 Sec, 72⁰C 45 Sec 
213 
IL10 
(3586) 
rs1800872 F: GGACAGCTGAAGAGGTGGAA 
R: GAGGGGGTGGGCTAAATATC 
60 ⁰C 95⁰C 15min, 94⁰C 45 Sec 
60⁰C 45 Sec, 72⁰C 1 min 
166 
rs1800871  
 
F: TCATTCTATGTGCTGGAGATGG 
R: TGGGGGAAGTGGGTAAGAGT 
60 ⁰C 95⁰C 15min, 94⁰C 45 Sec 
60⁰C 45 Sec, 72⁰C 45 Sec 
208 
rs1800896 
 
F: TTCCCCAGGTAGAGCAACAC 
R: GATGGGGTGGAAGAAGTTGA 
56 ⁰C 95⁰C 15min, 94⁰C 45 Sec 
56⁰C 45 Sec, 72⁰C 45 Sec 
238 
PGR 
(5241) 
rs10895068 F: GTACGGAGCCAGCAGAAGTC 
R: GAGGACTGGAGACGCAGAGT 
56 ⁰C 95⁰C 15min, 94⁰C 45 Sec 
56⁰C 45 Sec, 72⁰C 1 min 
220 
rs1042838 F: TTCGAAACTTACATATTGATGACCA 
R: CACTTAAAATAACAAAAACAACAAAAG 
56 ⁰C 95⁰C 15min, 94⁰C 45 Sec 
56⁰C 45 Sec, 72⁰C 45 Sec 
180 
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Table continues…………….. 
 
 
      
FSHR 
(2492) 
rs6166 F: GCAAGTGTGGCTGCTATGAA 
R: GTGACATACCCTTCAAAGGC 
55 ⁰C 95⁰C 15min, 95⁰C 1min 
55⁰C 1 min, 72⁰C 1 min 
231 
  rs6165 F: CCTGCACAAAGACAGTGATG 
R: TGGCAAAGACAGTGAAAAAG 
55 ⁰C 95⁰C 15min, 95⁰C 1min 
55⁰C 1 min, 72⁰C 1 min 
577 
 
*SNP: Single nucleotide polymorphism 
   F: Forward; R: Reverse 
*bp: base pair 
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      Table 3.4: Primer, annealing temperature, PCR program and product size of PCOS polymorphisms. 
 
Gene 
ID 
*SNPs ID Primer sequence Annealing 
temperature 
(◦C) 
PCR Program 
(35 cycles) 
Product 
size 
(*bp) 
ADIPOQ 
(9370) 
rs2241766 F:GAAGTAGACTCTGCTGAGATGG 
R:TATCAGTGTAGGAGGTCTGTGATG 
56 ⁰C 95⁰C 15min, 93⁰C 45 Sec 
56⁰C 30 Sec, 72⁰C 45 Sec 
372 
  rs1501299 
 
F: CCTGGTGAGAAGGGTGAGAA 
R: AGATGCAGCAAAGCCAAAGT 
56 ⁰C 95⁰C 15min, 93⁰C 45 Sec 
56⁰C 30 Sec, 72⁰C 45 Sec 
241 
  rs2241767 
 
F: CCTGGTGAGAAGGGTGAGAA 
R: AGATGCAGCAAAGCCAAAGT 
56 ⁰C 95⁰C 15min, 93⁰C 45 Sec 
56⁰C 30 Sec, 72⁰C 45 Sec 
241 
INSR 
(3643) 
 
rs1799817  
F: CCAAGGATGCTGTGTAGATAAG 
R: TCAGGAAAGCCAGCCCATGTC 
56 ⁰C 95⁰C 15min, 93⁰C 45 Sec 
56⁰C 30 Sec, 72⁰C 45 Sec 
317 
  rs1799815 F: CCAAGGATGCTGTGTAGATAAG 
R: TCAGGAAAGCCAGCCCATGTC 
56 ⁰C 95⁰C 15min, 93⁰C 45 Sec 
56⁰C 30 Sec, 72⁰C 45 Sec 
317 
   
rs2059806 
F: CGGTCTTGTAAGGGTAACTG 
R: GAATTCACATTCCCAAGACA 
62 ⁰C 95⁰C 15min, 93⁰C 45 Sec 
62⁰C 30 Sec, 72⁰C 45 Sec 
324 
   
rs2229429 
F: CGGTCTTGTAAGGGTAACTG 
R: GAATTCACATTCCCAAGACA 
62 ⁰C 95⁰C 15min, 93⁰C 45 Sec 
62⁰C 30 Sec, 72⁰C 45 Sec 
324 
FSHR 
(2492) 
rs6166 F: GCAAGTGTGGCTGCTATGAA 
R: GTGACATACCCTTCAAAGGC 
55 ⁰C 95⁰C 15min, 95⁰C 1min 
55⁰C 1 min, 72⁰C 1 min 
231 
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Table continues……………. 
 
  rs6165 
 
F: CCTGCACAAAGACAGTGATG 
R: TGGCAAAGACAGTGAAAAAG 
55 ⁰C 95⁰C 15min, 95⁰C 1min 
55⁰C 1 min, 72⁰C 1 min 
577 
FSHB 
(2488) 
 rs6169 F: TGTTAGAGCAAGCAGTATTCAATTTCT 
R: GTATGTGGCCTGAAATGTCCACTGATC 
60 ⁰C 95⁰C 15min, 94⁰C 1min 
60⁰C 30 Sec, 72⁰C 1 min 
357 
LHCGR 
(3973) 
rs61996318 F: TGATGGTGGTGGTGATGATG 
R: GGTTTCTAGCCAGCCAGTTG 
60 ⁰C 95⁰C 15min, 94⁰C 1 min 
60⁰C 40 Sec, 72⁰C 1 min 
379 
  rs111834744 F: TGATGGTGGTGGTGATGATG 
R: GGTTTCTAGCCAGCCAGTTG 
60 ⁰C 95⁰C 15min, 94⁰C 1 min 
60⁰C 40 Sec, 72⁰C 1 min 
379 
LHB 
(3972) 
rs1800447 F: GTCTCAGACCTGGGTGAAGC 
R: GCACAGATGGTGGTGTTGAC 
58 ⁰C 95⁰C 15min, 94⁰C 45 Sec 
58⁰C 45 Sec, 72⁰C 45 Sec 
185 
  rs4002462 F: GTCTCAGACCTGGGTGAAGC 
R: GCACAGATGGTGGTGTTGAC 
58 ⁰C 95⁰C 15min, 94⁰C 45 Sec 
58⁰C 45 Sec, 72⁰C 45 Sec 
186 
ESR1 
(2099) 
rs2234693 F: CTGCCACCCTATCTGTATC 
R: ACCCTGGCGTCGATTATCT 
53 ⁰C 95⁰C 15min, 95⁰C 45 Sec 
53⁰C 45 Sec, 72⁰C 1 min 
1366 
  rs9340799 F: CTGCCACCCTATCTGTATC 
R: ACCCTGGCGTCGATTATCT 
53 ⁰C 95⁰C 15min, 95⁰C 45 Sec 
53⁰C 45 Sec, 72⁰C 1 min 
1366 
ESR2 
(2100) 
rs4986938 F: CGGCAGAGGACAGTAAAAGC 
R: TGAGAGTTGGGAAGGTGGAG 
58 ⁰C 95⁰C 15min, 94⁰C 45 Sec 
58⁰C 45 Sec, 72⁰C 45 Sec 
213 
 
*SNP: Single nucleotide polymorphism;  F: Forward; R: Reverse; *bp: base pair
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3.6.4 Primer designing 
The forward and reverse primers were designed using primer 3 
(http://gmdd.shgmo.org/primer3/?seqid=47) website. The sequences of the PCR 
primers, forward and reverse sets (Figure 3.2), annealing temperature, cycling 
conditions and product size are shown in Table 3.3 and 3.4. The validity of primers 
was checked through NCBI database. 
 
(a) SNPs and primer sequence of ESR1 gene 
TGAAACTCCTTGCTAAGAGTCTGCTTTGTCAGGTCTGAATTCACTTAACCAGTCTTT
GCTTTGTTGGACTTCTCTCTGCCACCCTATCTGTATCATCATCCTCTCCATAAACCT
TTCTACTTAAAGCATTTTACTTCCTTATTTTCTTGGTTTTCCTAGAATCTCCTTACT
GTTCATTTTCAGCTTCCTTTCTGTGTTCCTCTTCTCTTCCTACATTTTTTTTTAGCT
TTCTACTTTCTTAAAGCATTTTACTTCCTTATTTTCTTGGTTTTCCTAGAATTTTCT
TACTGTTCATTTTCAGTTTCCTTTCTGTGTTCCTCTGATTGTCTCTCTTTCTACATT
TTTTTTTTCTGTGTTCCTCTGATTTTCACGCAGTCTGGAGTTGTCATGATCAATCAT
AGCCTACTGCAGCCTCGACATCCTAGGCTCAAGTGATTCTCCCACCTCAGCCTTACA
AGTAGCTAGGACTACAGTCACACATCACCATTCTCAGCTAATTTTTTTAAGAAGCAT
TTTTATAGAGATGGAGTCTTGCTATATTGTGCAGGCTGGGCTCAAACTACAGGGCTT
AAACAATTCTCCTGCTTTGGCCTCCCAAAGTGCTGGGATTCCAGGCATGAACCACCA
TGCTCAGTCTCTACATGTTCCTAAAGAGGAGTTTTGAATATTGAAGAACAGTATTTT
CAAATTACATTATTCAAGTTATAAAAACTGATATCCAGGGTTATGTGGCAATGACGT
AAAAATTTGAATTGTTATTTTTTTGACACATGTTCTGTGTTGTCCATCAGTTCATCT
GAGTTCCAAATGTCCCAGCTGTTTTATGCTTTGTCTCTGTTTCCCAGAGACCCTGAG
TGTGGTCTAGAGTTGGGATGAGCATTGGTCTCTAATGGTTCTGAAATAATTGTATAT
TCCTGCAAAAACATTAAGTCTATTAGAAACCAGCTAATTTCATTTTGTCATTTTTAT
AGGTAACATATTCTGGTGCAGGTAGTATGTTTTTAAAACAAGTTTGCAATAAACAAT
TTCCCCTCAAGGTTAATATAATAGGCAACACCTTTTGCTGCAACAGACGGCAAGAGG
TAATGAAAGATTAGCTTACATTATGATTCATTATTTCAAAATGTCAGGATAAAGTGG
ATCTGCTGCATCTCCCAGAGAGTGCATGTTTTGCTTTTCTAATGTTAATGGATTTAC
TGTTTTTTTCCCCCCAGGCCAAATTCAGATAATCGACGCCAGGGTGGCAGAGAAAGA
TTGGCCAGTACCAATGACAAGGGAAGTATGGCTATGGAATCTGCCAAGGAGACTCGC
TACTGTGCAGTGTGCAATGACTATGCTTCAGGCTACCATTATGGAGTCTGGTCCTGT
GAGGGCTGCAAGGCCTTCTTCAAGAGAAGTATTCAAGGTAATAGTGTGTTGAAAACG
ACTTCTATTTTTGATCCTATGAGCAGATCCTAAGAGCCAAAGCGACTGGACTGGACT 
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(b) SNPs and primers sequences of IL10 gene promoter region 
GACTATAGAGTGGCAGGGCCAAGGCAGAGCCCAGGCCTCCTGCACCTAGGTCAGTGT
TCCTCCCAGTTACAGTCTAAACTGGAATGGCAGGCAAAGCCCCTGTGGAAGGGGAAG
GTGAAGGCTCAATCAAAGGATCCCCAGAGACTTTCCAGATATCTGAAGAAGTCCTGA
TGTCACTGCCCCGGTCCTTCCCCAGGTAGAGCAACACTCCTCGCCGCAACCCAACTG
GCTCCCCTTACCTTCTACACACACACACACACACACACACACACACACACACACACA
CACAAATCCAAGACAACACTACTAAGGCTTCTTTGGGAAGGGGAAGTAGGGATAGGT
AAGAGGAAAGTAAGGGACCTCCTATCCAGCCTCCATGGAATCCTGACTTCTTTTCCT
TGTTATTTCAACTTCTTCCACCCCATCTTTTAAACTTTAGACTCCAGCCACAGAAGC
TTACAACTAAAAGAAACTCTAAGGCCAATTTAATCCAAGGTTTCATTCTATGTGCTG
GAGATGGTGTACAGTAGGGTGAGGAAACCAAATTCTCAGTTGGCACTGGTGTACCCT
TGTACAGGTGATGTAATATCTCTGTGCCTCAGTTTGCTCACTATAAAATAGAGACGG
TAGGGGTCATGGTGAGCACTACCTGACTAGCATATAAGAAGCTTTCAGCAAGTGCAG
ACTACTCTTACCCACTTCCCCCAAGCACAGTTGGGGTGGGGGACAGCTGAAGAGGTG
GAAACATGTGCCTGAGAATCCTAATGAAATCGGGGTAAAGGAGCCTGGAACACATCC
TGTGACCCCGCCTGTACTGTAGGAAGCCAGTCTCTGGAAAGTAAAATGGAAGGGCTG
CTTGGGAACTTTGAGGATATTTAGCCCACCCCCTCATTTTTACTTGGGGAAACTAAG
GCCCAGAGACCTAAGGTGACTGCCTAAGTTAGCAAGGAGAAGTCTTGGGTATTCATC
CCAGGTTGGGGGGACCCAATTATTTCTCAATCCCATTGTATTCTGGAATGGGCAATT
TGTCCACGTCACTGTGACCTAGGAACACGCGAATGAGAACCCACAGCTGAGGGCCTC
TGCGCACAGAACAGCTGTTCTCCCCAGGAAATCAACT 
 
(c) SNPs and primers sequence of FSHB gene 
AATCCTGTCATGTTTTTCATCATTTTTCTATGCTAAAATTCAAAGTTCCTTTATATTTTGAA
AAATAGTTAATATTTTGATATAGCCATAGGAAGTAAGAAAAGAAATTACTTGTATTTTCTGG
AAGATTTCAAGAACAATTTAGAAATGTAAATAGCATATAGGTCATTTATGAGGTCATGTTTT
AATGGGTAAATGTTAGAGCAAGCAGTATTCAATTTCTGTCTCATTTTGACTAAGCTAAATAG
GAACTTCCACAATACCATAACCTAACTCTCTTCTTAAACTCCTCAGGATCTGGTGTATAAGG
ACCCAGCCAGGCCCAAAATCCAGAAAACATGTACCTTCAAGGAACTGGTATACGAAACAGTG
AGAGTGCCCGGCTGTGCTCACCATGCAGATTCCTTGTATACATACCCAGTGGCCACCCAGTG
TCACTGTGGCAAGTGTGACAGCGACAGCACTGATTGTACTGTGCGAGGCCTGGGGCCCAGCT
ACTGCTCCTTTGGTGAAATGAAAGAATAAAGATCAGTGGACATTTCAGGCCACATACCCTTG
TCCTGAAGGACCAAGATATTCAAAAAGTCTGTGTGTGTGCAATGTGCCCAGGGGACAAACCA
CTGGATCAGGGGATTCAGACTCTACTGATCCCTGGTCTACTGGCAGAGGGAACTCTGGGAAT
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TGAGAGTGCTGGGGGCCAGGACTCCATCATGATTCAGCTCTATATTCCTAGGTCTGATTTCA
TAAGGTTT 
(d) SNPs and primers sequence of INSR gene 
GTAGCATCATTCCATAGCAAGGGTCTGAAATCAGACAAGAAGGATGGGGATGCAGGT
TTGCCTCAGGACATATTGGCCAGGATCTTGGACCAGTTGTGGCTCCTTCCTTGAGTC
TCTGCCATGCCCTCTCCATGGGTGCAGATGCCTGTCCTGTTCTCGGCCATATGCCCA
GTGCCCGGCATGGGTCCTGGATCACAGAACTCATTTCATGAGTGTTTTCGAGGGGGT
TTGGGTGAGGGCTTGGGTGGAAGGTGGCTGCAGACCCCCAAGGGATCCTCCAAGGAT
GCTGTGTAGATAAGTAAGAAGTAGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGT
GGGAGGTGTCTCGAGAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCG
GCATGGTGTATGAGGGCAATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCG
TGGCGGTGAAGACGGTCAACGAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCA
ATGAGGCCTCGGTCATGAAGGGCTTCACCTGCCATCACGTGGTGAGTCCAGTGGGGG
TGGGACATGGGCTGGCTTTCCTGACCCTTCCCTTTCTCTGCCTCCTCCTCCTGCACA
GAGCGACAGAGGACACAGGGTGTAACCTCCTACCCACCCCTCACTCCACTAAGCTTC
CCATCCTAGAGGTGTGAGGAGGGATCATTCCCTTCTCAAATCCCATCCTCTCCCACT
TCGCCTGGAACCAGACTCTATCACTGTCTCATCACTTTCTGGAATGTTTCATTGCTT
TCCAGAATCTTTCATCACTTTC 
Figure 3.2: The sequence highlighted blue represent the forward and reverse 
primers and arrows (purple) shows SNP (a-d). 
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3.6.5 PCR Analysis 
PCR was carried out in a total volume 25 μl reaction mixtures consisting of 50-100 ng 
of DNA template, 10 μmol of each primer, 10 mM dNTP , 10X PCR buffer 
containing15 mM MgCl2 and 5 U/μl Hotstart Taq DNA polymerase (Qiagen, Hilden 
Germany). A DNA-free control was also run at parallel conditions. 
 
PCR reaction mixture 
 Volume of reaction 
 Single reaction 96 reactions 
Master mix   
10X PCR buffer including 
MgCl2 
2.5ul 240ul 
Primer forward 0.5 ul 48 ul 
Primer reverse 0.5 ul 48 ul 
dNTPs 0.5 ul 48 ul 
Hot star Taq polymerase 0.5 ul 48 ul 
Total master mix 4.5 ul 432 ul 
Template DNA Variable according to the 
concentration 
 
Molecular grade water                  Adjustable  
Total volume of reaction 25 ul  
 
3.6.6 Gel electrophoresis and verification of PCR products 
PCR products were visualized by ethidium bromide staining on a 2 % agarose gel 
(Sigma Aldrich, St.Louis Missouri) (Annexure IV). The identities of the PCR 
products were verified by sequencing. The gel electrophoresis of optimized PCR 
products of selected genes was presented in Annexure V. 
 
3.6.7 Purification of PCR product 
The amplification PCR products were purified with Qiaquick PCR purification kit 
(Qiagen, Hilden Germany). The PCR product was purified from nucleotides, primers, 
salts and polymerases using Qiaquick spin columns. (The reagent preparation was 
given in Annexure VI). 
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Procedure 
In 25 µl of PCR sample 125 µl of PB buffer was added and mixed. The QIAquick 
spin column was placed in a provided 2 ml collection tube. The DNA of sample 
bound to the QIAquick column after centrifugation for 30–60 seconds. The flow-
through was discarded and the QIAquick column was placed back into the same tube. 
The membrane bounded DNA was washed by adding 750 µl buffer PE to the 
QIAquick column and centrifuge for 30–60 seconds. The flow-through was discarded 
and placed the QIAquick column back in the same tube then centrifuged the column 
for an additional 1 minute. The QIAquick column was placed in a clean 1.5 ml micro-
centrifuge tube. The DNA was eluted with DEPC treated water (pH 7.0–8.5) to the 
center of the QIAquick membrane and centrifuged the column for 1 minute. The DNA 
concentration and purity were measured using an absorbance ratio of 260/280 nm by 
nanodrop (Thremoscientific, Nanodrop 2000). 
 
3.6.8 DNA sequencing 
The purified products were subject to direct sequencing with either the forward or 
reverse primers. DNA sequencing was carried out with Applied Biosystems, 3730xL 
capillary instruments at Keck Biotechnology Resource Laboratory Yale University 
USA.  The Sanger chemistry for this platform involves dideoxy terminators (ddNTPs) 
tagged with a difference fluorescent dye (Big Dye Terminators), along with AmpliTaq 
polymerase.  The sample undergoes cycle sequencing in a thermo-cycler and then the 
product is bead purified with Beckman Coulter’s Clean SEQ particles (Applied 
Biosystem, New Haven CT). 
 
3.6.9 DNA sequencing data interpretation 
The electrophoretic chromatogram data were received as a computer readable 
sequence file through file transfer protocol (ftp). For each gene the sequence data was 
assembled using the DNA star software to ensure the sequence counting. 
Polymorphisms were identified by using the Laser gene DNA Star sequence counting 
program and were confirmed manually. Each genomic variant was verified only if it 
was observed with forward and reverse primer. All the sequence entries were BLAT 
using UCSC (https://genome.ucsc.edu/cgi-bin/hgBlat?command=start) to confirm the 
related relevance of SNPs with PCOS and endometriosis in prior publications. 
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Then specificity of the selected optimized DNA fragment of all the SNPs were 
validated against human genome from NCBI database by two sequence nucleotide 
alignment BLAST.  
(http://blast.stva.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SP
EC=blast2seq&LINK_LOC=align2seq).  
 
3.7 Hormonal Analysis  
The hormonal analysis of gonadotropins (FSH), sex steroids (Testosterone and 
progesterone) hormones of the samples was measured using specific commercially 
available ELISA kits according to the manufacturer’s instructions. 
 
3.7.1 Follicle stimulating hormone (FSH) 
The hormone, FSH was measured in PCOS women and controls by an ELISA kit 
(Monobind Lake forest, CA, USA), that uses an enzyme immunoassay performed in 
micro-titre plate. With every plate a standard curve was also run and the absorbance 
of the unknown were read against this standard curve. The standards S0-S5 have the 
following concentrations of FSH (0, 5, 10, 25, 50 and 100 mIU/ml). All the samples 
and standards were run in duplicate.  
 Expected values for the FSH ELISA test system (mIU/ml) 
Follicular phase 3.0-12.0 
Mid cycle 8.0-22.0 
Luteal phase 2.0-12.0 
 
The cross-reactivity of the FSH Monobind ELISA test system to selected substances 
was evaluated by adding the interfering substances to a serum matrix at various 
concentrations. 
Substance Cross reactivity Concentration 
Follitropin (FSH) 1.0000 - 
Lutropin Hormone (hLH) <0.0001 1000 ng/ml 
Chorionic Gonadotropin (hCG) <0.0001 1000 ng/ml 
Thyrotropin (TSH) <0.0001 1000 ng/ml 
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3.7.2 Testosterone 
The elevated level of testosterone was measured in PCOS and control group to assess 
the phenotype of the disease.  Competitive Enzyme Immunoassay (EIA) was 
performed to measure the serum level of testosterone by using an ELISA kit 
(Monobind, Lake forest, CA, USA). Testosterone concentration in the sample is 
calculated based on a series of standard. The concentration of standards S1-S5 was 0, 
0.1, 0.5, 1.0, 2.5 and 5 ng/ml. Intra and inter-assay coefficient of variance have been 
determined at multiple points on the standard curve. 
Expected values for the testosterone ELISA test system (ng/ml) 
Female 0.2-0.95 
Male 2.5-10.0 
 
The cross-reactivity of the testosterone Monobind ELISA test system to selected 
substances was evaluated by adding the interfering substances to a serum matrix at 
various concentrations. 
 
 
 
 
 
3.7.3 Progesterone 
Progesterone hormone was measured in endometriosis women and control group 
using an ELISA kit (Monobind, Lake forest, CA, USA). A standard curve was plotted 
and progesterone concentrations in samples were determined by interpolation the 
standard curve. 
 
Expected values for the testosterone ELISA test system (ng/ml) 
Follicular phase 0.15-1.40 
Luteal phase 2.0-25.0 
Substance Cross reactivity 
Testosterone 1.0000 
Dihydotestosterone 0.0178 
Cortisol <0.0001 
Progesterone <0.0001 
Estradiol <0.0001 
  
79 
 
The cross-reactivity of the testosterone Monobind ELISA test system to selected 
substances was evaluated by adding the interfering substances to a serum matrix at 
various concentrations. 
 
 
 
 
 
 
 
 
 
3.8 Statistical analysis 
A simple chi-square test was used to test for Hardy–Weinberg equilibrium in the 
cases and controls. The odd ratios and confidence interval was calculated using 
SigmaPlot 11.0. The mean of various anthropometric parameters was compared by 
student t-test. The maximum likelihood haplotype frequency estimates and standard 
errors were computed using the HAPLO software (Hawley & Kidd, 1995) which 
implements the expectation-maximization (E-M) algorithm of Dempster et al. (1977).  
 
3.9 Haplotype and linkage disequilibrium analysis 
The estimation of haplotype frequencies was carried out by employing the 
FORTRAN software called HAPLO described in Hawley and Kidd (1995). This set 
of computer programs applies the Expectation-Maximization (EM) algorithm of 
Dempster et al (1977) which has been widely applied to estimation problems that can 
only be solved by iterative calculations. The HAPLO calculations for this thesis 
project were run using a Linux compiler on the Louise cluster at the Yale University 
Biomedical High Performance Computing Center which is supported by NIH grants 
RR19895 and RR029676-01. 
“HAPLO is designed to compute haplotype frequency estimates from phenotype data 
based on samples of unrelated individuals. The EM algorithm is a generalized 
iterative maximum likelihood approach to estimation that is useful when data are 
Substance Cross reactivity 
Progesterone  100.00 
Testosterone 0.015 
Androstenedione 0.158 
Dihydotestosterone 0.006 
Cortisol 0.005 
Estradiol 0.004 
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ambiguous and/or incomplete. The next three paragraphs quoted from Hawley and 
Kidd (1995) presents the key ideas underlying the estimation of the haplotype 
frequencies and standard errors.” 
"The EM algorithm is an iterative process; each iteration gives a set of frequency 
estimates that converge to Table maximum likelihood estimates. The iterations start 
with all haplotypes (alleles) at equal frequency. It is easy to show that the frequency 
estimates for haplotypes that are not definitely “observed,” i.e., required to explain a 
phenotype, will go to zero."  
"The HAPLO program optionally estimates standard errors in two ways. First a 
jackknife procedure is used. Estimates of all haplotype frequencies are recalculated 
with each individual in turn removed from the data set. For each haplotype the 
standard deviation of those frequency estimates is an estimate of the standard error of 
the original frequency estimate. This estimate of the standard error takes into account 
the added uncertainty in the data because of the ambiguity and missing data as well as 
the sampling error. The second estimate of the standard error of each haplotype 
frequency applies the formula for the binomial standard error assuming all haplotypes 
were directly observed and counted. This assumption can be correct or a very close 
approximation in some instances and in any case the binomial standard error estimate 
serves as a lower bound check on the jackknife estimates, which can become 
inaccurate when the number of observations is small."  
"The use of a genotype-phenotype correspondence list gives users great flexibility in 
defining the haplotype system. Because the user defines the correspondence, it is not 
necessary to supply any explicit information about the component polymorphic 
systems. Definitions need to be entered only for the observed phenotypes and 
whatever genotypes may be implied; it is not necessary to define all the possible 
combinations of alleles. It is possible to define phenotypes that make use of any 
available phase information or that cover cases where data on the component systems 
are incomplete. Individuals with an ambiguous phenotype that is partially or fully 
resolved are included in the analysis by simply defining a new phenotype that 
corresponds to only the single or few remaining genotype(s). Individuals with missing 
data are included by defining a phenotype that corresponds to the set of genotypes that 
includes all phenotypes at the missing site but only those possible for the typed sites." 
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CHAPTER 4 
RESULTS 
4.1 Population characteristics 
The selected anthropometric characteristics of the study population are summarized in 
Table 4.1-4.3 for endometriosis, PCOS and controls women. The women of 
reproductive active age group between 20 to 40 years were selected. No significant 
difference (p > 0.05) was observed in endometriosis, PCOS and controls regarding 
Body Mass Index (BMI), Waist/Hip Ratio (WHR) and mean age of menarche, they 
were well matched on all other demographic characteristics (Table 4.2, 4.3). The 
proportion of obese women was 96.87 % vs. 95.83% within the PCOS and control 
group respectively (p > 0.05) (Table 4.3). 
The clinical manifestation of various anthropometric characteristics associated with 
endometriosis and PCOS (primary, secondary infertility, pelvic pain and 
dysmenorrhea; oligomenorrhea, hirsutism, infertility and obesity) were represented in 
Figure 4.1, 4.2. The women volunteered as control were without oligomenorrhea, 
hirsutism, dysmenorrhea and infertility. 
 
4.2 Genotype, allele frequencies and Haplotype 
The genotype distribution and relative allele frequencies of all the studied 
polymorphism of ninety-six PCOS patients, fifty-two endometriosis and one hundard-
fourty eight controls were investigated in the female population of Pakistan. The 
Tables in the preceding section illustrates the number of relative genotypes (n), 
percentage of genotype (%), allele frequencies and their percentage, estimated 
heterozygosity (E het), chi square value (χ2)  and odd ratios (OR) at 95% confidence 
interval (CI) along with the p-values. The genotype frequencies of all the single 
nucleotide polymorphisms fit the Hardy-Weinberg principle in all endometriosis, 
PCOS and controls; non-significant p values suggest that alleles are in equilibrium. 
No noteworthy deviations of Hardy-Weinberg ratios were observed for all of the 
SNPs studied and tested separately in the affected and control groups since the 
expected and observed genotype frequencies were not significantly different using a 
“p” value of 1%. The genotype and allele frequencies of the polymorphisms in the 
study were determined by simple allele and genotype counting. 
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Table 4.1: Anthropometric characteristics of PCOS, endometriosis and controls. 
Population  
characteristics 
PCOS (n= 96) Endometriosis (n= 52) Controls (n= 148) 
n (%) n (%) n (%) 
Education 
   Illiterate 37 (38.5) 19 (36.5) 47 (31.8) 
Up to primary 11 (11.5) 8 (15.4) 23 (15.5) 
Higher secondary 33 (34.4) 18 (34.6) 56 (37.8) 
Graduate and above 16 (16.7) 7 (13.5) 22 (19.9) 
Age of patients 
   20-30 years 47 (48.9) 21 (40.4) 63 (42.6) 
31-40 years 49 (51.1) 31 (59.6) 85 (57.4) 
Duration of 
marriage 
   01-05 years 35 (36.4) 25 (48.0) 67 (45.3) 
06-10 years 31 (32.2) 17 (32.7) 54 (36.5) 
11-15 years 14 (14.6) 8 (15.4) 17 (11.4) 
16 and above 16 (16.6) 2 (3.8) 10 (6.7) 
Primary Infertility 59 (61.5) 30 (57.6) 0 
Secondary 
Infertility 37 (38.5) 22 (42.3) 0 
Family H/O 
   Hirsutism 23 (23.9) 4 (9.6) 9 (6.0) 
Obesity 43 (44.8) 11 (21.2) 29 (30.2) 
Menstrual problems 23 (23.9) 7 (13.5) 5 (5.2) 
Thyroid 
abnormalities 
3 (3.13) 
0 
0 (0) 
DM 39 (40.6) 9 (17.3) 11 (11.5) 
Infertility 23 (23.9) 2 (3.8) 1  (1.04) 
PCOS 19 (19.8) 1 (1.9) 0 
Endometriosis 
 
13 (25) 
 Patient H/O 
   Diabetes Mellitus  11 (11.5) 0 16 (10.8) 
Infertility 86 (89.6) 49 (94.2) 0 
Weight gain 88 (91.7) 5 (9.6) 13 (8.8) 
Hirsutism 89 (92.7) 0 0 
Facial hair 90 (93.75) 2 (3.9) 4 (2.7) 
Acne 70 (72.9) 7 (13.5) 9 (6.0) 
Oligomenorrhea 88 (91.7) 0 
 
Diagnosis  
   Ultrasound, Clinically 87 (90.6) 37 (71.1) - 
Clinically 9 (9.3) 15 (28.8) 
 Age of Menarche 
   11-13 year 88 (91.7) 47 (90.3) 131 (88.5) 
14 to onward 8 (8.3) 5 (9.6) 17 (11.5) 
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Table Continued… 
 
    
Pattern of cycle 
   Regular 9 (9.4) 23 (44.2) 131 (88.5) 
Irregular 87 (90.6) 29 (55.7) 11 (7.5) 
History of pain 
   Pelvic pain 23 (24.0) 43 (82.7) 11 (7.4) 
Back pain 27 (28.1) 44 (84.5) 44 (29.7) 
Dysmenorrhea 11 (11.5) 37 (71.2) 23 (15.5) 
Dyschezia 5 (5.2) 27 (51.9) 5 (3.4) 
Dysuria 7 (7.3) 11 (21.2) 4 (2.7) 
Dyspareunia 11 (11.5) 31 (59.6) 19 (12.8) 
 
 
 
Table 4.2: Anthropometric characteristics of women with endometriosis and 
controls, the values given are mean ± S.D. The mean values of two groups were 
compared by “t” test. 
 
Characteristics Endometriosis  
(n= 52) 
Controls  
(n= 52) 
p 
Mean ± S.D Mean ± S.D 
Age (year) 30.25 ± 5.46 30.59 ± 4.95 > 0.05 
BMI (Kg/m
2
) 25.12 ± 2.72 25.57 ± 2.08 > 0.05 
WHR 0.80 ± 0.04 0.79 ± 0.06 > 0.05 
    
Gynaecological history n (%) n (%)  
Primary Infertility 30 (57.69) 0 < 0.001 
Secondary Infertility 22 (42.31) 0 < 0.001 
Pelvic pain 49 (94.23) 12 (23.07) < 0.001 
Dysmenorrhea 50 (96.15) 6 (11.53) < 0.001 
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Table 4.3: Anthropometric characteristics of women with PCOS and controls. 
The values given are mean ± S.D. The mean values of two groups were compared 
by “t” test. 
Characteristics PCOS (n= 96) Controls (n= 96)  
Mean ± S.D Confidence  
Level 95% 
Mean ± S.D Confidence 
 Level 95% 
p 
Age (Year) 26.87 ± 4.42 0.89 26.02 ± 3.52 0.561 > 0.05 
BMI (Kg/m
2
) 31.10 ± 1.47 0.83 30.49 ± 1.66 0.742 > 0.05 
WHR 1.16 ± 0.07 0.01 1.12 ± 0.05 0.011 > 0.05 
Age of Menarche 
(Year) 
13.09 ± 1.06 0.21 13.07 ± 1.52 0.022 > 0.05 
 
Gynecological history 
 
Characteristics n= 96 % n= 96 % p 
Oligomenorrhea 
(Less than 9 menses 
 per year) 
88 91.67 0 0 < 0.001 
H/O irregular 
menses with weight 
gain 
85 88.54 0 0 < 0.001 
 
Family history 
 
Hirsutism 23 23.96 0 0.00 < 0.001 
Obesity 43 44.79 29 30.21 < 0.001 
Menstrual problems 23 23.96 5 5.21 < 0.001 
Thyroid 
abnormalities 
3 3.13 0 0.00 < 0.001 
DM 39 40.63 11 11.46 < 0.001 
Infertility 23 23.96 1 1.04 < 0.001 
PCOS 19 19.79 0 0.00 < 0.001 
Subject  Symptoms 
Infertility 86 89.58 0 0.00 < 0.001 
Obesity 93 96.87 92 95.83 > 0.05 
Hirsutism 89 92.71 0 0.00 < 0.001 
Facial hair 90 93.75 0 0.00 < 0.001 
Acne 70 72.91 0 0.00 < 0.001 
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Figure 4.1: Clinical manifestation of anthropometric characteristics in 
endometriosis compared with control along with percentage symptoms. 
 
 
Figure 4.2: Clinical manifestation of anthropometric characteristics in PCOS 
compared with control along with percentage symptoms. 
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4.3 Endometriosis 
The SNPs and genetic variations of ESR1, ESR2, PGR, IL10 and FSHR genes 
associated with the diagnosis of endometriosis with infertility were studied. 
 
4.3.1 Estrogen receptor alpha (ESR1) 
The contribution of the genomic variants of ESR1 was studied for two SNPs 
rs2234693 and rs9340799. Both ESR1 polymorphisms are in intron 1 and separated 
by only 51 base pairs. The rs2234693 polymorphism is characterized by a T→C 
transition 397 nucleotide upstream in the intron 1. The rs9340799 polymorphism 
marks an A→G transition 351 nucleotides upstream in intron 1. The mutations of 
ESR1 gene in two sequence BLAST alignment are shown in Figure 4.3. The sequence 
chromatogram showed homozygous and heterozygous form of T/C base substitution 
of rs2234693 (Figure 4.4). The genotype distribution and relative allele frequencies 
for ESR1 gene are shown in Table 4.4. The frequency of the rs2234693 “C” allele was 
43.3% in the patients and 35.6 % in the control group. No significant differences were 
observed for comparative genotype distribution and relative allele frequencies of SNP 
rs2232693 between endometriosis and controls (p = 0.301, OR = 1.381, 95% CI = 
0.79-2.41, χ2 = 0.99). We had also found no statistically significant differences in the 
genotypes and allele frequencies between endometriosis and control group for 
rs9340799 (p = 0.220, OR = 1.425, 95% CI = 0.82-2.47, χ2 = 1.26). A novel SNP 
rs11155815 was found during the screening of DNA sequencing map. Two were 
homozygous for rs11155815 T allele, 16 were heterozygous and there were 34 
subjects homozygous for C allele. The heterozygotes CT were 30.8% in patients with 
endometriosis and 21.2% in controls. As the homozygous TT genotype and 
heterozygous CT genotype was rare both in endometriosis and controls, the TT and 
CT were combined together and are referred as variants genotype of this new SNP. 
The frequency of variant genotype was different in both groups. The frequency of the 
rs11155815 “T” allele was 19.2% in the patients and 12.5% in the control group. 
Comparison of frequencies between patients and control groups show no statistically 
significant difference between them (p = 0.150, OR = 1.833, 95% CI = 0.87-3.87, χ2 = 
2.02). The SNPs rs8179176, rs11155816, rs4986936 and rs4986937 were not 
significantly associated with endometriosis (Table 4.4). This suggested that the 
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genetic variants of ESR1 gene were not related in the occurrence of endometriosis in 
Pakistani women. Interestingly, the haplotype analysis showed distinct variations 
among endometriosis and control groups. The frequency of haplotypes “GAT, AAC 
and GGC” was 0.301, 0.091 and 0.164 respectively in endometriosis whereas the 
haplotypes “GAC, AAT and GGT” were common in controls with frequencies 0.301, 
0.035 and 0.264 respectively (Table 4.5; Figure 4.5). The overall haplotype 
distributions in the two groups differ at a p-value of less than 0.005. Also the highly 
significant value (p < 0.005, χ2 = 24.3) of genetic heterogeneity test showed that the 
haplotype frequency estimates for the population samples being compared are from 
the same population. The pairwise linkage disequilibrium (LD) or Delta-squared 
value for the ESR1 gene is shown in Figure 4.6.  
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(a) Alignment of two sequences BLAST (Endometriosis) 
 
 
Query  493   CCAATGCTCATCCCAACTCTAGACCACACTCAGGGTCTCTGGGAAACAGAGACAAAGCAT  552 
             ||||||||||||||||||| |||||||||||||||||||||||||||||||||||||||| 
Sbjct  327   CCAATGCTCATCCCAACTCCAGACCACACTCAGGGTCTCTGGGAAACAGAGACAAAGCAT  386 
 
Query  553   AAAACAGCTGGGACATTTGGAACTCAGATGAACTGATGGACAACACAGAACATGTGTCAA  612 
             ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  387   AAAACGGCTGGGACATTTGGAACTCAGATGAACTGATGGACAACACAGAACATGTGTCAA  446 
 
 
(b) Alignment of two sequences BLAST (Control) 
 
Query  480   GAACCATTAGAGACCAATGCTCATCCCAACTCTAGACCACACTCAGGGTCTCTGGGAAAC  539 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  316   GAACCATTAGAGACCAATGCTCATCCCAACTCTAGACCACACTCAGGGTCTCTGGGAAAC  375 
 
Query  540   AGAGACAAAGCATAAAACAGCTGGGACATTTGGAACTCAGATGAACTGATGGACAACACA  599 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  376   AGAGACAAAGCATAAAACAGCTGGGACATTTGGAACTCAGATGAACTGATGGACAACACA  435 
 
Figure 4.3: Two sequence BLAST alignment of ESR1 gene polymorphisms. 
 
 
 
 
Figure 4.4: Sequence chromatogram showing homozygous and heterozygous 
form of T/C base substitution of rs2234693. 
C 
T 
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Figure 4.5: Multi-SNPs haplotype percent frequency distribution for 
endometriosis and controls at ESR1 gene. 
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Table 4.4: Frequency distribution of single nucleotide polymorphisms of ESR1 gene with risk of endometriosis in Pakistani women. 
SNPs ID Genotype/allele 
frequencies 
Endometriosis  
(n= 52) 
Controls  
(n= 52) 
OR  (95% CI)  χ2 p HWE 
n % n % 
rs2234693 TT 17 32.7 22 42.3 0.662       
(C>T) CT 25 48.1 23 44.2 (0.29-1.47) 0.65 0.410 >.05 
Intron 1 CC 10 19.2 7 13.5         
  Allele frequency                 
  C allele  45 43.3 37 35.6 1.381       
  T allele  59 56.7 67 64.4 (0.79-2.41) 0.99 0.301 >.05 
  E(HET)   49   46         
rs9340799 AA 15 28.8 20 38.5 0.686       
(G>A) GA 25 48.1 24 46.2 (0.30-1.56) 0.48 0.480 >.05 
Intron 1 GG 12 23.1 8 15.4         
  Allele frequency                 
  G allele  49 47.1 40 38.5 1.425       
  A allele  55 52.9 64 61.5 (0.82-2.47) 1.26 0.220 >.05 
  E(HET)   50   47         
rs11155815 CC 34 65.4 40 76.9 0.567       
(C>T) CT 16 30.8 11 21.2 (0.24-1.34) 1.17 0.270 >.05 
Intron 1 TT 2 3.8 1 1.9         
  Allele frequency                 
  C allele  84 80.8 91 87.5 1.833       
  T allele  22 19.2 13 12.5 (0.87-3.87) 2.02 0.150 >.05 
Table continues…………… 
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  E(HET)   31   22         
rs8179176 CC 41 78.8 48 92.3 0.285       
(C>T) CT 11 21.1 4 7.7 (0.08-0.95) 3.69 0.060 >.05 
Intron 1 TT 1 1.9 0 0         
  Allele frequency                
  C Allele  96 92.3 100 96.5 0.295       
  T Allele  13 12.5 4 3.8 (0.09-0.93) 3.46 0.050 >.05 
   E(HET)   20   7         
rs11155816 TT 46 88.5 46 88.5 1       
(C>T) TC 5 9.6 6 11.5 (0.30-3.31) 0.09 0.750 >.05 
Intron 1 CC 1 1.9 0 0         
  Allele frequency                 
  C Allele  7 6.7 6 5.8 1.212       
  T Allele  97 93.3 98 94.2 (0.35-4.10) 0.05 1.000 >.05 
   E(HET)   13   11         
rs4986936 TT 46 88.5 51 98.1 0.150       
(G>A) CT 5 9.6 1 1.9 (0.01-1.29) 2.45 0.110 >.05 
Intron 1 CC 1 1.9 0 0         
  Allele frequency                 
  G Allele  7 6.7 1 99 6.280       
  A Allele  97 93.3 103 1 (0.88-45.02) 7.28 0.070 >.05 
   E(HET)   9   2         
rs4986937 GG 46 88.5 48 92.3 0.640       
(C>T) AG 6 11.5 4 7.7 (0.17-2.41) 0.11 0.730 >.05 
 
 
        
  
92 
 
Table Continue…... 
 
Intron 1 AA 0 0 0 0         
  Allele frequency                 
  G Allele  98 94.2 100 96.2 1.531       
  A Allele  6 5.8 4 3.8 (0.41-5.59) 0.11 0.701 >.05 
 
SNPs ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg equilibrium; χ2: Chi square. 
 
Table 4.5: Multi-SNPs haplotype frequency estimates for endometriosis and controls at ESR1 gene. 
Groups Haplotype frequencies ± S.E.E Exp. 
Het 
Global LD  
LR ChiSq 
p Genetic 
Heterogeneity 
Test 
GAT GAC GGT GGC AAC AGT AGC AAT  Chi Sq p 
Endometriosis 0.301 
± 
0.037 
0.174 
± 
0.017 
0.168 
± 
0.016 
0.164 
± 
0.010 
0.091 
± 
0.015 
0.059 
± 
0.033 
0.043 
± 
0.023 
0.000 
± 
0.000 
81.00 4.70 0.050 
24.30 0.005 
Control 0.268 
± 
0.028 
0.310 
± 
0.067 
0.264 
± 
0.039 
0.033 
± 
0.060 
0.032 
± 
0.049 
0.049 
± 
0.062 
0.009 
± 
0.029 
0.035 
± 
0.018 
75.70 10.40 0.050 
 
Exp. Het: Expected Heterozygosity; Global LD LR Chi Sq: Global likelihood ratio chi-square; Chi Sq: Chi square; S.E.E: Standard error of estimation; p: Significance
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Figure 4.6: Pairwise linkage disequilibrium of ESR1 gene in endometriosis and 
controls. 
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4.3.2 Estrogen receptor beta (ESR2) 
The ESR2 gene was studied for polymorphism rs4986938 which is a G→A change at 
position 1859 in the 3′-untranslated region (3′-UTR) of exon 8. The genotype 
frequency of G/A polymorphism in endometriosis group was significantly different 
from that of controls. The mutant allele “A” was in significantly higher frequency 
among the endometriosis (38.5%) compared to the controls (20.2%) yielding an odds 
ratio of 2.470 (p = 0.006, OR: 1.360; CI: 0.16-0.80; χ2 = 7.52). As the homozygous 
GG genotype was more frequent in controls (63.5%) compared with (38.5%) in 
endometriosis (Table 4.6). The heterozygous GA genotype and the AA were 
combined together and are referred as variants genotype of rs4986938. The frequency 
of variant genotype of rs4986938 was different in both groups (32/52 vs. 19/52 in 
endometriosis and controls respectively). 
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       Table 4.6: Frequency distribution of single nucleotide polymorphism of ESR2 gene with risk of endometriosis in Pakistani 
        women. 
SNP ID Genotype/allele 
frequencies 
Endometriosis 
(n= 52) 
Controls 
(n= 52) 
OR (95% CI)  χ2 p HWE 
n % n % 
                   
rs4986938 GG 20 38.5 33 63.5 1.360       
(G>A) AG 24 46.2 17 32.7 (0.16-0.80) 5.54 0.010 >.05 
UTR-3 AA 8 15.4 2 3.8        
  Allele frequency                
  G allele 64 61.5 83 79.8 2.470       
  A allele  40 38.5 21 20.2 (0.20-0.75) 7.52 0.006 >.05 
  E(HET)   47   32         
 
SNP ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg equilibrium; χ2: Chi square. 
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4.3.3 Interleukin 10 (IL10) 
To determine whether the IL10 SNP loci were associated with endometriosis; we 
initially compared the single-point genotype and allele distribution of these SNPs in 
the endometriosis and control groups. The mutations of IL10 gene in two sequence 
BLAST alignment for endometriosis and controls are shown in Figure 4.7. The 
sequence chromatogram showed homozygous and heterozygous form of T/C base at 
rs1800871 (Figure 4.8). We observed an association of IL10 gene polymorphism and 
endometriosis group, the genotype distribution and relative allele frequencies of the 
inflammation mediator gene are shown in Table 4.7. The IL10 rs1800872 mutant 
allele “A” was significantly overexpressed (2.379 folds) in women with endometriosis 
than controls (44.2% vs. 25%; p < 0.006, OR = 2.379, 95% CI = 0.23-0.75). We found 
highly significant association between different genotypes (Table 4.7) with 
endometriosis group. In SNP rs1800871 the frequency of T allele was higher in 
endometriosis patient (38.5% vs. 26%; p = 0.010, OR = 0.443, 95% CI = 0.19-0.92). 
In the IL10 PCR products DNA sequencing map, a new SNP rs1800894 was found at 
genomic position 206946666 in which the substitution is G to A. No significant 
association was found in both groups with this SNP (Table 4.7). In rs1800896 a 
statistically significant (p = 0.007) higher frequency of the “G” allele was observed in 
patients than in controls (Table 4.7). The frequency of “A” (51.9% in endometriosis 
and 71.2% in controls) and “G” (48.1% in endometriosis and 28.8% in control) allele 
differ significantly in endometriosis and control groups (p = 0.007, OR = 1.435, 95% 
CI = 0.24-0.77). 
Haplotype estimation analysis of three SNPs genotype data by means of maximum 
likelihood method revealed that estimated overall haplotype frequencies in 
endometriosis and control groups differ significantly (Table 4.8). Eight major 
haplotypes of IL10 were present in the study population and the frequency of most 
common haplotypes is shown in Figure 4.9. In single haplotype association the ATG, 
CTG and ACG are more frequent in the endometriosis group, while the haplotype 
CCA, CCG and CTA were found frequent in the control group. The other low 
frequencies haplotypes showed borderline difference. The genetic heterogeneity test 
showed a strong significance (p < 0.005, χ2 = 22.2) between endometriosis and control 
groups. The pairwise LD analysis between four loci revealed week R-squared or 
Delta-squared value in both the groups (Figure 4.10). 
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(a) Alignment of two sequences BLAST (Endometriosis) 
 
Query  13   AATTCTCAGTTGGCACTGGTGTACCCTTGTACAGGTGATGTAACATCTCTGTGCCTCAGT  72 
            ||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||| 
Sbjct  46   AATTCTCAGTTGGCACTGGTGTACCCTTGTACAGGTGATGTAATATCTCTGTGCCTCAGT  105 
 
Query  73   TTGCTCACTATAAAATAGAGACGGTAGGGGTCATGGTGAGCACTACCTGACTAGCATATA  132 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  106  TTGCTCACTATAAAATAGAGACGGTAGGGGTCATGGTGAGCACTACCTGACTAGCATATA  165 
 
(b) Alignment of two sequences BLAST (Control) 
Query  15   AATTCTCAGTTGGCACTGGTGTACCCTTGTACAGGTGATGTAATATCTCTGTGCCTCAGT  74 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  46   AATTCTCAGTTGGCACTGGTGTACCCTTGTACAGGTGATGTAATATCTCTGTGCCTCAGT  105 
 
Query  75   TTGCTCACTATAAAATAGAGACGGTAGGGGTCATGGTGAGCACTACCTGACTAGCATATA  134 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  106  TTGCTCACTATAAAATAGAGACGGTAGGGGTCATGGTGAGCACTACCTGACTAGCATATA  165 
 
Figure 4.7: Two sequence BLAST alignment of IL10 gene polymorphisms. 
 
 
 
 
 
Figure 4.8: Sequence chromatogram showing homozygous and heterozygous 
form of C/T base substitution of rs1800871. 
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Figure 4.9: Multi-SNPs haplotype percent frequency distribution for 
endometriosis and controls at IL10 gene. 
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Table 4.7: Frequency distribution of single nucleotide polymorphisms of IL10 gene with risk of endometriosis 
 in Pakistani women. 
SNPs ID Genotype/allele 
frequencies 
Endometriosis 
(n= 52) 
Controls  
(n= 52) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                   
rs1800872 CC 17 32.7 29 55.8 0.385      
(C>A) AC 24 46.2 20 38.5 (0.17-0.85) 4.71 0.030 >.05 
UTR-5 AA 11 21.2 3 5.8        
  Allele frequency                
  C allele  58 55.8 78 75 2.379      
  A allele  46 44.2 26 25 (0.23-0.75) 7.67 0.006 >.05 
  E(HET)   47   38        
rs1800871 CC 19 36.5 30 57.7 0.422      
(C>T) TC 24 46.2 20 38.5 (0.24-0.80) 3.86 0.049 >.05 
UTR-5 TT 9 17.3 2 3.8        
  Allele frequency                 
  C allele  62 61.5 80 74 0.443       
  T allele  42 38.5 24 26 (0.19-0.92) 6.41 0.010 >.05 
  E(HET)   48   38         
rs1800894 GG 44 84.6 48 92.3 0.357      
(G>A) AG 7 13.5 4 7.7 (0.12-1.60) 0.85 0.357 >.05 
UTR-5 AA 1 1.9 0 0         
  Allele frequency                
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Table continues………… 
  G allele  95 91.3 100 96.2 0.543       
  A allele  9 8.7 4 3.8 (0.15-1.91) 0.43 0.501 >.05 
rs1800896 AA 14 26.9 26 50 0.368       
(G>A) AG 26 50 22 42.3 (0.16-0.83) 4.91 0.027 >.05 
UTR-5 GG 12 23.1 4 7.7         
  Allele 
frequency 
                
  A allele  54 51.9 74 71.2 1.435       
  G allele  50 48.1 30 28.8 (0.24-0.77) 7.33 0.007 >.05 
  E(HET)   50  41        
                    
 
 SNPs ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg Equilibrium; χ2: Chi square.     
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Table 4.8: Multi-SNPs haplotype frequency estimates for endometriosis and controls at IL10 gene. 
 
Groups Haplotype frequencies ± S.E.E Exp. 
Het 
Global 
LD LR 
ChiSq 
p Genetic 
Heterogeneity 
Test 
CCA CCG CTA ACA ACG CTG ATG ATA  
ChiSq 
p 
Endometriosis 
0.186 
± 
0.029 
0.165 
± 
0.038 
0.120 
± 
0.031 
0.169 
± 
0.042 
0.075 
± 
0.028 
0.087 
± 
0.025 
0.154 
± 
0.027 
0.044 
± 
0.030 
84.70 4.90 0.050 
22.20 0.050 Control 
0.368 
± 
0.031 
0.195 
± 
0.062 
0.161 
± 
0.016 
0.165 
± 
0.081 
0.042 
± 
0.058 
0.026 
± 
0.035 
0.025 
± 
0.052 
0.018 
± 
0.057 
78.40 2.00 0.050 
 
Exp. Het: Expected Heterozygosity; Global LD LR Chi Sq: Global likelihood ratio chi-square; Chi Sq: Chi square; S.E.E: Standard error of estimation; p: Significance 
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Figure 4.10: Pairwise linkage disequilibrium of IL10 gene in endometriosis and 
controls. 
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4.3.4 Progesterone receptor (PGR) 
PGR gene was analyzed for rs1042838 in exon 4 and rs10895068 in promoter region 
by direct sequencing. In SNP rs1042838 the genotype and allele frequencies showed 
distinct variations (Table 4.9) in endometriosis group. In contrast little variations were 
found in control group. The frequency of “T” (22.1% in endometriosis and 6.7% in 
control) and “G” (77.9% in endometriosis and 93.3% in controls) allele differ 
significantly in endometriosis and control groups (p = <0.003, OR = 1.935, 95% CI = 
0.10-0.62). The PGR rs1042838 mutant allele “T” was significantly overexpressed 
(1.935 folds) in women with endometriosis than controls (p < 0.003). We studied 
another polymorphism in rs10895068, no significant difference in genotype and allele 
frequencies was observed between endometriosis and control groups (p = 0.210) 
(Table 4.9).  
Much stronger associations were observed when the two SNPs were considered 
together as haplotypes. When the estimated haplotype frequencies were compared 
between endometriosis and control, the most common haplotype GG (0.875 vs. 0.679 
in controls and endometriosis respectively) was found to be more prevalent in the 
control group (Figure 4.11) whereas the TG (0.205 vs. 0.067 in endometriosis and 
controls respectively), GA (0.099 vs. 0.058 in endometriosis and controls 
respectively) was more common among endometriosis patients (Table 4.10). The 
genetic heterogeneity test comparing the affected and control haplotype frequencies 
overall differ from each other at p-value = 0.010 significance level. The pairwise LD 
analysis revealed week LD for the pairs of loci in the endometriosis and control group 
(Figure 4.12). 
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Figure 4.11: Multi-SNPs haplotype percent frequency distribution for 
endometriosis and controls at PGR gene. 
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   Table 4.9: Frequency distribution of single nucleotide polymorphisms of PGR gene with risk of endometriosis in Pakistani women. 
SNPs ID Genotype/allele 
frequencies 
Endometriosis 
(n= 52) 
Controls  
(n= 52) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                   
rs1042838 GG 32 61.5 45 43.3 1.249      
(G>T) TG 17 32.7 7 6.7 (0.09-0.65) 7.20 0.007 >.05 
Exon 4 TT 3 5.8 0 0        
  Allele frequency                
  G allele  81 77.9 97 93.3 1.935      
  T allele  23 22.1 7 6.7 (0.10-0.62) 8.76 0.003 >.05 
  E(HET)   34   13         
  GG 41 78.8 46 88.5 0.482       
rs10895068 AG 10 19.2 6 11.5 (0.16-1.40) 1.12 0.280 >.05 
(G>A) AA 1 1.9 0 0         
UTR Allele frequency                
  G allele  92 88.5 98 94.2 1.130       
  A allele  12 11.5 6 5.8 (0.17-1.30) 1.52 0.210 >.05 
  E(HET)   20   11         
 
        SNPs ID: single nucleotide polymorphisms identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg Equilibrium; χ2: Chi square.     
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Table 4.10: Multi-SNPs haplotype frequency estimates for endometriosis and controls at PGR gene. 
Groups Haplotype frequencies ± S.E.E Exp. Het Global LD  
LR ChiSq 
p Genetic 
Heterogeneity 
Test 
GG TG GA TA  Chi Sq p 
Endometriosis 0.679±0.046 0.205±0.040 0.099±0.029 0.017±0.013 48.90 0.40 0.050 
12.60 0.010 
Control 0.875±0.032 0.067±0.025 0.058±0.023 0.000±0.000 22.70 0.90 0.050 
 
Exp. Het: Expected Heterozygosity; Global LD LR Chi Sq: Global likelihood ratio chi-square; Chi Sq: Chi square; S.E.E: Standard error of estimation; p: Significance 
 
 
 
 
 
 
 
 
 
Figure 4.12: Pairwise linkage disequilibrium of PGR gene in endometriosis and controls 
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4.3.5 Follicle stimulating hormone receptor (FSHR) 
The two common polymorphisms of the FSHR gene in exon 10 were screened among 
104 individuals (52 endometriosis and 52 controls). The mutations of FSHR gene in 
two sequence BLAST alignment are shown in Figure 4.13. The sequence 
chromatogram showed homozygous and heterozygous form of A/G base substitution 
of rs6166 (Figure 4.14).The genotype, allele and haplotype frequencies of both the 
polymorphisms were agreed with the Hardy-Weinberg equilibrium in endometriosis 
and controls. The distribution of allele and genotype frequency along with odd ratios 
and significance for association with endometriosis are shown in Table 4.11. In SNP 
rs6166 A>G, the frequencies of genotype AA, AG and GG were 46.2% (24/52), 
44.2% (23/52) and 9.6 % (5/52) in women with endometriosis while 11.5% (6/52), 
44.2% (23/52) and 44.2 % (23/52) in healthy controls respectively. Moreover, we 
observed that in SNP rs6166 the women with endometriosis had significantly higher 
frequency of allele A in comparison with control (68.3% vs. 33.7%; OR. 4.240, 95% 
CI. 2.37- 7.57, p < 0.001). In SNP rs6165 A>G the frequencies of genotype AA, AG 
and GG were 46.2% (24/52), 42.3% (22/52) and 11.5 % (6/52) in the women with 
endometriosis while 13.5% (7/52), 48.1% (25/52) and 38.5 % (20/52) in healthy 
controls respectively. In rs6165 the frequency of allele A was 67.3 vs. 37.5 in 
endometriosis and in controls respectively (OR = 3.430, 95% CI = 1.94-6.07, p < 
0.001). 
The frequency of AA haplotype was 45.5% and 16.3% in patients and controls. 
Interestingly the frequency of GG haplotype was inverse, 9.9% and 45.2% was 
observed in patients and controls respectively Figure 4.15. The haplotypes AA and 
GG showed distinct difference both in women with endometriosis and controls (Table 
4.12). The pairwise LD value was 0.76 for both sites. This r
2
 value suggests that these 
two polymorphisms are in strong linkage disequilibrium (Figure 4.16). 
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(a) Alignment of two sequences BLAST (Endometriosis) 
 
Query  93   TCTTCAGCTCCCAGAGTCACCAGTGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTA  152 
            |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
Sbjct  62   TCTTCAGCTCCCAGAGTCACCAATGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTA  121 
 
Query  153  GCCCAAAACTAAAACACAATGTGAAAATGTATCTGAGTATTGAATGATAATTCAGTCTTG  212 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  122  GCCCAAAACTAAAACACAATGTGAAAATGTATCTGAGTATTGAATGATAATTCAGTCTTG  181 
 
(b)  Alignment of two sequences BLAST (Control) 
Query  95   TTCAGCTCCCAGAGTCACCAGTGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGC  154 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  66   TTCAGCTCCCAGAGTCACCAGTGGTTCCACTTACATACTTGTCCCTCTAAGTCATTTAGC  125 
 
Query  155  CCAAAACTAAAACACAATGTGAAAATGTATCTGAGTATTGAATGATAATTCAGTCTTGCC  214 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  126  CCAAAACTAAAACACAATGTGAAAATGTATCTGAGTATTGAATGATAATTCAGTCTTGCC  185 
 
Figure 4.13: Two sequence BLAST alignment of FSHR gene polymorphisms. 
 
 
 
 
Figure 4.14: Sequence chromatogram showing homozygous and heterozygous 
form of A/G base substitution of rs6166. 
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Figure 4.15: Multi-SNPs haplotype percent frequency distribution for 
endometriosis and controls at FSHR gene. 
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Table 4.11: Frequency distribution of single nucleotide polymorphisms of FSHR gene with risk of endometriosis in Pakistani  women. 
SNPs ID Genotype/allele 
frequencies 
Endometriosis  
(n= 52) 
Controls 
(n= 52) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                    
 rs6166 AA 24 46.2 6 11.5 6.570       
(A>G) AG 23 44.2 23 44.2 (2.39-18.01) 13.53 0.001 >.05 
Exon 10 GG 5 9.6 23 44.2        
  Allele frequency                
  A Allele  71 68.3 35 33.7 4.240       
  G Allele  33 31.7 69 66.3 (2.37- 7.57) 23.56 0.001 >.05 
  E(HET)   43   45        
rs6165 AA 24 46.2 7 13.5 5.511       
(A>G) AG 22 42.3 25 48.1 (2.09-14.46) 11.76 0.001 >.05 
Exon 10 GG 6 11.5 20 38.5         
  Allele frequency                 
  A Allele  70 67.3 39 37.5 3.430       
  G Allele  34 32.7 65 62.5 (1.94-6.07) 17.35 0.001 >.05 
  E(HET)   44   47         
 
SNPs ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg Equilibrium; χ2: Chi square.     
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 Table 4.12: Multi-SNPs haplotype frequency estimates for endometriosis and controls at FSHR gene. 
Groups Haplotype frequencies ± S.E.E Exp. 
Het 
Global LD  
LRChiSq 
p Genetic 
Heterogeneity 
Test 
AA GA AG GG  Chi Sq p 
Endometriosis 0.455±0.049 0.218±0.041 0.228±0.041 0.099±0.029 68.90 0.00 >0.05 
38.60 0.001 
Control 0.163±0.051 0.212±0.061 0.173±0.054 0.452±0.049 69.90 1.00 >0.05 
 
Exp. Het: Expected Heterozygosity; Global LD LR Chi Sq: Global likelihood ratio chi-square; Chi Sq: Chi square; S.E.E: Standard error of estimation; p: Significance 
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Figure 4.16: Pairwise linkage disequilibrium of FSHR gene polymorphisms in endometriosis and controls. 
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4.4 PCOS 
The SNPs of ADIPOQ, INSR, FSHR, FSHB, LHCGR, LHB, ESR1 and ESR2 genes 
were investigated in PCOS Pakistani women. 
 
4.4.1 Adiponectin (ADIPOQ) 
To determine whether the adiponectin SNP loci at exon 2 (45T→G) and Intron 2 
(276G→T) were associated with PCOS; we initially compared the single-point 
genotype and allele distribution of these SNPs in the PCOS and control groups. The 
mutations of ADIPOQ gene in two sequence BLAST alignment are shown in Figure 
4.17. The sequence chromatogram showed homozygous and heterozygous form of 
T/C base substitution of rs2241766 (Figure 4.18). We observed an association of 
ADIPOQ gene polymorphism and PCOS group, the gene and allele frequencies are 
given in Table 4.13. Seventy five subjects were homozygous for rs2241766 T allele, 
20 were heterozygous GT and there was 1 subject homozygous for G in PCOS group. 
The ADIPOQ rs2241766 “TT” genotype compared with “TG and GG” genotypes was 
associated with a 3.725 folds increased risk for PCOS in the study population (p < 
0.001, OR = 3.725, 95% CI = 1.98-6.97). Furthermore, the ADIPOQ rs2241766 
mutant allele “T” was significantly overexpressed (3.345 folds) in women with PCOS 
(88.5%) than controls (69.8%), (p < 0.001, OR = 3.345, 95% CI = 1.95-5.74). In 
rs1501299 the homozygous TT genotype and heterozygous TG genotype was 
infrequent both in PCOS and controls (Table 4.13), the TT and TG was combined 
together as referred variants genotype of rs1501299. The frequency of variant 
genotype of rs1501299 was different in both groups. We did find a moderate 
significant association between different genotypes (Table 4.13) in both the groups. In 
SNP rs1501299 the frequency of T allele was higher in PCOS patient (23.4% vs. 
15.1%, p = 0.050, OR = 0.581, 95% CI = 0.34-0.97). In the ADIPOQ PCR products 
DNA sequencing map, we found a new SNP rs2241767 in ADIPOQ gene at +345 
coding reference gene positions in intron 2, in which the substitution is A to G. In 
PCOS group, there were 2 homozygous “GG” of this new SNP and heterozygous 
frequency was higher in PCOS than that in controls (26% vs. 14.6%; p = 0.030, OR = 
0.436, 95% CI = 0.21-0.89). On 3q27.3, the most significant SNP was rs2241766 
which locates in the exon 2 of ADIPOQ gene. 
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Haplotype estimation analysis of three SNPs genotype data by means of maximum 
likelihood method revealed that estimated overall haplotype frequencies in PCOS and 
controls groups differ significantly (Table 4.14). Seven major haplotypes of ADIPOQ 
were present in the study population (Figure 4.19). The frequency of most common 
haplotypes TGA, TTA, GGA and GGG was 63.9%, 22.1%, 0.00% and 10.9 % in 
PCOS; while 53.7%, 12.0%, 24.2% and 3.0% in controls groups (p < 0.001, LR Chi 
Sq = 79.100, 3.200 respectively in PCOS and controls). Whereas in single haplotype 
association the TGA, TTA and GGG are more frequent in PCOS group, while the 
haplotype GGA was found only in controls group (Figure 4.19). The other low 
frequencies haplotypes showed borderline difference. So the null hypothesis that the 
haplotype frequency distributions of the two groups are the same is rejected strongly. 
The genetic heterogeneity test showed a strong significance (p < 0.001, χ2 = 69.4) 
between PCOS and controls.  In order to study the linkage disequilibrium between 
exon 2 and intron 2 loci, we performed pairwise LD analysis between rs2241766, 
rs1501299 and rs2241767. The R-squared or Delta-squared value for the PCOS 
between rs2241766 and rs2241767 was 0.78 (p < 0.001) and for the Control group 
was 0.06 (p < 0.001). This revealed very strong LD for the pair of loci which are 
located approximately 300 bp from each other and haplotype correlate well in the 
PCOS group as compared to the control group (Figure 4.20). The polymorphisms in 
the ADIPOQ were in linkage disequilibrium. 
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(a) Alignment of two sequences BLAST (PCOS) 
 
Query  105  GCTCAGGATGCTGTTGCTGGGAGCTGTTCTACTGCTATTAGCTCTGCCCGGTCATGACCA  164 
            ||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||| 
Sbjct  79   GCTCAGGATGCTGTTGCTGGGAGCTGTTCTACTGCTATTAGCTCTGCCCGGGCATGACCA  138 
 
Query  165  GGAAACCACGACTCAAGGGCCCGGAGTCCTGCTTCCCCTGCCCAAGGGGGCCTGCACAGG  224 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  139  GGAAACCACGACTCAAGGGCCCGGAGTCCTGCTTCCCCTGCCCAAGGGGGCCTGCACAGG  198 
 
(b) Alignment of two sequences BLAST (Control) 
 
Query  105  GCTCAGGATGCTGTTGCTGGGAGCTGTTCTACTGCTATTAGCTCTGCCCGGTCATGACCA  164 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  75   GCTCAGGATGCTGTTGCTGGGAGCTGTTCTACTGCTATTAGCTCTGCCCGGTCATGACCA  134 
 
Query  165  GGAAACCACGACTCAAGGGCCCGGAGTCCTGCTTCCCCTGCCCAAGGGGGCCTGCACAGG  224 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  135  GGAAACCACGACTCAAGGGCCCGGAGTCCTGCTTCCCCTGCCCAAGGGGGCCTGCACAGG  194 
 
 
Figure 4.17: Two sequence BLAST alignment of ADIPOQ gene polymorphisms. 
 
 
 
 
 
Figure 4.18: Sequence chromatogram showing homozygous and heterozygous 
form of T/G base substitution of rs2241766. 
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Figure 4.19: Multi-SNPs haplotype percent frequency distribution for PCOS and 
controls at ADIPOQ gene. 
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Table 4.13: Frequency distribution of single nucleotide polymorphisms of ADIPOQ gene with risk of PCOS in Pakistani women. 
SNPs ID Genotype/allele 
frequencies 
PCOS 
(n= 96) 
Controls 
(n= 96) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                   
rs2241766 TT 75 78.1 47 49 3.725      
(T>G) GT 20 20.8 40 41.7 (1.98-6.97) 16.39 0.001 >.05 
Exon 2 GG 1 1 9 9.4        
  Allele frequency                
  T Allele  170 88.5 134 69.8 3.345      
  G Allele  22 11.5 58 30.2 (1.95-5.74) 19.34 0.001 >.05 
   E(HET)   20   42        
rs1501299 GG 56 58.3 69 71.9 0.548      
(G>T) TG 35 36.5 25 26 (0.30-1.00) 3.30 0.060 >.05 
Intron 2 TT 5 5.2 2 2.1        
  Allele frequency                
  T Allele  45 23.4 29 15.1 0.581      
  G Allele  147 76.6 163 84.9 (0.34-0.97) 3.77 0.050 >.05 
   E(HET)   36   26        
rs2241767 AA 69 71.9 82 85.4 0.436      
(A>G) GA 25 26 14 14.6 (0.21-0.89) 4.46 0.030 >.05 
Intron 2 GG 2 2.1 0 0        
  Allele frequency                
  A Allele  163 86.5 178 92.7 1.262      
  G Allele 29 13.5 14 7.3 (0.22-0.86) 5.13 0.020 >.05 
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Table 4.14: Multi-SNPs haplotype frequency estimates for PCOS and controls at ADIPOQ gene. 
 
Groups Haplotype frequencies ± S.E.E Exp. 
Het 
Global LD  
LR ChiSq 
p Genetic 
Heterogeneity 
Test 
TGA TTA GGA GGG TGG GTA TTG  Chi Sq p 
PCOS 0.639 
± 
0.035 
0.221 
± 
0.030 
0.000 
± 
0.000 
0.109 
± 
0.023 
0.018 
± 
0.010 
0.005 
± 
0.005 
0.008 
± 
0.006 
53.10 79.10 0.001 
69.40 0.001 
Control 0.537 
± 
0.039 
0.120 
± 
0.027 
0.242 
± 
0.031 
0.030 
± 
0.017 
0.042 
± 
0.017 
0.029 
± 
0.003 
0.000 
± 
0.000 
63.60 3.20 0.050 
 
Exp. Het: Expected Heterozygosity; Global LD LR Chi Sq: Global likelihood ratio chi-square; Chi Sq: Chi square; S.E.E: Standard error of estimation; p: Significance 
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Figure 4.20: Pairwise linkage disequilibrium of ADIPOQ gene in PCOS and 
controls. 
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4.4.2 Insulin receptor (INSR) 
INSR gene was analyzed for rs1799817, rs1799815 of exon 17 and SNPs rs2059806, 
rs2229429 of exon 8 by direct sequencing. This revealed presence of association of 
these polymorphisms with PCOS as shown in Table 4.15. In SNP rs1799817 a silent 
polymorphism C/T SNP at 1085 site (His-His) was observed. The genotype and allele 
frequencies are shown in Table 4.15. In contrast the frequency of “C” (76% in PCOS 
and 57.8% in controls) and “T” (24% in PCOS and 42.2% in controls) allele differ 
significantly in PCOS and control groups (p < 0.001, OR = 2.316, 95% CI = 1.45-
3.59). The frequency of CC genotype was overrepresented as compared to CT_TT 
genotype in PCOS (p < 0.001, OR = 2.935, 95% CI = 1.62-5.29). We also observed 
another novel polymorphism in exon 17 rs1799815. The frequency of CC, CT and TT 
genotypes is shown in Table 4.15. The frequency of “T” and “C” allele differ 
significantly between PCOS and control group (p = 0.05, OR = 0.261, 95% CI = 0.07-
0.95). We analyzed exon 8 for polymorphism rs2059806 (G/A). In SNP rs2059806 
the genotype and allele frequency of GG, GA and AA in PCOS and controls is shown 
in Table 4.15. The frequency of “A” allele was high in PCOS group as compared to 
controls (24% vs. 16.1%, p = 0.030, OR = 0.520, 95% CI = 0.34-0.92) and was 
statistically significant. During the screening of exon 8 we found another SNP 
rs2229429. The genotype distribution of rs2229429 C/T polymorphism in PCOS 
group was significantly different from that of controls.  
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Figure 4.21: Multi-SNPs haplotype percent frequency distribution for PCOS and 
controls at INSR gene. 
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      Table 4.15: Frequency distribution of single nucleotide polymorphisms of INSR gene with risk of PCOS in Pakistani women. 
SNPs ID Genotype/allele 
frequencies 
PCOS 
(n= 96) 
Controls 
(n= 96) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                  
rs1799817 CC 56 58.3 31 32.3 2.935      
(C>T) TC 34 35.4 49 51 (1.62-5.29) 12.1 0.001 >.05 
Exon 17 TT 6 6.3 16 16.7        
  Allele frequency                 
  C Allele  146 76 111 57.8 2.316      
  T Allele  46 24 81 42.2 (1.45-3.59) 13.6 0.001 >.05 
   E(HET)   36   49        
rs1799815 CC 86 89.5 93 96.8 0.277      
(C>T) TC 9 9.3 3 3.1 (0.07-1.04) 2.97 0.080 >.05 
Exon 17 TT 1 1.9 0          
  Allele frequency      0        
  C Allele  181 94.2 189 98.4 0.261       
  T Allele 11 5.7 3 1.6 (0.07-0.95) 3.63 0.050 >.05 
   E(HET)   6   3        
rs2059806 GG 54 58.7 67 72.8 0.557       
(G>A) AG 35 38 27 29.3 (0.30-1.00) 3.21 0.070 >.05 
Exon 8 AA 7 7.6 2 2.2         
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Table continues…………… 
 
  Allele frequency                 
  G Allele  143 76 161 83.9 0.520       
  A Allele  49 24 31 16.1 (0.34-0.92) 4.56 0.030 >.05 
   E(HET)   37   29         
rs2229429 CC 33 38 57 59.4 0.358       
(C>T) CT 45 46.8 35 36.4 (0.19-0.64) 11.06 0.001 >.05 
Exon 8 TT 18 18.7 4 4.1         
  Allele frequency                
  C Allele  111 57.8 149 77.6 0.395       
  T Allele  81 42.2 43 22.4 (0.25-0.61) 16.31 0.001 >.05 
   E(HET)   49   35         
 
SNPs ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg Equilibrium; χ2: Chi square.    
 
 
 
 
 
 
 
  
123 
 
 
 
 
 
 
Table 4.16: Multi-SNPs haplotype frequency estimates for PCOS and controls at INSR gene. 
 
 
        Exp. Het: Expected Heterozygosity; Global LD LR Chi Sq: Global likelihood ratio chi-square; Chi Sq: Chi square; S.E.E: Standard error of estimation; p: Significance 
Groups Haplotype frequencies ± S.E.E Exp. 
Het 
Global LD  
LR Chi Sq 
p Genetic 
Heterogeneity 
Test 
CGC CGT TGC CAC TGT TAC CAT TAT  Chi Sq p 
PCOS 0.308 
± 
0.033 
0.27 
± 
0.032 
0.139 
± 
0.025 
0.105 
± 
0.022 
0.044 
± 
0.015 
0.027 
± 
0.019 
0.078 
± 
0.019 
0.029 
± 
0.012 
79.30 2.30 1.000 
54.60 0.001 
Control 0.401 
± 
0.045 
0.101 
± 
0.034 
0.214 
± 
0.038 
0.076 
± 
0.021 
0.122 
± 
0.031 
0.086 
± 
0.021 
0.000 
± 
0.00 
0.000 
± 
0.000 
75.50 11.70 0.050 
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Figure 4.22: Pairwise linkage disequilibrium of INSR gene in PCOS and 
controls. 
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A similar trend toward association with features of insulin resistance was observed for 
the “TT and CT” genotype at position 1638 (Table 4.15). There was also a significant 
difference in the “C” (57.8% in PCOS vs. 77.6% in controls) and “T” (42.2% in PCOs 
vs. 22.4% in controls) allele frequencies between the two groups (p < 0.001, OR = 
0.395, 95% CI = 0.25-0.61). 
 Single point analysis was expanded to pair of loci haplotype analysis to depict the 
estimated haplotype frequencies of the three SNPs of INSR gene of unknown phase in 
the PCOS and control groups. Much stronger associations were observed when the 
three SNPs were considered together as haplotypes. The SNP rs1799815 was 
excluded from haplotype analysis due to low variations. When the estimated 
haplotype frequencies were compared between PCOS and controls, the most common 
haplotype CGC (0.401 vs. 0.308 in controls and PCOS respectively) and TGC (0.214 
vs. 0.139 in controls and PCOS respectively) was found to be more prevalent in the 
control group, whereas the CGT (0.270 vs. 0.101 in PCOS and controls respectively), 
CAC (0.105 vs. 0.076 in PCOS and controls respectively) and CAT (0.078 vs. 0.000 
in PCOS and controls respectively) was more common among PCOS patients (Table 
4.16; Figure 4.21). So the null hypothesis that the haplotype frequency distributions of 
the two groups are the same is rejected strongly. The genetic heterogeneity test 
showed strong association (p < 0.001, χ2 = 54.6). In order to study the extent of 
linkage disequilibrium between exon 17 and exon 8 loci, we performed pairwise LD 
analysis. The pairwise LD analysis revealed week LD for the pairs of loci in the 
PCOS and control group (Figure 4.22). 
 
4.4.3 Follicle stimulating hormone receptor (FSHR) 
Genotype distribution of genes encoding sex hormones and hormones regulator SNPs 
rs6166 and rs6165 are shown in Table 4.17. The allele “A” and “G” frequencies of 
SNP rs6166 were not different between PCOS and controls (p = 0.350, OR = 1.232, 
95% CI = 0.85-1.84). We also did not find any statistically significant differences in 
the genotypes and allele frequencies between PCOS and controls for rs6165 in exon 
10 (p = 0.470, OR = 1.181, 95% CI = 0.79-1.76). Haplotype-specific tests for 
association were also performed. Four major haplotypes of FSHR were present in the 
study population (Table 4.18). The haplotype frequencies were significantly different 
between the patients and controls for the two SNPs as shown in Figure 4.23.  
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The haplotype “AA” (0.504 vs. 0.305 in PCOs and controls) and “GG” (0.431 vs. 
0.326 in PCOs and controls) were more common in PCOS while haplotype “GA” 
(0.022 vs. 0.179 in PCOs and controls) and “AG” (0.043 vs. 0.190 in PCOs and 
controls) were frequent in controls (p < 0.001, LR Chi Sq=117.4, 6.1 respectively in 
PCOS and controls). The genetic heterogeneity test gives a p-value of <0.001 (Table 
4.18). To calculate the extent of LD in pairwise combinations of the SNPs, we 
calculate LD value. The pairwise LD values were 0.76 (p < 0.001) for both sites 
which are situated in exon 10 within only hundreds of bases of each other (Figure 
4.24).  
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Figure 4.23: Multi-SNPs haplotype percent frequency distribution for PCOS and 
controls at FSHR gene.
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Table 4.17: Frequency distribution of single nucleotide polymorphisms of FSHR gene with risk of PCOS in Pakistani women. 
SNPs ID Genotype/allele 
frequencies 
PCOS 
(n= 96) 
Controls 
 (n= 96) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                   
 rs6166 AA 29 30.2 24 25 0.777       
(A>G) AG 47 48.9 47 48.9 (0.40-1.45) 0.41 0.510 >.05 
Exon 10 GG 20 20.8 25 26        
  Allele frequency                
  A Allele  105 54.7 95 49.5 1.232       
  G Allele  87 45.3 97 50.5 (0.85-1.84) 0.85 0.350 >.05 
  E(HET)   50   50         
rs6165 AA 27 28.1 22 22.9 1.310       
(A>G) AG 47 48.9 49 51 (0.68-2.52) 0.44 0.500 >.05 
Exon 10 GG 22 22.9 25 26         
  Allele frequency                
  A Allele  101 52.6 93 48.4 1.181       
  G Allele  91 47.4 99 51.6 (0.79-1.76) 0.51 0.470 >.05 
  E(HET)   50   50         
 
SNPs ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg Equilibrium; χ2: Chi square.    
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Table 4.18: Multi-SNPs haplotype frequency estimates for PCOS and controls at FSHR gene. 
Groups Haplotype frequencies ± S.E.E Exp. 
Het 
Global LD  
LR Chi Sq 
p Genetic 
Heterogeneity 
Test 
AA GG GA AG  Chi Sq p 
PCOS 0.504±0.036 0.431±0.036 0.022±0.028 0.043±0.028 55.70 117.40 0.001 
58.30 0.001 
Control 0.305±0.042 0.326±0.038 0.179±0.037 0.190±0.035 73.30 6.10 0.050 
 
Exp. Het: Expected Heterozygosity; Global LD LR Chi Sq: Global likelihood ratio chi-square; Chi Sq: Chi square; S.E.E: Standard error of estimation; p: Significance 
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Figure 4.24: Pairwise linkage disequilibrium of FSHR gene in PCOS and controls. 
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4.4.4 Follicle stimulating hormone beta (FSHB) 
FSHB gene was analyzed for SNP rs6169 T/C in exon 3. The mutations of FSHB gene 
in two sequence BLAST alignment are shown in Figure 4.25. The sequence 
chromatogram showed homozygous and heterozygous form of T/C base substitution 
of rs6169 (Figure 4.26).Genotype and allele frequencies were significantly different 
for PCOS and controls. A statistically significant (p < 0.005) higher frequency of the 
“T” allele was observed in patients than in controls (Table 4.19). The frequency of 
“C” (34.4% in PCOS and 46.4% in controls) and “T” (65.6% in PCOS and 53.6% in 
controls) allele differ significantly in PCOS and control groups (p= 0.020, OR= 0.606, 
95% CI= 0.40-0.91). The frequency of TT genotype was overrepresented as compared 
to CT_CC genotype in PCOS (p = 0.020, OR = 2.094, 95% CI = 1.14-3.83).  
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(a) Alignment of two sequences BLAST (PCOS) 
Query  94   CTCAGGATCTGGTGTATAAGGACCCAGCCAGGCCCAAAATCCAGAAAACATGTACCTTCA  153 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   CTCAGGATCTGGTGTATAAGGACCCAGCCAGGCCCAAAATCCAGAAAACATGTACCTTCA  120 
 
Query  154  AGGAACTGGTATACGAAACAGTGAGAGTGCCCGGCTGTGCTCACCATGCAGATTCCTTGT  213 
            ||||||||||||| |||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AGGAACTGGTATATGAAACAGTGAGAGTGCCCGGCTGTGCTCACCATGCAGATTCCTTGT  180 
 
 
(b) Alignment of two sequences BLAST (Control) 
Query  94   CTCAGGATCTGGTGTATAAGGACCCAGCCAGGCCCAAAATCCAGAAAACATGTACCTTCA  153 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   CTCAGGATCTGGTGTATAAGGACCCAGCCAGGCCCAAAATCCAGAAAACATGTACCTTCA  120 
 
Query  154  AGGAACTGGTATACGAAACAGTGAGAGTGCCCGGCTGTGCTCACCATGCAGATTCCTTGT  213 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AGGAACTGGTATACGAAACAGTGAGAGTGCCCGGCTGTGCTCACCATGCAGATTCCTTGT  180 
 
Figure 4.25: Two sequence BLAST alignment of FSHB gene polymorphisms. 
 
 
 
 
Figure 4.26: Sequence chromatogram showing homozygous and heterozygous 
form of T/C base substitution of rs6169. 
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Table 4.19: Frequency distribution of single nucleotide polymorphisms of FSHB gene with risk of PCOS in Pakistani women. 
SNP ID Genotype/allele 
frequencies 
PCOS 
(n= 96) 
Controls 
(n= 96) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                    
rs6169 TT 42 43.7 26 27 2.094       
(T>C) CT 42 43.7 51 53.1 (1.14-3.83) 5.12 0.020 >.05 
Exon 3 CC 12 13.5 19 19.7         
  C Allele 66 34.4 89 46.4 0.606       
  T Allele  126 65.6 103 53.6 (0.40-0.91) 5.24 0.020 >.05 
   E(HET)   45   50         
  
SNPs ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg Equilibrium; χ2: Chi square.     
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4.4.5 Luteinizing hormone choriogonadotropin receptor (LHCGR) 
LHCGR gene on region 2p16.3 was analyzed for rs61996318. Heterozygotes CA were 
greater in patients (16.6%) than controls (7.2%). As the homozygous AA genotype 
and heterozygous CA genotype was rare both in cases and controls (Table 4.20), the 
AA and CA were combined together and are referred as variants genotype of 
rs6199318. The frequency of variant genotype of rs6199318 was different in both 
groups. We did find a significant association between different genotypes (Table 
4.20). In SNP rs61996318 the genotype frequencies CC, CA and AA were 82.2% 
(79/96), 16.6% (16/96), 1.0% (01/96) in PCOS whereas 92.7% (89/96), 7.2% (07/96) 
and 0% (0/96) in controls. Although the genotype and allele frequencies showed little 
variations but these were statistically significant (p = 0.030, OR = 1.366, 95% CI = 
0.14-0.89).  
 
A novel SNP in LHCGR 
In LHCGR PCR product DNA sequencing map, we found a new SNP at 48941073 
nucleotide position, where there was a loss of base “A” in which the gene sequence 
changes at AGCC A GAG. In PCOS group, there were 28 homozygous of this new 
SNP and in controls there were 6.  Heterozygotes D/T was greater in patients (50%) 
than controls (36.4%) which increased the risk of disease. A statistically significant 
higher frequency of the “missing” allele was observed in patients than in controls 
(54.2% vs. 24.5%, p < 0.001, OR = 1.270, 95% CI = 0.18-0.42). As the homozygous 
D/D genotype and heterozygous D/T genotype was prevalent in PCOS (Table 4.20), 
the D/D and D/T was combined together and referred as variants genotype of this new 
SNP. The frequency of variant genotype of new SNP was different in both groups 
(76/96 vs. 41/96 in PCOS and controls respectively). The frequency of D/D genotype 
was overrepresented as compared to TT_DT genotype in PCOS (p < 0.001, OR = 
1.220, 95% CI = 0.11-0.43).  
The haplotype analysis revealed that the most common haplotype “TC” was frequent 
in controls as compared with PCOS group (72.4% vs. 40.9% in controls and PCOS 
respectively) (Figure 4.27). Whereas the other three nonzero haplotypes; DC (0.497 
vs. 0.239 in PCOS and controls), TA (0.049 vs. 0.031 in PCOS and controls) and DA 
(0.045 vs. 0.006 in PCOS and controls) were more common in PCOS group (Table 
4.21). The genetic heterogeneity test showed strong significance (p < 0.001,  
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Figure 4.27: Multi-SNPs haplotype percent frequency distribution for PCOS and 
controls at LHCGR gene.
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Table 4.20: Frequency distribution of single nucleotide polymorphisms of LHCGR gene with risk of PCOS in Pakistani women. 
SNPs ID Genotype/allele 
frequencies 
PCOS 
(n= 96) 
Controls 
(n= 96) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                    
rs61996318 CC 79 82.2 89 92.7 0.365       
(C>A) CA 16 16.6 7 7.2 (0.14-0.92) 3.86 0.050 >.05 
Exon AA 1 1 0 0         
  Allele frequency                 
  C Allele  174 90.6 185 96.4 1.366       
  A Allele  18 9.4 7 3.6 (0.14-0.89) 4.28 0.030 >.05 
  E(HET)   17   7         
 
rs111834744 
TT 20 20.8 55 57.2 1.220       
(D>T) DT 48 50 35 36.4 (0.11-0.43) 20.3 0.001 >.05 
Intron DD 28 29.1 6 6.2         
  Allele frequency                
  T Allele  88 45.8 145 75.5 1.270       
  D Allele  104 54.2 47 24.5 (0.18-0.42) 34.22 0.001 >.05 
  E(HET)   50   37         
 
SNPs ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg Equilibrium; χ2: Chi square.     
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Table 4.21: Multi-SNPs haplotype frequency estimates for PCOS and controls at LHCGR gene. 
Groups Haplotype frequencies ± S.E.E Exp. Het Global LD  
LR ChiSq 
p Genetic 
Heterogeneity 
Test 
TC DC TA DA  Chi Sq p 
PCOS 0.409±0.036 0.497±0.035 0.049±0.015 0.045±0.016 58.10 0.20 0.05 
40.80 0.001 
Control 0.724±0.034 0.239±0.035 0.031±0.010 0.006±0.015 47.70 0.10 0.05 
 
Exp. Het: Expected Heterozygosity; Global LD LR Chi Sq: Global likelihood ratio chi-square; Chi Sq: Chi square; S.E.E: Standard error of estimation; p: Significance 
 
 
 
 
 
 
 
 
Figure 4.28: Pairwise linkage disequilibrium of LHCGR gene in PCOS and controls. 
LHCGR PCOS 
 
LHCGR PCOS 
rs
6
1
9
9
6
3
1
8
 
rs
1
1
1
8
3
4
7
4
4
 
 
rs
6
1
9
9
6
3
1
8
 
rs
1
1
1
8
3
4
7
4
4
 
.26 
0 0 
.04 
0 0 
  
137 
 
χ2 = 40.8) between the PCOS and control groups. The pairwise LD values were week 
for both sites (Figure 4.28).  
 
4.4.6 Luteinizing hormone beta (LHB) 
The LHB was analyzed for two polymorphisms rs1800447 and rs4002462. The 
mutations of LHB gene in two sequence BLAST alignment are shown in Figure 4.29. 
The sequence chromatogram showed homozygous and heterozygous form of T/C base 
substitution of rs4002462 (Figure 4.30). Overall, there was no statistically significant 
(p > 0.05) difference in the distribution of either polymorphism between PCOS and 
controls, the genotype frequency and allele frequency showed little variations among 
both groups. This indicate that individual polymorphism of LHB may not be 
associated with increased risk of PCOS (Table 4.22). Haplotype-specific tests for 
association were also performed. Three major haplotypes of LHB were present in the 
study population (Table 4.23).  
However the haplotype analysis showed that the most common haplotype “AC” 
(94.3% vs. 86.5%) was more frequent in controls than in PCOS (Figure 4.31). 
Whereas, the haplotypes “AT and GC” were frequent in PCOS group (Table 4.23). 
The genetic heterogeneity test showed a border line significance among the two 
groups (p = 0.05, χ2 = 6.7). The pair wise LD analysis revealed no significant 
association (Figure 4.32). 
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(a) Alignment of two sequences BLAST (PCOS) 
Query  94   CTGTTTCTTTCAGTTTCTTCCCATTCCTAAACCCTCTCCTCCCTCCTTCAGCAAACTATA  153 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  60   CTGTTTCTTTCAGTTTCTTCCCATTCCTAAACCCTCTCCTCCCTCCTTCAGCAAACTATA  119 
 
Query  154  TGGAAATGGATTTGAAGAAGTAAAAAGTCATGCATTCAATGGGACGACACTGACTTCACT  213 
            |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
Sbjct  120  TGGAAATGGATTTGAAGAAGTAGAAAGTCATGCATTCAATGGGACGACACTGACTTCACT  179 
 
(b) Alignment of two sequences BLAST (Control) 
Query  99   TCTTTCAGTTTCTTCCCATTCCTAAACCCTCTCCTCCCTCCTTCAGCAAACTATATGGAA  158 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  65   TCTTTCAGTTTCTTCCCATTCCTAAACCCTCTCCTCCCTCCTTCAGCAAACTATATGGAA  124 
 
Query  159  ATGGATTTGAAGAAGTAGAAAGTCATGCATTCAATGGGACGACACTGACTTCACTGTAAG  218 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  125  ATGGATTTGAAGAAGTAGAAAGTCATGCATTCAATGGGACGACACTGACTTCACTGTAAG  184 
 
Figure 4.29: Two sequence BLAST alignment of LHB gene polymorphisms. 
 
 
 
 
 
 
Figure 4.30: Sequence chromatogram showing homozygous and heterozygous 
form of A/G base substitution of rs4002462. 
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Figure 4.31: Multi-SNPs haplotype percent frequency distribution for PCOS and 
controls at LHB gene. 
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Table 4.22: Frequency distribution of single nucleotide polymorphisms of LHB gene with risk of PCOS in Pakistani women. 
SNPs ID Genotype/allele 
frequencies 
PCOS 
(n= 96) 
Controls 
(n= 96) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                    
rs1800447 CC 80 83.3 88 91.7 0.450       
 (C>T) TC 15 15.6 8 8.3 (0.18-1.40) 2.33 0.140 >.05 
Exon TT 1 1 0 0        
  Allele frequency                
  A Allele  183 95.3 189 98.4 0.323       
  G Allele  9 4.7 3 1.6 (0.08-1.21) 2.15 0.120 >.05 
  E(HET)   9   3         
rs4002462 AA 87 90.6 93 96.9 0.312       
(A>G) AG 9 9.4 3 3.1 (0.08-1.11) 2.22 0.130 >.05 
Intron GG 0 0 0 0         
  Allele frequency                
  A Allele  175 91.1 184 95.8 0.448       
  G Allele  17 8.9 8 4.2 (0.18-1.06) 2.74 0.090 >.05 
  E(HET)   16   8         
 
SNPs ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg Equilibrium; χ2: Chi square.     
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Table 4.23: Multi-SNPs haplotype frequency estimates for PCOS and controls at LHB gene. 
Groups Haplotype frequencies ± S.E.E Exp. Het Global LD  
LR ChiSq 
p Genetic 
Heterogeneity 
Test 
AC AT GC  ChiSq p 
PCOS 0.865±0.025 0.088±0.020 0.046±0.015 24.10 0.30 1.000 
6.70 0.050 
Control 0.943±0.017 0.042±0.014 0.016±0.009 10.90 0.30 1.000 
 
Exp. Het: Expected Heterozygosity; Global LD LR Chi Sq: Global likelihood ratio chi-square; Chi Sq: Chi square; S.E.E: Standard error of estimation; p: Significance 
 
 
 
 
 
 
 
 
Figure 4.32: Pairwise linkage disequilibrium of LHB gene in PCOS and controls. 
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4.4.6 Estrogen receptor alpha (ESR1) 
The contribution of the genomic variants of ESR1 was studied for seven SNPs. The 
genotype distribution and relative allele frequencies for ESR1 gene polymorphisms 
are shown in Table 4.24. Twenty two subjects were homozygous for rs2234693 C 
allele, 47 were heterozygous and there were 27 subjects homozygous for T allele. The 
frequency of the rs2234693 “C” allele was 47.4% in the PCOS and 32.8 % in the 
control group. Significant differences were observed for comparative genotype 
distribution and relative allele frequencies of SNP rs2232693 between PCOS and 
controls (p < 0.005, OR = 1.845, 95% CI = 1.22-2.79, χ2 = 7.90). We had also find 
statistically significant differences in the genotypes and allele frequencies between 
PCOS and control group for rs9340799 (p < 0.010, OR = 1.688, 95% CI = 0.96-2.19, 
χ2 = 5.74).  
A new SNP rs8179176 was found during the screening of DNA sequencing map. Two 
were homozygous for new SNP T allele, 23 were heterozygous and there were 71 
subjects homozygous for C. Heterozygotes CT were greater in patients (24%) than 
controls (10.4%). As the homozygous TT genotype and heterozygous CT genotype 
was rare both in cases and controls, the AA and GA were combined together and are 
referred as variants genotype of this new SNP. The frequency of variant genotype of 
was different in both groups. The frequency of the rs8179176 “T” allele was 14.1 % 
in the patients and 5.2% in the control group. Comparison of frequencies between 
patients and control groups show statistically difference between them (P < 0.006, OR 
= 1.336, 95% CI= 0.15-0.71, χ2 = 7.66). This suggested that these genetic variants are 
related in the occurrence of PCOS in Pakistani women. However the genotype and 
allele frequencies of SNPs rs11155816, rs4986936 and rs4986937 were not 
significantly different between PCOS women and controls (Table 4.24). 
 Interestingly, the haplotype analysis showed distinct variations among PCOS and 
control groups. Two haplotypes “AT and GC” are more frequent in PCOS whereas 
the other two haplotypes “AC and GT” are common in controls (Table 4.25; Figure 
4.33). Also the genetic heterogeneity test showed a highly significant association 
between PCOS and controls (p < 0.001, χ2 = 75.5). LD value between rs2234693 and 
rs9340799 was 0.46 (p < 0.001) in PCOS group which are located 51 bp from each 
other. This showed a strong LD for the pair of loci and haplotype correlate well in the 
PCOS group as compared to the control group (Figure 4.34).  
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Figure 4.33: Multi-SNPs haplotype percent frequency distribution for PCOS and 
controls at ESR1 gene. 
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          Table 4.24: Frequency distribution of single nucleotide polymorphisms of ESR1 gene with risk of PCOS in Pakistani women. 
SNPs ID Genotype/allele 
frequencies 
PCOS 
(n= 96) 
Controls 
(n= 96) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                  
rs2234693 TT 27 28.1 43 44.8 0.482       
(C>T) CT 47 49 43 44.8 (0.26-0.87) 5.05 0.020 >.05 
Intron 1 CC 22 22.9 10 10.4         
  Allele frequency                
  C Allele  91 47.4 63 32.8  1.845       
  T Allele  101 52.6 129 67.2 (1.22-2.79) 7.90 0.005  >.05 
   E(HET)   49   45         
rs9340799 AA 28 29.2 42 43.8 0.529       
(G>A) GA 47 49 43 44.8 (0.29-0.96) 3.80 0.050 >.05 
Intron 1 GG 21 21.9 11 11.5         
  Allele frequency                 
  G Allele  89 46.4 65 33.9 1.688       
  A Allele  103 53.6 127 66.1 (0.96-2.19) 5.74 0.010 >.05 
   E(HET)   49   45         
rs8179176 CC 71 74 86 89.6 0.330       
(C>T) CT 23 24 10 10.4 (0.40-0.73) 6.85 0.009 >.05 
Intron 1 TT 2 2.1 0 0         
  Allele frequency                 
  C Allele  165 85.9 182 94.8 1.336       
  T Allele  27 14.1 10 5.2 (0.15-0.71) 7.66 0.006 >.05 
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Table continues……………….. 
   E(HET)   24   10         
rs11155816 CC 81 84.4 87 90.6 0.559       
(C>T) TC 14 14.6 9 9.4 (0.23-1.34) 1.19 0.210 >.05 
Intron TT 1 1 0 0         
  Allele frequency                 
  T Allele  16 8.3 9 4.7 1.848       
  C Allele  176 91.7 183 95.3 (0.79-4.29) 1.54 0.215 >.05 
   E(HET)   15   9         
  
rs11155815 
TT 66 68.8 75 78.1 0.616       
(C>T) CT 28 29.2 20 20.8 (0.32-1.17) 1.70 0.180 >.05 
Intron CC 2 2.1 1 1         
  Allele frequency                 
  C Allele  160 83.3 170 88.5 0.647       
  T Allele  32 16.7 22 11.5 (0.36-1.16) 1.75 0.186 >.05 
   E(HET)   28   20         
rs4986936 TT 86 89.6 94 97.9 0.183       
(G>A) CT 10 10.4 2 2.1 (0.03-0.85) 4.35 0.031 >.05 
Intron CC 0 0 0 0         
  Allele frequency                 
  C Allele  10 5.2 2 99 5.22       
  T Allele  182 94.8 190 1 (1.12-24.14) 4.21 0.040 >.05 
   E(HET)   10   2         
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Table continues……………….. 
rs4986937 GG 89 92.7 93 96.9 0.41     >.05 
(C>T) AG 7 7.3 3 3.1 (0.10-1.63) 0.95 0.310   
  AA 0 0 0 0         
  Allele frequency                 
  G Allele  185 96.4 189 98.4 0.42       
  A Allele  7 3.6 3 1.6 (0.10-1.64) 0.92 0.336 >.05 
   E(HET)   7   3         
 
   SNPs ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance;    HWE: Hardy Weinberg Equilibrium; 
   χ2: Chi square.   
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Table 4.25: Multi-SNPs haplotype frequency estimates for PCOS and controls at ESR1 gene. 
 
Groups Haplotype frequencies ± S.E.E Exp. Het Global LD  
LR ChiSq 
p Genetic 
Heterogeneity 
Test 
AT AC GT GC  Chi Sq p 
PCOS 0.479±0.036 0.073±0.035 0.084±0.020 0.364±0.019 62.60 62.30 0.001 
75.50 0.001 
Control 0.384±0.042 0.267±0.029 0.267±0.038 0.082±0.039 70.30 2.70 0.060 
 
Exp. Het: Expected Heterozygosity; Global LD LR Chi Sq: Global likelihood ratio chi-square; Chi Sq: Chi square; S.E.E: Standard error of estimation; p: Significance 
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Figure 4.34: Pairwise linkage disequilibrium of ESR1 gene in PCOS and 
controls. 
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4.4.7 Estrogen receptor beta (ESR2) 
The ESR2 gene was studied for polymorphism rs4986938 which is a G→A change at 
position 1859 in the 3′-untranslated region (3′-UTR) of exon 8. The genotype 
frequency of G/A polymorphism in PCOS group was significantly different from that 
of controls. The mutant allele “A” was in significantly higher frequency among the 
cases (41.7%) compared to the controls (27.6%) yielding an odds ratio of 0.534 (p = 
0.005, 95% CI = 0.35-0.81, χ2 = 7.78). As the homozygous GG genotype was more 
frequent in controls (52.1%) compared with (34.4%) in PCOS (Table 4.26). The 
heterozygous GA genotype and the AA were combined together and are referred as 
variants genotype of rs4986938. The frequency of variant genotype of rs4986938 was 
different in both groups (63/96 vs. 46/96 in PCOS and controls respectively). 
 
4.5 Hormonal analysis 
 The results regarding the hormonal levels in controls, endometriosis and PCOS 
women are given in the following paragraphs. 
 
4.5.1 Follicle stimulating hormone (FSH) 
 FSH levels (mIU/ml) in controls and PCOS women were different from each 
other. The difference between the 2 groups was significant statistically (p < 0.005). 
The detail can be seen in Figure 4.35. Different genotypes, i.e, AA, AG and GG seem 
to affect the FSH levels in PCOS group; details are given in Figure 4.36-4.38. 
 
4.5.2Testosterone 
The testosterone (ng/ml) titres were lower in controls group (p < 0.001) as compared 
to women with PCOS. The profile of testosterone is presented in Figure 4.39.  
4.5.3 Progesterone 
Serum progesterone (ng/ml) was lower in endometriosis women as compared with 
controls (p < 0.001) (Figure 4.40).  
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Table 4.26: Frequency distribution of single nucleotide polymorphisms of ESR2 gene with risk of PCOS in Pakistani women. 
SNP ID Genotype/allele 
frequencies 
PCOS 
(n= 96) 
Controls 
(n= 96) 
OR  (95% CI)  χ2 p HWE 
n % n % 
                   
rs4986938 GG 33 34.4 50 52.1 0.482       
(G>A) GA 46 47.9 39 40.6 (0.27-0.86) 5.43 0.020 >.05 
UTR-3 AA 17 17.7 7 7.3        
  Allele frequency                
  G Allele 112 58.3 139 72.4 0.534       
  A Allele  80 41.7 53 27.6 (0.35-0.81) 7.78 0.005 >.05 
  E(HET)   48   41         
 
SNPs ID: single nucleotide polymorphism identity; OR: Odd ratios; CI: Confidence interval; p: Significance; HWE: Hardy Weinberg Equilibrium; χ2: Chi square.     
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Figure 4.35: Serum concentration of FSH in women with PCOS and controls. 
Values given are mean in mIU/ml of FSH ± S.D. The asterisk shows the significant 
difference between 2 groups according to the “t” test. 
 
Figure 4.36: Comparison of mean FSH values in women with PCOS and controls 
according to rs6166 genotype of FSHR gene. . The asterisk shows the significant difference 
between 2 groups according to the “t” test. 
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Figure 4.37: Comparison of mean FSH values in women with PCOS and controls 
according to rs6165 genotype of FSHR gene. 
 
 
Figure 4.38: Comparison of mean FSH values in women with PCOS and controls 
according to rs6169 genotype of FSHB gene. 
  
153 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.39: Serum concentration of Testosterone in women with PCOS and 
controls. Values given are mean in ng/ml of testosterone ± S.D. The asterisk shows the 
significant difference between 2 groups according to the “t” test. 
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Figure 4.40: Serum concentration of progesterone in women with endometriosis 
controls. Values given are mean in ng/ml of progesterone ± S.D. The asterisk shows 
the significant difference between 2 groups according to the “t” test.  
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CHAPTER 5 
DISCUSSION 
Infertility is a common public health problem in developing countries.  
However a limited data is available about the prevalence of infertility. Generally it is 
believed that more than 70 million couples affect from infertility worldwide (Boivin 
et al., 2007). The pathogenesis of diseases is better understood on the base of genetic 
studies, which help to improve the treatment of patients (Simoni et al., 2008). 
 This is the first integrated study on the single nucleotide polymorphism of ESR1, 
ESR2, PGR, IL10, ADIPOQ, INSR, FSHR, FSHB, LHCGR and LHB genes, to identify 
genetic factors which might have an impact on the etiology of the endometriosis and 
PCOS in Pakistani women. All SNPs in this study were chosen for their functional 
relevance to endometriosis and PCOS after searching databases and previous 
publications. Study of genomic variants and genes contributing in molecular 
mechanism develop understanding of disease pathogenesis involving DNA sequence 
among individuals. Current studies provide novel and detailed information on 
polymorphism of various genes in Pakistani subpopulation of women. Since this is the 
first study on Pakistani women, the present data will be compared with the results of 
all the polymorphisms investigated with similar studies conducted on other 
populations. 
5.1 Population characteristics 
The excess body fat is commonly measured in terms of Body Mass Index 
(BMI). The BMI classified as overweight 25 kg/m
2
 < BMI < 30 kg/m
2
 and obese with 
BMI > 30 kg/m
2
 (Lo et al., 2006). In current study the women with PCOS were obese 
when compared with respective controls. The mean BMI was 31.10 kg/m
2
 in PCOS 
women and 30.49 kg/m
2
 in controls but this difference were not statistically 
significant (p > 0.05). The prevalence of obesity in PCOS women varied (BMI > 
30kg/m
2
) across different Asian countries reported by several authors (Al-Azemi et 
al., 2004; Lam et al., 2005; Haq et al., 2007; Kurioka et al., 2007; Li et al., 2007; Shi 
et al., 2007). Obesity, mainly the abdominal phenotype may be responsible for 
hyperinsulinemia and associated with insulin resistance in PCOS women (Broekmans 
et al., 2006; Lo et al., 2006; Norman et al., 2007). In USA the PCOS constitutes a 
significant economic and health burden estimated over $4 billion with 12.2% for 
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infertility care, >30.1% costs hormonal related treatment due to menstrual 
dysfunction, 40.5% for diabetes mellitus 2 and 14.2% for hirsutism treatment (Azziz 
et al., 2005). The published trials on different populations showed the prevalence and 
prediction of metabolic syndrome from 33.4 to 47.3% in PCOS women (Apridonidze 
et al., 2005; Dokras et al., 2005; Ehrmann et al., 2005). The ethnicity of PCOS 
women showed variations in hormonal, metabolic and clinical characteristics.  
5.2 Endometriosis 
In spite of high prevalence the molecular mechanism involved in the 
development of endometriosis puzzled many investigators for years and still remain 
enigmatic. Endometriosis is considered as sex hormone dependent disease that affects 
women of reproductive age and regresses after menopause (Kitawaki et al., 2002a). 
The interaction between multiple genes and environmental factors is involved in the 
pathogenesis of endometriosis. The identification of genes or genetic polymorphisms 
involved in susceptibility of endometriosis has attracted a growing interest in recent 
years (Falconer et al., 2007). In view of the involvement of various genes, present 
study explores the association between genetic polymorphisms with the predisposition 
of endometriosis.  
Estrogen receptor genes harbour certain DNA sequence variants that may 
contribute to the risk of infertility. In the present study no association was observed in 
genotype and allele frequencies between genetic variants rs2234693 and rs9340799 of 
ESR1 gene polymorphisms and endometriosis (p > 0.050). In contrast, distinct 
variations were observed in haplotype frequencies (p < 0.005) indicated that the 
polymorphisms in ESR1 gene may affect the other regions of the gene in study 
population. During screening of the ESR1 gene the other five genetic polymorphisms 
rs11155815, rs8179176, rs11155816, rs4986936 and rs4986937 were also 
investigated. These genetic variants were more frequent in women with endometriosis 
than control however these were statistically not significant (p ≥ 0.050). These 
findings were in agreement with the prior studies when compared with other 
populations (Table 2.1). A study on Japanese women failed to detect an association 
between ESR1 gene polymorphisms and endometriosis (Matsuzaka et al., 2012). In 
Estonian women no association was observed in genetic variants of ESR1 rs2234693 
with endometriosis (Lamp et al., 2011). In the present study the polymorphisms 
rs2234693 and rs9340799 may act through linkage disequilibrium (LD = 0.48; p = 
  
157 
 
0.005) for a functional sequence variation in the gene of endometriotic women. By 
contrast a highly significant (p = 0.006) difference was observed in the genotype and 
allele frequencies of rs4986938 of ESR2 gene polymorphism in the endometriosis 
compared with control group. A study on Japanese population showed that the ESR2 
gene polymorphism was associated with an increased risk of endometriosis (Wang et 
al., 2004). In Brazilian women, the polymorphism in ESR2 gene has been associated 
with the risk of endometriosis development, irrespective to the stage of endometriosis 
(Bianco et al., 2009). However a study conducted on Korean women with 
endometriosis and controls suggests that the polymorphism rs4986938 of ESR2 gene 
may not be associated with the severity of disease (Lee et al., 2007). The allele 
frequencies of rs4986938 of ESR2 gene was significantly (p = 0.003) associated with 
endometriosis in women from Brazil population (Bianco et al., 2009; Zulli et al., 
2010). 
In the progesterone receptor gene two polymorphisms, rs10895068 in the 
promoter region and rs1042838 in exon 4 were studied. A highly significantly (p = 
0.003) association between endometriosis and progesterone receptor gene rs1042838 
was observed in present population. Both polymorphisms of PGR gene are present in 
the coding region of genome so it is predictable that these polymorphisms are 
associated with the susceptibility of endometriosis. In current study the low level of 
progesterone in serum was observed with endometriosis patient when compared with 
their controls (p < 0.001). This elevation in serum progesterone level indicates the fact 
that the production of this hormone was affected by PGR gene. Previously a German 
study revealed that both these polymorphisms influenced the function of progesterone 
receptors (Romano et al., 2007). A study on Dutch population investigated an 
association of rs10895068 polymorphism (p < 0.050) with endometriosis (van Kaam 
et al., 2007). However, no association with any of the variant rs1042838 and 
rs10895068 polymorphism was observed with the susceptibility of endometriosis in a 
pooled analysis from Australia and India (Treloar et al., 2005).  
Interleukin 10 is the chief immune-modulatory cytokine and function to 
terminate and limit the inflammatory responses (Moore et al., 2001). The associations 
of IL10 promoter polymorphism and endometriosis have been investigated in various 
populations. 
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The genotype and allele frequencies at each 4 SNPs of IL10 gene 
polymorphisms rs1800872, rs1800871, rs1800894 and rs1800896 of promoter region 
differ significantly (p ≤ 0.005) in endometriosis women when compared with control 
group. In IL10 gene, multi-SNP haplotypes at each 3 SNPs (rs1800872, rs1800871 
and rs1800896) differ significantly (p = 0.005) in endometriosis women compared 
with their controls, suggesting that “ATG” genotype may contribute to the risk of 
disease. Interestingly this haplotype was not reported in any previous population 
suggesting that “ATG” was a novel haplotype in Pakistani women with 
endometriosis. The findings of present study in terms of association are in line with 
the previous studies. A study on Chinese women with endometriosis revealed that the 
patients having rs1800871 polymorphism had a higher IL10 level when compared 
with controls (Zhang et al., 2007). A recent study suggests that the ACC/ACC 
haplotype, which is known to be a “low-producer” of IL10, is associated with 
endometriosis (Riiskjaer et al., 2011). However in present study population the 
ATG/ATG haplotype in the promoter region is related to the risk of endometriosis. In 
Pakistani women the frequency of GCC is 16.5 % in endometriosis and 19.5 % in 
controls. In addition the frequency of haplotype GCC is about 50% in European 
females, 20% in African females while lowest below 5% in Asian female that is 
(Meenagh et al., 2002). 
No statistically significant (p > 0.050) difference was observed in allele and 
genotype frequencies of rs1800872 and rs1800896 in Japanese patients with 
endometriosis compared with controls (Kitawaki et al., 2002b). In contrast, a 
significant association of endometriosis with rs1800872 in the promoter region of 
IL10 was found in Taiwanese population (Hsieh et al., 2003). The frequency of C 
allele of rs1800872 was lower in endometriosis patients (55.8 %) than in controls (78 
%). A study on Chinese patients with endometriosis revealed the higher frequency of 
C allele at rs1800872 as compared to controls (Zhang et al., 2007). Moreover, the 
polymorphism in promoter region of IL10 gene was also studied in Chinese women 
with endometriosis compared with controls. The distinct variations (p < 0.050) in 
allele frequency were observed at rs1800872 and rs1800871 of IL10 gene, this seems 
to be associated with endometriosis while the polymorphism rs1800896 was 
conserved with no difference in allele frequency (Xie et al., 2009). These findings 
were in agreement with the prior studies when compared with other populations 
(Table 2.3). 
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5.3 PCOS 
 In current study the polymorphisms of various genes ADIPOQ, INSR, FSHR, 
FSHB, LHCGR, LHB, ESR1 and ESR2 and their association with the development of 
PCOS was investigated. PCOS is the second reproductive disorder studied in the 
present research. 
 In this study, the association of three individual SNPs rs2241766, rs1501299 and 
rs2241767 of ADIPOQ gene along with their haplotypes with susceptibility to PCOS 
was studied. The rs2241766 has synonymous variation in the exon 2 (Gly-Gly) 
whereas rs1501299 and rs2241767 are located in intron. The allele frequencies at each 
of 3 above mentioned SNPs rs2241766, rs1501299 and rs2241767 (p < 0.001) as well 
as multi-SNP haplotypes differ significantly (p < 0.001) between PCOS patients and 
controls, suggesting that these SNPs may contribute to the risk development of PCOS. 
Current findings are in line with previous studies (Panidis et al., 2004; San Millan et 
al., 2004; Zhang et al., 2008) showing a significant association between the ADIPOQ 
rs2241766 polymorphism and risk of PCOS. In addition, “T” allele of rs2241766 was 
more frequent in PCOS women compared with control. However in a study on Han 
Chinese women “G” allele was related to an increased risk of PCOS, this may be due 
to difference in ethnicities (Demirci et al., 2010). In present study “TT” genotype of 
ADIPOQ genetic variant rs2241766 was associated with a 3.725 folds increased risk 
for PCOS patients similar with a study in Iran where 1.93-fold increase risk for PCOS 
with the same genotype was observed (Ranjzad et al., 2012). A previous study on the 
same gene ADIPOQ revealed that there are two strong LD blocks, one LD block 
reside in the putative promoter and other appears to extend over the region between 
rs2241766 and rs1501299 (Heid et al., 2006). In current study strong LD value (r
2
 = 
0.78; p < 0.001) in ADIPOQ gene in Pakistani women with PCOS supports previous 
finding. In addition, a new SNP at 186571196 genomic position was also investigated, 
the heterozygous gene frequency was 26.0 % in PCOS women than 14.6 % in 
controls. Moreover, rs2241767 showed strong linkage disequilibrium with rs2241766 
present in the coding region of genome. The rs2241767 was not observed in any 
population previously. The distribution of allele frequencies of rs2241766 and 
rs1501299 polymorphisms of ADIPOQ gene in present study were in agreement with 
the prior studies (Table 2.4a and 2.4b). 
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 PCOS is a heterogeneous disorder; the patients of PCOS have an increased 
susceptibility of type 2 diabetes as insulin resistance and glucose tolerance (San 
Millan et al., 2004).  In the present study a novel substitution of T→C within the 
rs1799817 exon 17 of INSR gene with significantly different allele and genotype 
frequencies (p = 0.001) was observed. Previous studies of exon 17 have shown that a 
C→T substitution was associated with PCOS (Siegel et al., 2002). In current study, 
the frequency of mutant homozygous “CC” genotype was significantly higher (58.3 
%) in women with PCOS compared with (32.3 %) in controls (p = 0.001)). 
Interestingly the frequency of “T” allele was significantly higher 42.2 % in control 
group than 24 % in PCOS (p < 0.001). However one previous study reported the T/C 
polymorphism associated with PCOS and decreased insulin sensitivity in Chinese 
population (Jin et al., 2006). In present study another novel SNP, rs1799815 was 
detected during the screening of exon 17. Whereas, no other novel polymorphism was 
observed in a study on Indian PCOS women other than rs1799817 in exon 17 of INSR 
gene (Mukherjee et al., 2009). The exon 8 of INSR gene is rarely studied for 
association of polymorphism with PCOS. Furthermore, the association of genetic 
variant rs2229429 in exon 8 of INSR gene with PCOS risk was also investigated 
currently, which was not analysed previously in any study. A highly significant 
difference (p = 0.001) in the genotype and allele frequencies was observed among the 
PCOS and control group for this polymorphism. The haplotype frequencies showed a 
clear difference in control group and PCOS women where the haplotype “CAT” 
(0.078) and “TAT” (0.029) was observed only in PCOS women (p = 0.001).  
The polymorphism of FSHR rs6166 and rs6165 was not responsible for any 
significant association (p > 0.050) with PCOS in the current studied population. The 
frequency of non-synonymous polymorphisms rs6166 and rs6165 in coding region of 
exon 10 of FSH gene was greater than 30% in normal population. In a previous study 
on Italian women no significant association was studied in FSHR gene 
polymorphisms rs6166 and rs6165 in PCOS group (Orio et al., 2006). Similar results 
in these two polymorphisms were reported in Chinese Singapore patients with PCOS 
(Tong et al., 2001). However the haplotype analysis showed distinct variations 
between the PCOS and control group. In present findings two haplotypes GG (43.1 
%) and AA (50.4 %) were more frequent in PCOS than 32.6 % and 30.5 % 
respectively in controls (p < 0.001)). This suggest that at least one susceptible locus 
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for PCOS lies within or very close to the region spanning rs6166 and rs6165 in the 
FSHR gene in Pakistani women. This explained that the haplotype analysis has strong 
effect than individual genetic markers in association analysis; therefore haplotype 
analysis takes into account the correlation between these markers (Dudbridge, 2003). 
Both the polymorphisms of FSHR gene were in strong linkage disequilibrium, which 
shows that they may act as haplotype rather than individual marker. The two SNPs of 
FSHR gene rs6166 and rs6165 are in linkage disequilibrium but most focused is on 
rs6165 variant. Several studies demonstrate the effect of these polymorphisms on 
reproduction and influence on FSHR functional activity (Simoni et al., 2008).  
 This study found that in rs6169 polymorphism of FSHB gene the allele 
frequency and homozygosity was significantly higher (p = 0.020) in patients with 
PCOS when compared with controls. The FSHB rs6169 polymorphism was 
previously found to be associated with obese PCOS patients in Southeast Asian 
population (Liao et al., 1999; Tong et al., 2000). A more recent study in Italy revealed 
that the joint conjunction of genetic polymorphisms in FSHR and FSHB demonstrated 
that serum FSH level may be affected by these polymorphisms (La Marca et al., 
2013). Currently serum FSH level was higher in PCOS women as compared to 
controls (p < 0.005).  However, the previous studies revealed that the PCOS women 
either have normal limits of FSH level or there is slight increase in serum FSH level 
when compared with their controls (Laven et al., 2003). 
 The polymorphism rs61996318 of LHCGR gene seems to be a stable locus in 
Pakistani women (p > 0.050), and it was not related with the development and 
pathogenesis of PCOS. A similar finding was observed in Chinese Han women 
suggesting that LHR rs6168318 polymorphism may be highly conserved in the 
studied subpopulation (Liu et al., 2012).  A novel SNP of LHCGR was found in 
current study where there is a loss of base “A”. The frequency of missing base was 
significantly higher (54.2 %) in PCOS women than (24.5 %) in controls (p < 0.001). 
This showed that this novel SNP had a strong relation with the development and 
susceptibility of PCOS in Pakistani women.  
 In present study two polymorphisms rs1800447 and rs4002462 in LHB gene 
were also studied. Both of these LHB polymorphisms in Pakistani women were not 
associated with PCOS (p > 0.050). Similar findings were observed in a previous study 
where polymorphisms of LHB gene were not associated with PCOS and infertility in 
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various populations (Lamminen et al., 2002). However, another study on Finland, 
Netherland, United Kingdom and United State showed that the silent mutation of the 
LHB genomic variant may have influenced the polymorphism rs1800447 which might 
lead to ovulatory disorder (Tapanainen et al., 1999). In PCOS women the LH is 
overexpressed in theca cells and its function is altered by multiple polymorphisms in 
the LHRCGR gene (Jakimiuk et al., 2001). LH stimulates the ovarian theca cells to 
secrete androgens which consequently arrest follicular maturation (Laven et al., 
2002). Mutations in LHB subunit gene are rarely studied. The allelic frequency of this 
variant varies extensively between different ethnic groups. The wide occurrence of 
this polymorphism in populations with different evolutionary histories and wide 
frequency variability may imply that this polymorphism represent an ancient form of 
LH (Lamminen & Hutaniemi 2001). 
 In the present study the polymorphisms rs2234693 and rs9340799 of ESR1 gene 
may act through linkage disequilibrium (41 %) for a functional sequence variation in 
the gene (p = 0.001). A significant (p = 0.005) difference was observed in genotype 
and allele frequencies of rs2234693 and rs9340799 polymorphisms in PCOS and 
control group. In a recent study on these polymorphisms in Greek women; no 
difference in genotype frequency was observed among PCOS and controls, however 
the association of rs2234693 and rs9340799 with insulin resistance and FSH level 
suggests the possible contribution of these genomic variants to the phenotype of 
PCOS (Nectaria et al., 2012). The present study provides data showing that the two 
polymorphisms may be associated with PCOS, but the mechanism underlying this 
association remains to be elucidated. In addition rs2234693 and rs9340799 
polymorphisms do not result in amino acid change; the observed effect may be due to 
linkage disequilibrium among these polymorphisms. The present study suggests the 
association of ESR2 rs4986938 polymorphism with the PCOS (p = 0.005). A previous 
study evaluating the rs4986938 in women with ovulatory dysfunction found a higher 
frequency of this polymorphism in PCOS patients than in controls (Sundarrajan et al., 
2001). In our study the strong LD value (p < 0.001) and genetic heterogeneity test (p 
< 0.001) of ADIPOQ, FSHR and ESR1 genes in PCOS group revealed that these 
polymorphisms may act through linkage disequilibrium for a functional sequence 
variation in the gene.  
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Reproduction in vertebrates is under the control of hormonal regulation by 
hypothalamus-pituitary-gonadal axis. Gonadotropins and steroids control the process 
of reproduction. Androgens are correlated with gonadal development. In present study 
the serum level of FSH and testosterone was higher (p = 0.005) in PCOS women. The 
increase level of testosterone presents a classic picture of PCOS symptoms in study 
population (i.e hirsutism, acne, weight gain and obesity) while the serum level of 
progesterone was lower in endometriosis women when compared with normal control 
(p = 0.005). 
In conclusion, this study demonstrates that genetic variation in the studied 
genes is associated with the diagnosis of endometriosis and PCOS with infertility in 
Pakistani (Punjabi) women in a fashion similar to reports in other ethnic groups. The 
consistent and new finding of these associations suggests a biologically plausible role 
for genetic polymorphisms in the etiology of endometriosis and PCOS. To conclude, 
endometriosis and PCOS are complex genetic disorders and previous studies have 
investigated many genes for their possible role as susceptibility loci. This is the first 
report to explore in Pakistani women from Punjab the association between different 
polymorphisms of the ESR1, ESR2, PGR, IL10, ADIPOQ, INSR, FSHR, FSHB, 
LHCGR and LHB genes and the development of endometriosis and PCOS. This study 
provides evidence that susceptibility loci for endometriosis and PCOS lie within or 
very close to the chromosomal region spanning these genes. By investigating, the 
functional role of these SNPs in Pakistani women and building up more information’s 
underlying the genetic basis for PCOS; the onset of disease in the individuals at risk 
can be delayed by changing the life style that will reduce expenditures to control the 
disease and its complications. Further this information could also be beneficial for the 
prevention of other long term complications such as obesity, diabetes and heart 
diseases. Moreover, samples from other Provinces should be investigated for any 
change in SNP to get the true picture of the country. 
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Annexure I 
3.2 CONSENT FORM 
  
Genetic and endocrinological studies of female reproductive dysfunction 
GC University Lahore 
 
I __________________, wife/daughter of ________________ hereby, fully agree to 
participate in the above mentioned study under ID #__________________________ 
I understand that the study is designed to add to the medical knowledge.  I have been 
informed about possible risks/discomforts involved and had the opportunity to ask 
any question about the study. I agree to give my medical history and blood sample. 
All the information collected in the data sheet will be kept confidential and will only 
be used solely for research purposes. I have no objection if in case the data obtained 
from my investigation is published in any scientific journal. 
 
           
           
           
           
        ________________ 
Patient’s Signature  
Date: ____________ 
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Annexure II 
3.2 SUBJECT DATA SHEET 
 
Patient Identity No.: _______________  Date: ______________ 
Name: _______________________             Age: ______________  
W/O or D/O: __________________   DOB: ______________ 
 Phone Number: _________________   Cast: ______________ 
Postal Address: 
_____________________________________________________________________ 
_____________________________________________________________________ 
Marital Status: Married__________ Unmarried___________ 
Pregnant:          Yes ___________ No__________ No. of children: _______________ 
General physical examination: 
Height: _________  Weight: ________ Kg BMI: _____________ 
Waist circumference: _____________ Cm    Hip circumference: __________ 
Cm 
WHR: _________________ Pulse: ___________ Blood pressure: ____________  
Cardiovascular system: _____________   Central Nervous system: ____________  
Family H/O: 
Smoking ________    HTN ______    DM ______  
IHD _______     PCOS _____    Endometriosis 
_____ 
Did you have any history of?  Yes    No  
Diabetes Mellitus (DM)   ___   ___ 
Hypertension ( HTN)    ___   ___ 
Smoking     ___   ___ 
Alcohol     ___   ___ 
Hyperthyroidism    ___   ___ 
Any hospitalization in past   ___   ___ 
Ischemic heart (IHD)    ___   ___ 
Any concurrent medical illness  ___   ___ 
Any surgery in past    ___   ___ 
 (Hysterectomy, Oophorectomy) 
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Gynecological history 
Menstrual history: 
Age of Menarche: ____________ Pattern of cycle:  Regular ___ Irregular_______ 
Less than 9 menses per year: Yes _____ No _____ 
H/O irregular menses with weight gain: Yes _____ No _____ 
Pelvic pain: __________    Back pain: ____________ 
Dysmenorrhea: _________    Abnormal vaginal discharge: ________ 
Dyschezia: ____________ Dysuria: _______________ Dyspareunia ____________ 
Have you had a physician give you a medical diagnosis of Polycystic Ovarian 
Syndrome (PCOS)? YES__________ NO ___________ 
If yes, how was the diagnosis made? ________________ 
Do you have a history of any of the following? 
Endometriosis _______  Uterine fibroids________ 
Ovarian cysts________  Breast lumps (or fibrocystic breast disease) 
________  
Do you have a family history of any of the following? 
PCOS _______    Excessive hair growth_______ 
Infertility_______    Obesity_______ 
Menstrual problems _______  Thyroid abnormalities_______ 
Hormonal problems_______   Miscarriage_______ 
Which symptoms you are currently experiencing as a result of your PCOS? 
Infertility_______    Anxiety_______ 
Weight gain_______    Insulin resistance_______ 
Food cravings _______   Facial hair_______ 
Specifically: _______    Mood swings_______  
Acne _______    Depression_______ 
 
Which of the following treatments for PCOS have you attempted? 
Low carbohydrate diet_______  Acne medication_______ 
General healthy eating_______  Psychological counseling_______ 
Insulin sensitizing medications_______ Nutritional counseling_______ 
Oral Contraceptive_______   Antidepressants_______ 
Exercise/Personal Trainer_______  Mood stabilizing medication ______ 
Other_______ 
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Medications to regulate period_______ Please describe: 
Did you take any contraceptic medicine in past Yes ______ No ______ 
If yes, for how long _____________ 
Did you take any other hormonal medication in past Yes ______ No ______ 
If yes, for how long _____________ 
Did you take any anti-obesity drugs Yes ______ No ______ 
If yes, for how long _____________ 
Did you take any anti-diabetic medicine Yes ______ No ______ 
If yes, for how long _____________ 
Any history of miscarriage: 
How many previous pregnancies were attempted ______________? 
Successful pregnancies ______________________ 
How many previous attempted pregnancies were without success 
______________ 
History of hirsutism: _____________ History of Acne: _____________ 
History of obesity: _______________  History of prostin: _________________ 
Pattern of obesity: Generalized ___________Visceral __________ Buffalo hump 
_______ 
Ovarian ultrasound:  
Rt ovary: ___________ Lt ovary: ___________Size: _________ Morphology: 
__________ 
Any cyst: _______________ If cysts present then blood flow: ____________ 
 
Investigations 
Pelvic scan: ________ Laparoscopic findings: ________USG _______ TVS _____ 
Rectosigmoidoscopy _________  Cystoscopy _________ CA-125: ______________  
CT SCAN (pelvis/abdomen) ___________  MRI. Pelvis/abdomen ____________ 
Laboratory tests 
Fasting glucose: _______ Fasting insulin: ________Serum Estradiol: ___________ 
Serum Testosterone: _____________ Serum LH: _________________ 
Serum FSH: _________ Serum Progesterone __________ Serum Prolactin _______ 
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QUESTIONNAIRE FOR DIAGNOSIS PCOS (Sue et al., 2007) 
-*If score is equal or more than 2, PCOS is present 
* If score is less than 2, not consistent with diagnosis of PCOS 
1. Between ages of 16-40 years about how long was your average menstrual cycle 
 Less than 25 days 
 25-35 
 36-60 
 More than 60 
 Totally variable 
*1 score for 36 days onward 
2. During your menstruation years (not including your pregnancy period) did you have a 
tendency to grow dark, coarse hair on your 
 Upper lip 
 Chin 
 Breast 
 Back 
 Belly 
 Upper arm 
 Upper thigh 
 Chest b/w breast 
* For more than 3 sites _______ I score 
3. Were you ever overweight and obese b/w ages of 16-40 years 
 Yes __________ 1 score 
 No ________ 0 
4. Between ages of 16-40 years, have you ever noticed a milky discharge from your 
nipples ( not including during pregnancy or recent child birth) 
 Yes __________ - 1 
 No ___________ 0 
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Annexure III 
3.6.1 Preparation of solutions  
 
1L 1M Tris-HCl  
Weigh 121.1g tris base (2-Amino-2-hydroxymethyl-propane-1,3-diol), dissolve into 
700 ml distilled H2O, adjust pH to 7.4-8.0, raise final volume to 1L, autoclave and “if 
possible” filter the solution and store at room temperature.  
1L 3M sodium acetate  
Weigh 246.1 × 3g sodium acetate, dissolve into distilled H2O, adjust pH to 5.2, raise 
final volume to 1L, autoclave and “if possible” filter the solution and store at room 
temperature.  
1L 10M NaOH  
Weigh 40 × 10g sodium hydroxide (NaOH), dissolve into 700 ml distilled H2O, raise 
final volume to 1L and store at room temperature.   
1L 1M HCl  
Measure 86.2 ml of 11.6M HCl, dilute into 913.8 ml distilled H2O and store at room 
temperature. Precaution Add acid into distilled H2O not distilled H2O into acid.    
1L 0.5M EDTA 
 Weigh 372.2/2g ethylene-diamine-tetraacetic acid (EDTA), dissolve into 700 ml 
distilled H2O, adjust pH to 8.0 by using NaOH pellets or 10M NaOH solution, raise 
final volume to 1L, autoclave and “if possible” filter the solution and store at room 
temperature. Note The dissolution of EDTA is pH-sensitive. EDTA will start 
dissolving on stirrer only when pH is increased towards 8.0 by the pellet-wise or 
drop-wise addition of NaOH into the starting mixture. Once EDTA solution becomes 
clear, stop adding NaOH. If excessive NaOH is added during EDTA dissolution, pH 
may become greater than 8.0, which will then be adjusted to 8.0 by using 1M HCl.  
1L TE buffer (10 mM Tris-HCl, 2 mM EDTA, pH 8.0) 
 Dilute 10 ml of 1M Tris-HCl solution and 4 ml of 0.5M EDTA solution into 500 ml 
distilled H2O, raise final volume to 1L and store at room temperature. 
50 ml 10% SDS  
Dissolve 5g sodium dodecyl sulphate (SDS) into 45 ml distilled H2O, heat up to 68
o
C 
for  dissolution, adjust pH to 7.2 by using 1M HCl and “if possible” filter the solution 
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and store at room temperature. Note Don’t use fume hood while preparing SDS 
solution.  
10 ml 10 µg/µl proteinase K  
Dissolve 100 mg proteinase K into 10 ml distilled H2O, make aliquots of 100 µl and 
store at -20
o
C. 
500 ml chloroform: isoamyl alcohol (24:1) 
 Mix 480 ml chloroform into 20 ml isoamyl alcohol and store at 4
o
C.  
500 ml 70% ethanol  
Mix 350 ml absolute ethanol into 150 ml distilled H2O and store at 4
o
C.    
100 ml low TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0)  
Dilute 1 ml of 1M Tris-HCl solution and 200 µl of 0.5M EDTA solution into 50 ml 
distilled H2O; raise final volume to 100 ml and store at room temperature. 
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Annexure IV 
 
3.6.3 Agarose Gel Electrophoresis 
 
The lengths of optimized DNA fragments of PCR products were quantify and 
visualized through agarose gel electrophoresis. 
 
TAE Buffer 1L 
4.84 g Tris Base 
1.14 ml Glacial Acetic Acid 
2 ml 0.5M EDTA (pH 8.0) 
The Tris base was added to 500 ml of distilled H2O. After Adding acetic acid and 
EDTA the solution was mixed. The volume was made 1 liter with more distilled 
water. For convenience a concentrated stock of TAE buffer of 50X was prepared and 
before use it was diluted with distilled water to 1X concentration. 
1L 10X TBE buffer  
Dissolve 108g tris-borate, 55g boric acid and 40 ml of 0.5M EDTA solution into 700 
ml distilled H2O, raise final volume to 100 ml and store at room temperature.  
1L 1XTBE buffer 
 Dilute 100 ml of 10× TBE buffer into 900 ml distilled H2O and store at room 
temperature.  
10 ml 10 µg/µl ethidium bromide (EtBR)  
Dissolve 100 mg EtBR into 10 ml distilled H2O or low TE buffer, make aliquots of 1 
ml, cover tubes with aluminum foil and store at room temperature. Note EtBR is a 
strong mutagen and protection from exposure is needed. 
50 ml 6× loading dye  
Dissolve 0.125g bromophenol blue (0.25%), 0.125g xylene cyanol FF (0.25%) and 15 
ml of 100% glycerol (30%) or 20g sucrose (40%) or 7.5g Ficoll type 400 (15%) into 
distilled H2O for making final volume up to 50 ml and store at 4
o
C or -20
o
C. 
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Preparing the Agarose gel 
 
Take 100 ml TAE Buffer to the 250 ml flask and add 1 g of Agarose powder. The 
flask was heated in a microwave until the solution became clear. The solution was 
cooled to about 50-55°C and added 2 l of Ethidium Bromide in 100 ml solution, 
swirling the flask occasionally to cool evenly. Place the combs in the gel casting tray. 
Poured the melted agarose solution into the casting tray and cooled it until it is solid 
(it should appear milky white). Carefully pull out the combs. Placed the gel in the 
electrophoresis chamber.  
Loading the gel 
Added 1 l of Sample Loading Dye to 5l of PCR product on a thin film and mix it. 
The order of the samples loading was recorded. Carefully pipette 6 l of each sample 
Loading Buffer mixture into separate wells in the gel. Pipette 2 l of the DNA ladder 
into at least one well of on the gel. 
Running the gel 
Placed the lid on the gel box, connecting the electrodes. Connected the electrode 
wires to the power supply, making sure the positive (red) and negative (black) were 
correctly connected. Turned on the power supply, about 100 volts for 30 minutes. The 
power run until the blue dye approaches the end of the gel. Remove the lid of the 
electrophoresis chamber. Carefully removed the tray and gel with DNA bands were 
observed in gel doc system (BioRad, Gel doc system) 
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Annexure V 
3.6.6 Optimization of selected fragments of DNA of various genes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: PCR product size: LHCGR 379 bp; FSHR 
577 bp (base pairs); column 1: DNA ladder; Column 2-
16: PCR products of different DNA samples 
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 Figure 3.2: PCR product size: FSHB 577 bp (base pairs);  
 column 1: DNA ladder; Column 2-15: PCR products of  
 different DNA samples 
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                           Figure 3.3: PCR product size: ADIPOQ 241 bp (base pairs);  
                       column 1: DNA ladder; Column 2-15: PCR products of  
different DNA samples 
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Figure 3.4: PCR product size: INSR 317 bp (base pairs); 
column 1: DNA ladder; Column 2-16: PCR products of 
different DNA samples 
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 Figure 3.5: PCR product size: PGR 238 bp (base pairs);  
 column 1: DNA ladder; Column 2-8: PCR products of  
 different DNA samples 
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Figure 3.6: PCR product size: IL10 208 bp (base pairs);  
column 1: DNA ladder; Column 2-8: PCR products 
of different DNA samples 
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Annexure VI 
3.6.7 PCR purification reagents preparation  
 
• Add molecular grade ethanol (98–100%) to Buffer PE  
• Add 1:250 volume pH indicator I to Buffer PB (add 600 μl pH 
indicator I to 150 ml Buffer PB). The yellow color of Buffer PB with pH indicator I 
indicates a pH of 7.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
205 
 
LIST OF PUBLICATIONS AND PRESENTATIONS FROM THESIS 
 
PUBLICATIONS 
 Liaqat, I., Jahan, N., Krikun, G. and Taylor, H.S. (2014). Genetic Polymorphisms 
in Pakistani Women with Polycystic Ovary Syndrome. Reproductive Sciences. 
22(3): 347-357. (DOI: 10.1177/1933719114542015).(IF. 2.23) 
 Liaqat, I., Jahan, N., Lone, K.P, Pakstis, A. and Taylor, H.S. (2013). Genetic 
polymorphisms associated with endometriosis in Pakistani women. Journal of 
Endometriosis. 5(4): 134 – 143. DOI:10.5301/je.5000165 (H. INDEX. 7). 
 Liaqat, I., Jahan, N., Lone, K.P, and Taylor, H.S. (2015). Genetic polymorphisms 
of INSR and ADIPOQ genes associated with PCOS Pakistani population. 
(Submitted to Plos One. Manuscript Number. Pone-S-15-20751: IF 3.730) 
 
ORAL PRESENTATIONS 
 Oral presentation entitled “Genetic polymorphisms in adiponectin and insulin receptor 
genes in Pakistani women with polycystic ovary syndrome”. 34th Pakistan Congress 
of Zoology (International). Feb. 25-27, 2014. CBGP-46. 
 Oral presentation entitled “Endometriosis and Genetic Polymorphisms in Pakistani 
Women”. IBPHR (International). May6-8, 2014. (BcGc-1406). 
 
POSTER PRESENTATION 
 Poster presentation entitled Genetic Polymorphisms Associated with Endometriosis in 
Pakistani Women at "Transforming Women's Health via Translational Investigation: 
A Global Perspective". SGI, Florence Italy. March 25-28, 2014. (F-246). 
 
ABSTRACTS 
 Liaqat, I., Jahan, N., Loneb, K. P., Pakstis, A., and Taylor, H. S. (2014). Genetic 
Polymorphisms Associated with Endometriosis in Pakistani Women. Reproductive 
Sciences. 21(3):318A-318A.  
 Liaqat, I., Jahan, N., Lone, K.P., Pakstis, A. and Taylor, H.S. (2014). Genetic 
polymorphisms in adiponectin and insulin receptor genes in Pakistani women with 
polycystic ovary syndrome. Abstracts of 34th Pakistan Congress of Zoology 
(International). Feb. 25-27, 2014. CBGP-46 
  
206 
 
 Liaqat, I., Jahan, N., Lone, K.P., Batool, A. and Taylor, H.S. (2014). Endometriosis 
and Genetic Polymorphisms (FSHR, IL10, ESR1) in Pakistani Women. IBPHR 
(International). May6-8, 2014. (BcGc-1406). 
 
 
